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Thesis Summary 
The work presented in this thesis focuses on a behavioural and histological 
characterisation of the HdhQ111 mouse model of Huntington’s disease (HD). Numerous 
mouse models of HD are currently available; however, before their use, each must be 
fully understood, validated and characterised, which will allow the most appropriate 
model to be used in scientific research. 
Chapter 1 provides a general introduction. Chapter 2 states the materials and 
methods used in this thesis. The work presented in Chapter 3 encompasses an 
extensive longitudinal immunohistological characterisation of the HdhQ111/+ mouse 
model, which includes immunohistochemical stains from animals at 3, 6, 9, 12, 15 and 
18 months of age, to understand the development of the underlying neuropathology 
associated with this mouse model. Chapter 4 builds on the knowledge gained from 
the previous chapter to explore the longitudinal progression of motor symptoms 
associated with the HdhQ111/+ mouse model.  
In Chapter 5 a longitudinal operant battery was conducted to explore cognitive 
dysfunction in the HdhQ111/+ mouse model. Operant tests of motivation, attention and 
implicit learning were conducted longitudinally at 6, 12 and 18 months of age. 
Chapter 6 uses the knowledge gained from Chapter 5 to explore the effects of operant 
pre-training, at a young age, and the impact that this has on latter operant task 
performance and the development of the disease phenotype at an older age. To further 
understand the cognitive deficits observed in the HdhQ111/+ mouse model, Chapter 7 
presents the creation, optimisation and utilisation of an operant delayed matching and 
delayed non-matching to position (DMTP/DNMTP) task, which could be used to test 
working memory and reversal learning in mouse models of neurological diseases 
including HD. Chapter 8 includes a general discussion of the work presented in this 
thesis. 
The studies presented within this thesis demonstrate the development of a clear 
neuropathological profile as well as significant motor and cognitive deficits in the 
HdhQ111 mouse model of Huntington’s disease. We can therefore conclude that the 
HdhQ111 mouse model is a valid mouse model for investigating the pathogenic 
mechanisms of the disease and for testing therapeutic interventions in HD. 
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Chapter 1 : General Introduction 
1.1 . Background 
The earliest recorded description of Huntington’s disease (HD) was by Charles 
Oscar Waters and dates back to 1842, in a letter published in Robley Dunglison’s 
Practice of Medicine. Waters accurately described a movement disorder, 
including its progressive chorea and hereditary nature. In addition to Waters, 
other early descriptions of the disease were produced by Charles Gorman in 
1846, who described the occurrence of HD in localised geographical regions, 
and Johan Christian Lund in 1860, who described dementia associated with 
jerking movements causing chorea that had a hereditary nature.  
However, the most widely acknowledged first description of HD was published 
in 1872 by the American physician George Huntington. Huntington clearly 
described patients that exhibited ‘dance like movements’ or chorea and 
accurately postulated cognitive deficits in patients as well as the hereditary 
nature of the disease (Huntington 1872). The worldwide prevalence of HD is 
now estimated to be approximately 3 per 100 000 (Harper 1992; Pringsheim et 
al. 2012). The disease is more common in European, American, and Australian 
populations where prevalence can be as high as 1 in 10 000 (McCusker et al. 
2000; Orth 2011; Pringsheim et al. 2012; Evans et al. 2013). However, it should 
be considered that the estimated prevalence of the disease is heavily affected by 
the number of people presenting to the medical profession, the associated stigma 
of the disease and health care provisions available in particularly countries. 
Therefore, the estimated prevalence of the disease is likely to be an 
underestimation of those who are affected globally. 
HD is an autosomal dominant inherited disorder which typically occurs in the 
third and fourth decades of life (Duyao et al. 1993). The progressive nature of 
the disease means symptoms will lead to death fifteen to twenty years after 
clinical diagnosis (Sørensen and Fenger 1992b; Vonsattel and DiFiglia 1998). 
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However, with increasing; awareness, understanding and therefore diagnosis of 
the disease, the time between diagnosis and mortality is often greater than has 
been previously predicted. Although some, limited, symptomatic treatments for 
HD are available (Ondo et al. 2002; Adam and Jankovic 2008; Mestre et al. 
2009) reviewed in (Bonelli and Wenning 2006; Bonelli and Hofmann 2007), 
there is currently no cure.     
1.2. The Genetic Cause of Huntington’s Disease 
The hereditary, autosomal dominant, nature of HD was postulated in the original 
descriptions of the disease (Waters 1842; Lund 1860; Huntington 1872). 
However, it was not until 1983 that the possible genetic cause of the disease was 
localised to chromosome 4p16.3 (Gusella et al. 1983). The precise genetic cause 
of HD is now known to be a trinucleotide polyglutamine repeat expansion of the 
nucleotides cytosine, adenine and guanine (CAG) within the first exon of the 
huntingtin gene (HTT) on the short arm of chromosome 4 (MacDonald et al. 
1993). HTT is a large gene which spans ~210kb and contains 67 exons. HTT 
contains an open reading frame for a polypeptide of over 3140 residues, known 
as the huntingtin protein (HTT) (MacDonald et al. 1993). 
The essential role of HTT in embryonic development and neurogenesis (White 
et al. 1997) has been demonstrated in knock-out mouse models (Nasir et al. 
1995) and HTT gene inactivated  models (Duyao et al. 1995; Zeitlin et al. 1995), 
which both exhibit embryonic lethality. Although attempts have been made to 
deduce the structure of HTT using alignment, modelling and crystallography 
studies (Poirier et al. 2005; Kelley et al. 2009; Kim et al. 2009), the exact 
structure, and therefore, function of the protein is still unknown. This is at least 
in part, due to the large size of the protein and the vast number of possible protein 
interactions (Wanker et al. 1997; Harjes and Wanker 2003; Li and Li 2004).  
1.2.1. The Mutant Huntingtin Protein 
Upon successful transcription and translation, the full length mutant huntingtin 
protein molecule (mHTT) is thought to undergo proteolysis, by either caspase or 
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calpain (Wellington et al. 2000; Wellington et al. 2002; Graham et al. 2006) due 
to the overlapping cleavage sites (Gafni et al. 2004). Proteolysis produces 
soluble monomeric fragments of mHTT (Kim et al. 2001; Landles et al. 2010) 
including N-terminal fragments which are thought to be more toxic than the full 
length mHTT (Hackam et al. 1998). Once formed, mHTT monomers increase in 
cytoplasmic concentration until a threshold concentration has been reached 
(Olshina et al. 2010). When the threshold value is reached monomers dimerise 
to form soluble intermediate oligomers which are in equilibrium with the 
monomer population (Ossato et al. 2010). Monomers and oligomers react 
together, via the formation of stabilising hydrogen bonds and covalent bonds 
between the glutamine residues of one mHTT and the amine residues of another, 
via the action of transglutaminase, to catalyse the formation of aggregate bodies 
both within the cytoplasm and the cellular nucleus (Zainelli et al. 2003; Landles 
et al. 2010; Marcellin et al. 2012), as shown in Figure 1.1. The aggregation of 
N-terminal fragments of mHTT within nuclear inclusions is thought to be 
proportional to the size of the CAG repeat length (Krobitsch and Lindquist 2000; 
Jana et al. 2001).   
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Schematic representation of aggregate formation in Huntington’s disease. Once mutant 
huntingtin (mHTT) has been transcribed and translated, the protein is cleaved into soluble monomers, which 
are in equilibrium with the oligomeric pool which they form. Aggregate bodies are then formed which may 
be targeted to the ubiquitin proteosome system (UPS) for subsequent degradation via ubiquitination or 
transported to the nucleus. 
The precise molecular role of mHTT, in neurodegeneration, and the associated 
effects of the protein, remains unclear. The expansion of CAG repeats, produces 
an abnormal three-dimensional protein structure which alters both the intra and 
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inter molecular interactions of the mutant protein (Huang et al. 1998; Nekooki-
Machida et al. 2009). Despite a plethora of research investigating the structure, 
function and interaction of the mHTT, the precise sequence of events which 
cause the mutant protein to lead to the manifestation of the disease remains 
unclear.  
1.2.2. CAG Repeat Length and Huntington’s Disease 
The precise number of CAG repeats within the mutant huntingtin gene (mHTT) 
has been shown to be a crucial factor in determining disease severity, penetrance 
and age of onset (Andrew et al. 1993; Duyao et al. 1993; Brandt et al. 1996; 
Brinkman et al. 1997a; Penney et al. 1997; Rosenblatt et al. 2006). The range of 
CAG repeats in unaffected individuals is typically 19-35, repeat lengths of 36-
41 are considered to be within the range of low penetrance and often demonstrate 
variable penetrance (Langbehn et al. 2004), whereas repeat lengths of over 42 
are considered to be pathogenic to the patient, often producing the full HD 
phenotype (Brinkman et al. 1997b; Menalled and Chesselet 2002). Estimates 
suggest that up to 90% of affected individuals are thought to have CAG repeat 
lengths in the rage of 40-50 repeats (Wexler 2004). The CAG trinucleotide repeat 
length observed in HD patients generally inversely correlates with the age of 
disease onset (Andrew et al. 1993). However, there is often a large degree of 
variation in age of onset and the range of symptoms exhibited, despite 
similarities in CAG repeat length (MacMillan et al. 1993). 
Although, the number of CAG repeats is a critical factor in determining age of 
symptom onset, it has been suggested that CAG repeat length may account for 
only 40% of the variation in the age of disease onset (Wexler 2004). Therefore, 
other genetic, neurobiological and environmental factors have also been 
associated with disease progression and age of onset (Duyao et al. 1993; 
Kieburtz et al. 1994; Leeflang et al. 1995; Brinkman et al. 1997b; Wexler 2004; 
Andresen et al. 2007a; Andresen et al. 2007b; Gayán et al. 2008; Brocklebank 
et al. 2009). A particularly interesting example of this involves cases of 
monozygotic twins. Many studies have demonstrated that monozygotic twins 
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differ in the age of symptom onset, disease severity and disease progression 
despite both twins possessing an identical number of CAG repeats 
(Myrianthopoulos and Rowley 1960; Bird and Omenn 1975; Georgiou et al. 
1999; Anca et al. 2004; Gomez-Esteban et al. 2006). While the reasons for this 
remain unclear, environmental, neurodevelopmental and epigenetic factors are 
all considered as possible reasons to explain the differences demonstrated in 
cases of monozygotic twins with HD (Petronis and Kennedy 1995; Crow 1997; 
Ketelaar et al. 2012) .  
Genetic anticipation is demonstrated in HD and longer repeat lengths are often 
found in offspring in comparison to parents (Ranen et al. 1995). Molecularly, 
this has been attributed to the presence of a meitotically unstable intermediate 
allele (Goldberg et al. 1993), which can cause both sporadic and inherited cases 
of HD (Myers et al. 1993). Genetic anticipation is particularly prevalent in those 
cases which are passed through the male germ line (Erickson 1985; Ridley et al. 
1988) and this is thought to be due to larger variations in CAG repeat length in 
sperm (Duyao et al. 1993; Telenius et al. 1995). 
 
1.3. The Neuropathology of Huntington’s Disease  
1.3.1. The Structure of the Striatum  
HD predominantly affects the striatum of the basal ganglia. In primates the basal 
ganglia comprises the striatum (including the caudate nucleus and putamen, 
which are divided by the internal capsule), the ventral striatum (nucleus 
accumbens and olfactory tubercle) and the internal and external segments of the 
globus pallidus (GPi and GPe, respectively). The pars reticulata and pars 
compacta of the substantia nigra (SNr, and SNc respectively) and the 
subthalamic nucleus (STN) are also functionally connected to the basal ganglia 
(Parent and Hazrati 1995). Although similar, the rodent basal ganglion lacks an 
internal capsule that divides the caudate nucleus from the putamen, thus the 
rodent striatum is a uniform structure, which has a similar functional 
organisation to the primate forebrain (Parent 1990). 
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1.3.2. Signal Transduction in the Striatum  
Familiarity of the corticostriatal circuitry of the brain is essential in 
understanding the causes of HD. Transmission of neuronal signals through the 
basal ganglia, including the striatum, can occur via two pathways; the direct 
pathway and indirect pathways, as seen in Figure 1.2. 
 
 
 
Figure 1.2. Connectivity map to show the direct and indirect pathways of the basal ganglia. Solid 
arrows represent excitatory connections and dashed arrows represent inhibitory connections. Green arrows 
indicate GABAergic signals, blue arrows represent glutamatergic signals and black arrows indicate 
dopaminergic signals. Excitatory efferent signals from cortical neurons stimulate the excitatory action of 
the direct pathway and dampen the inhibitory activity of the indirect pathway. (Abbreviations: D1: 
dopamine receptor 1; D2: dopamine receptor 2; GPe: globus pallidus extrenal; GPi: globus pallidus internal; 
STN: subthalamic nucleus; SNc: substantia nigra compacta; SNr: substantia nigra reticulata). 
In the direct pathway glutamatergic input from the cortex to the striatum inhibits 
GABAergic neurons resulting in an excitatory cortical input into the motor 
cortex, the GPi and the thalamus. In the indirect pathway the glutamatergic input 
from the cortex to the striatum inhibits GABAergic release causing an inhibition 
of the action of the GPe. This causes excitatory activity from the STN to the 
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GPi/SNR, leading to the repression of excitatory signals from the thalamus and 
cortex and resulting in inhibition of the excitatory signals received by the motor 
cortex (Alexander et al. 1991). Dopamine 2 (D2) receptors are predominantly 
expressed in the indirect pathway and dopamine 1 (D1) receptors are expressed 
in the direct pathway (Gerfen et al. 1990; Gerfen et al. 1995).  
In addition, the SNc projects a dopaminergic output into the basal ganglia, 
allowing the modulation of both the direct and indirect pathways. The direct and 
indirect pathways act via opposing mechanisms, with the direct pathway 
promoting movement and the indirect pathway preventing movement. 
Therefore, it is the balance of both pathways which controls the excitation and 
inhibition of motion (Albin et al. 1989; Surmeier et al. 2007). Both the direct 
and indirect pathways require careful regulation and modulation to allow 
striatally mediated functions, such as emotion, cognition and movement to occur 
in a controlled manner (Mink and Thach 1993). However, if the careful 
regulation and delicate balance between the direct and indirect pathways is lost, 
disease states such as Parkinson’s disease and Huntington’s disease can result 
(Cepeda et al. 2007), as shown in Figure 1.3.  
1.3.3. Dysfunction of the Striatum in Huntington’s Disease.  
The medium spiny neuron (MSN) degradation, described in HD (Deng et al. 
2004; Starr et al. 2008), results in a reduction in the action of the indirect 
pathway, which reduces overall inhibitory control, as the STN becomes more 
inhibited, this reduces excitatory stimulation to the GPi which in turn has a less 
inhibitory influence on the thalamus. Therefore, an increase in glutamatergic 
feedback to the cortex causes an over activation of the cortico-striato-thalamic 
feedback loop and this causes a lack of motor control as demonstrated in 
symptomatic HD patients (Hallett 1993; Graybiel et al. 1994), as shown in 
Figure 1.3. 
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Figure 1.3. Connectivity map to show the alterations of the direct and indirect pathways in 
Huntington’s disease. Solid arrows represent excitatory connections and dashed arrows represent 
inhibitory connections. Green arrows indicate GABAergic signals, blue arrows represent glutamatergic 
signals and black arrows indicate dopamine signals. Thicker arrows indicate a greater influence whereas 
thinner arrows indicate a decreased influence of the pathway.  Excitatory efferent signals from cortical 
neurons stimulate the excitatory action of the direct pathway and dampen the inhibitory activity of the 
indirect pathway. (Abbreviations: D1: dopamine receptor 1; D2: dopamine receptor 2; GPe: globus pallidus 
extrenal; GPi: globus pallidus internal; STN: subthalamic nucleus; SNc: substantia nigra compacta; SNr: 
substantia nigra reticulata). 
Although the indirect pathway (which is involved in preventing movement, as 
described above) is predominantly affected in the early symptomatic stages of 
HD, as the disease progresses choraic movements are often replaced by 
bradykinesia (Thompson et al. 1988; Berardelli et al. 1999b). The hypoactive 
phenotype reflects a more widespread neurodegeneration that includes loss of 
striatal MSNs and the D1 receptors of the direct pathway which causes a general 
loss of motor tone throughout the motor circuits (Thompson et al. 1988; Phillips 
et al. 1996; Berardelli et al. 1999b).   
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1.3.4. Gross Neuropathology of Huntington’s Disease 
Post mortem evidence, in human HD brains, generated an initial understanding 
of the gross neuropathology of HD in human patients, including cell loss and 
reduced size of the caudate and putamen (Lange et al. 1976; Vonsattel et al. 
1985; Vonsattel and DiFiglia 1998). Although the caudate and putamen are the 
most obvious sites of neurodegeneration in HD, it is now being increasingly 
recognised, particularly through the use of MRI studies (Reading et al. 2004; 
Rosas et al. 2008; Tabrizi et al. 2009), that other brain regions including the 
cerebral cortex, cerebellum and hippocampus are also affected early in HD 
disease progression (Braak and Braak 1992; Heinsen et al. 1996; Rosas et al. 
2008). The involvement of the cerebral cortex in HD was noted by Vonsattel 
who first introduced a grading system for scoring the severity of the 
neuropathology demonstrated in brain autopsies of HD patients (Vonsattel et al. 
1985). Vonsattel graded the severity of neuropathology from 0-4; the higher the 
score the more severe the phenotype, patients with scores of 3 and 4 typically 
exhibited neurodegeneration of the cerebral cortex as well as the striatum 
(Vonsattel et al. 1985). 
Recent advances in neuroimaging techniques have allowed in vivo brain atrophy 
measures to be correlated with disease stage and behavioural changes, to give a 
greater understanding of HD and the progression of the disease. Numerous 
imaging studies have concluded that structural changes in the brain, including; 
whole brain atrophy, caudate atrophy, white matter atrophy and grey matter 
atrophy, (Rosas et al. 2003; Reading et al. 2005; Henley et al. 2006; Rosas et al. 
2008; Henley et al. 2009; Tabrizi et al. 2009; Hobbs et al. 2010; Tabrizi et al. 
2011), can occur often decades prior to symptom onset. In addition, 
neuroimaging studies were included in the TRACK-HD study, which followed 
HD patients for three years in order to assess measurements which were suitable 
to use as ‘outcome measures’ in clinical trials. The TRACK-HD study allowed 
the correlation of functional change to symptom progression, disease burden and 
behavioural change (Tabrizi et al. 2009; Tabrizi et al. 2011; Tabrizi et al. 2013). 
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Therefore, there is now emerging evidence that HD is a disease of the whole 
brain rather than simply the striatum.  
1.3.5. Cellular and Molecular Features of Huntington’s Disease 
HD is caused by a specific loss of MSNs within the striatum of the basal ganglia 
(Deng et al. 2004; Starr et al. 2008) which results in interruption of the 
corticostriatal circuitry (Figure 1.3). The MSNs of the striatum project 
GABAergic connections into the SNr and the internal and external segments of 
the globus pallidus and secrete the inhibitory neurotransmitter γ-aminobutryic 
acid (GABA), which dampens the activity of post-synaptic target neurons. In 
HD, degradation of the MSNs in the striatum, is indicated by a reduction in the 
expression of numerous receptor subtypes including; D1 and D2 receptors 
(Weeks et al. 1996a; Surmeier et al. 2007; Crook and Housman 2012), CB1 
receptors (Denovan-Wright and Robertson 2000; Glass et al. 2000; Lastres-
Becker et al. 2002; Glass et al. 2004; McCaw et al. 2004), NMDA receptors 
(Arzberger et al. 1997; Luthi-Carter et al. 2003) and TrkB receptors (Ginés et 
al. 2006). An alteration in the levels of the receptor subtypes produced by MSNs 
disrupts the delicate balance of the direct and indirect pathways and alters 
neuronal transmission. In addition, some studies have shown the loss of both D1 
and D2 receptors in the striatum of asymptomatic HD patients (Seeman et al. 
1989; Weeks et al. 1996b; Augood et al. 1997) thus indicating neuronal 
dysfunction prior to symptom onset.  
Molecular aggregates that develop into neuronal intranuclear inclusions (NIIs) 
of mutant huntingtin protein, have been shown to form in neurons of HD affected 
individuals (Vonsattel et al. 1985; Sieradzan et al. 1999), often prior to the onset 
of symptoms (Gómez‐Tortosa et al. 2001). The precise cause of the formation 
of NIIs is still under debate. Many studies have indicated that inclusion 
formation is a toxic mechanism, which prevents the normal and proper 
functioning of the cells and neurons (Li et al. 2001; Lee et al. 2004; Miller et al. 
2010). Others have shown that mHTT to be pro-apoptotic (Saudou et al. 1998) 
and mHTT aggregates have been shown to recruit wild type huntingtin, which is 
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anti-apoptotic (Ho et al. 2001), specifically through the N-terminus of mHTT 
(Huang et al. 1998). Therefore, NII formation could prevent the anti-apoptotic 
action of wild type huntingtin protein. However, others have concluded that NII 
formation may be a neuroprotective mechanism, at least in the first instance 
(Saudou et al. 1998; Guidetti et al. 2001; Zhou et al. 2001; Arrasate et al. 2004; 
Mitra et al. 2009). Interestingly, the short stop mouse model of HD demonstrates 
frequent and widespread NIIs, despite an absence of neurodegeneration or 
behavioural abnormalities (Slow et al. 2005), therefore suggesting, in this 
particular mouse model, that inclusion formation is not a pathogenic mechanism. 
1.4. Clinical Symptoms of Huntington’s Disease 
Although HD is currently clinically diagnosed upon the onset of motor 
symptoms, cognitive and psychiatric deficits are now thought to precede later 
motor symptoms in the vast majority of cases (Diamond et al. 1992; Duff et al. 
2007; Paulsen et al. 2008b; Tabrizi et al. 2009; Tabrizi et al. 2011; Tabrizi et al. 
2013). The range of clinical symptoms demonstrated in HD led to the 
development of The Unified Huntington’s Disease Rating Scale (UHDRS) 
(Kremer and Group 1996; Siesling et al. 1998), a clinical scale to assess and 
track disease severity across multiple domains including; motor function, 
cognitive function, behavioural abnormalities and functional capacity. The 
UHDRS is now commonly used clinically to characterise disease severity 
although variations of the original scale exist, for example for later stage patients 
(Youssov et al. 2013) or shortened versions of the original scale (Siesling et al. 
1997).   
1.4.1. Motor Symptoms 
The more obvious motor symptoms of HD can include chorea, from the Greek 
meaning ‘to dance’, which results in uncontrollable involuntary jerking and 
writhing movements (Huntington 1872; Thompson et al. 1988; Kremer and 
Group 1996). Although, it should be noted that chorea is not present in all cases 
of HD, it is extremely common. Other obvious motor symptoms can, but do not 
Chapter 1                                                                              General Introduction 
12 
 
always include; hypokinesia including akinesia (impairment in starting a 
movement) (van Vugt et al. 1996) and bradykinesia (impairment and slowness 
in executing a movement) (Thompson et al. 1988), dystonia (abnormal muscle 
tone), rigidity, Tics and tremor (Huntington, 1872, (Hefter et al. 1987b; Phillips 
et al. 1996; Berardelli et al. 1999b; Louis et al. 1999). The abundance of motor 
symptoms significantly affect the gait of HD patients (Koller and Trimble 1985; 
Hausdorff et al. 1997; Reynolds et al. 1999; Grimbergen et al. 2008; Rao et al. 
2008), commonly leading to falls and stumbles (Grimbergen et al. 2008; Busse 
et al. 2009) and an eventual inability to walk. In addition to the more obvious 
motor symptoms of HD, ideomotor apraxia, difficulty in the planning and 
completing motor tasks, is common (Knopman and Nissen 1991; Shelton and 
Knopman 1991). Furthermore, impairments in the learning of motor skills 
(Heindel et al. 1988; Willingham and Koroshetz 1993) and dysphagia are 
common symptoms during the progression of the disease (Leopold and Kagel 
1985; Hunt and Walker 1989; Kagel and Leopold 1992; Hamakawa et al. 2004; 
Heemskerk and Roos 2011).  
Increasingly, subtle motor abnormalities, which often proceed the more obvious 
motor symptoms observed upon clinical diagnosis are being described in HD 
patients (de Boo et al. 1997). Subtle motor abnormalities, in self-paced finger 
tapping, gait and oculomotor measures were found to occur often decades prior 
to clinical diagnosis in HD patients (Paulsen et al. 2008b; Biglan et al. 2009; 
Tabrizi et al. 2009; Tabrizi et al. 2011; Tabrizi et al. 2013). In addition, an 
abundance of literature describes ocular motor abnormalities in both 
asymptomatic patients and patients in the early stages of the disease (Leigh et al. 
1983; Rothlind et al. 1993; Blekher et al. 2004; Golding et al. 2006).  
Despite the clear motor symptoms associated with HD, research is increasingly 
focused upon the psychiatric and cognitive symptoms that are often apparent 
earlier in the disease progression (Duff et al. 2007; Paulsen et al. 2008b; Tabrizi 
et al. 2009; Paulsen 2010; Tabrizi et al. 2011; Tabrizi et al. 2013), as these 
symptoms offer an earlier stage for potential therapeutic intervention in HD.  
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1.4.2. Psychiatric Symptoms 
Psychiatric symptoms are common in HD patients; it has been estimated that up 
to 98% of HD patients exhibit some sort of neuropsychiatric symptoms (Paulsen 
et al. 2001b). Psychiatric symptoms typically begin prior to motor dysfunction 
and are thought to worsen as motor symptoms become more prevalent and 
disease burden increases (Duff et al. 2007; van Duijn et al. 2013). It has been 
estimated that up to 80% of HD patients develop a non-cognitive psychiatric 
disorder within fifteen years of clinical diagnosis (Leroi et al. 2002), and some 
studies have estimated that up to a fifth of HD patients suffer with severe 
psychiatric problems (Orth 2011). Depression (Slaughter et al. 2001b), apathy, 
irritability, aggression and anxiety (Julien et al. 2007) are all common 
behavioural symptoms of HD (Burns et al. 1990; Craufurd et al. 2001; Paulsen 
et al. 2001b; Slaughter et al. 2001a; Duff et al. 2007; Reedeker et al. 2012; van 
Duijn et al. 2013). 
The PREDICT-HD study examined a large cohort of affected individuals and 
found that the range of psychiatric problems (apathy, anxiety, obsessive 
compulsive disorder and depression) exhibited in HD pre-symptomatic carriers 
was far greater than non-affected individuals and that the psychiatric problems 
had strong correlation with difficulties in undertaking everyday tasks (Duff et al. 
2007; Paulsen et al. 2008a). The suicide risk in HD patients and families affected 
by HD is high (Schoenfeld et al. 1984; Lipe et al. 1993; Almqvist et al. 1999) 
with suicide rates estimated to be up to four times greater in HD families 
compared to the general population (Di Maio et al. 1993). Some studies suggest 
that suicide attempts can be as high as ~25% in symptomatic patients with ~5% 
committing suicide (Farrer et al. 1986). Suicidal ideation is demonstrated in both 
pre-symptomatic and symptomatic patients (Paulsen et al. 2005; Hubers et al. 
2012) with the presence of pre-existing neuropsychiatric problems such as; 
depression, anxiety and aggression often increasing suicidal ideation (Hubers et 
al. 2013).  
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Sleep disturbances are often common in HD patients and alterations in circadian 
rhythm have been shown to effect the sleep-wake cycle, often causing nocturnal 
sleeping patterns (Hansotia et al. 1985; Wiegand et al. 1991; Morton et al. 2005; 
Arnulf et al. 2008; Aziz et al. 2008; Videnovic et al. 2009). The sleep 
disturbances observed may also contribute to the more general cognitive and 
psychiatric symptoms shown in HD (Drummond and Brown 2001; Aziz et al. 
2008).  
1.4.3. Cognitive Symptoms 
Cognitive deficits that precede profound motor dysfunction have been 
demonstrated in HD patients (Diamond et al. 1992; Lawrence et al. 1998b; 
Lawrence et al. 1998c; Kirkwood et al. 2000; Lemiere et al. 2004; Duff et al. 
2007; Robins Wahlin et al. 2007; Paulsen et al. 2008b; Tabrizi et al. 2009; 
Tabrizi et al. 2011; Tabrizi et al. 2013). The Unified Huntington’s Disease 
Rating Scale (UHDRS), is the most commonly used clinical scale to assess the 
clinical symptoms of HD. Although, this scale has been designed to classify the 
overall severity of HD, across a range of clinical symptoms. Therefore, although 
the UHDRS contains a cognitive component, other assessments have been 
specifically designed to assess cognitive dysfunction. In addition to the UHDRS, 
a range of assessments are used to classify cognitive dysfunction in HD 
including the Mini-Mental State Examination (MMSE) (Folstein et al. 1975) and 
the Montreal Cognitive Assessment (MoCA) (Videnovic et al. 2010). However, 
cognitive assessments such as these were not specifically designed to measure 
cognitive dysfunction in terms of HD. Therefore the usefulness, validity and 
sensitivity of cognitive assessments such as the MMSE and MoCA for 
specifically classifying cognitive dysfunction in HD patients are disputed (Feher 
et al. 1992; Videnovic et al. 2010; Gluhm et al. 2013).  
However, cognitive assessments are used in disease diagnosis and are crucial in 
the categorisation of disease progression, but the vast and broad array of 
cognitive symptoms demonstrated in HD, can make the overall classification of 
cognitive dysfunction difficult. Cognitive dysfunction has been demonstrated 
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relatively early in HD disease across a broad arrange of cognitive tasks (Stout et 
al. 2011) demonstrating specific deficits in: perseverance (Craufurd et al. 2001; 
Thompson et al. 2002a; Aron et al. 2003), reversal learning (Lawrence et al. 
1996; Lawrence et al. 1999), alternation (Kirkwood et al. 1999), set shifting 
(Lawrence et al. 1998b), olfactory recognition and discrimination (Moberg et al. 
1987; Nordin et al. 1995; Lazic et al. 2007), procedural memory (Caine et al. 
1977; Butters et al. 1985; Snowden et al. 2002), judgement and risk tasking 
(Craufurd et al. 2001; Stout et al. 2001), facial recognition and emotional 
recognition problems (Jacobs et al. 1995; Sprengelmeyer et al. 1996; Gray et al. 
1997; Sprengelmeyer et al. 1997; Milders et al. 2003; Johnson et al. 2007; Kipps 
et al. 2007; Snowden et al. 2008).  
Cognitive and psychiatric symptoms typically occur relatively early in disease 
progression (Diamond et al. 1992; Kirkwood et al. 2000; Lemiere et al. 2004; 
Robins Wahlin et al. 2007) and thus allow an opportunity for early potential 
therapeutic intervention, targeting HD as early as possible. Furthermore, there is 
considerable interplay between underlying cognitive and psychiatric symptoms 
and motor and peripheral symptoms which are also demonstrated in the disease. 
1.4.4. Peripheral Symptoms 
Further to a range of symptoms associated with the central nervous system 
(CNS), HD also causes many peripheral symptoms which can significantly 
affect the quality of life of patients. Weight loss is often demonstrated from the 
early stages of HD (Djousse et al. 2002) and progresses as disease burden 
increases (Robbinsa et al. 2006). The degree of weight loss observed has been 
correlated with an increase in CAG repeat length (Seong et al. 2005; Aziz et al. 
2008), although the precise reasons for the observed weight loss remain unclear. 
An abundance of literature has examined metabolic problems in HD patients 
(Koroshetz et al. 1997; Lodi et al. 2000; Mochel et al. 2007a; Goodman et al. 
2008; Mochel and Haller 2011), including mitochondrial dysfunction (Panov et 
al. 2002; Quintanilla and Johnson 2009; Kim et al. 2010; Oliveira 2010), which 
may relate to the weight loss observed.  
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In addition, to the underlying metabolic dysfunction, motor symptoms such as 
dysphagia and tremor (Huntington 1872; Hefter et al. 1987b; Phillips et al. 1996; 
Berardelli et al. 1999b; Louis et al. 1999), which are centrally controlled, not 
only increase sedentary energy expenditure (Pratley et al. 2000) but also 
physically affect the ability of patients in the late stages of HD to consume food 
independently (Leopold and Kagel 1985). Furthermore, underlying 
psychological symptoms such as apathy, lack of motivation and depression may 
also affect the willingness of the patient to consume food independently. Many 
other peripheral symptoms are shown in HD patients including; cardiac 
dysfunction and failure (Chiu and Alexander 1982; Lanska et al. 1988; Sørensen 
and Fenger 1992a), skeletal muscle abnormalities (Lodi et al. 2000; Turner et al. 
2007; Busse et al. 2008a), endocrine dysfunction including diabetes (Farrer 
1985) and gastrointestinal problems (Andrich et al. 2009; van der Burg et al. 
2011).             
HD is characterised by a range of symptoms, which can interact, and often vary 
in their severity and nature. Therefore, although there are commonalities in the 
symptoms observed in HD patients, the exact profile and severity of symptoms 
will vary depending on the individual patient.  
1.5. Juvenile Huntington’s Disease  
The CAG trinucleotide repeat length observed in HD patients generally inversely 
correlates with the age of disease onset (Andrew et al. 1993). But patients with 
particularly long CAG repeat lengths, typically in the range of 60 -120 repeats 
will develop juvenile Huntington’s disease (JHD) (Douglas et al. 2013), 
although cases of JHD have been described in patients with as few as 48 CAG 
repeats (Ribaï et al. 2007). Juvenile cases of HD account for approximately 10% 
of all cases and are typically diagnosed before 20 years of age (Van Dijk et al. 
1986b; Douglas et al. 2013). Some patients with expansions of up to 250 CAG 
repeats (Nance et al. 1999) have been shown to develop clinical symptoms as 
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young as 18 months of age (Nicolas et al. 2011), although such large expansions 
are exceedingly rare. 
In the majority of cases, JHD is inherited from the paternal germ line and genetic 
anticipation is observed (Van Dijk et al. 1986a). However unlike HD, JHD is 
thought to have a more rapid rate of disease severity and progression (Van Dijk 
et al. 1986a; Bhidayasiri and Tarsy 2012). The cognitive decline and psychiatric 
problems associated with JHD are similar to adult onset HD, including; 
depression, poor school performance, memory problems, irritability, depression 
and social withdrawal (Gómez-Tortosa et al. 1998; Srivastava et al. 1999; Ribaï 
et al. 2007; Bhidayasiri and Tarsy 2012). However, unlike adult onset HD which 
demonstrates choreic movements, JHD typically demonstrates motor symptoms 
of rigidity, bradykinesia and dystonia (Van Dijk et al. 1986a; O'Shea and Falvey 
1991; Srivastava et al. 1999; Geevasinga et al. 2006). Furthermore, seizures and 
epilepsy are common in JHD patients. In addition to the characteristic motor 
disturbances observed in JHD the neuropathology of the disease is thought to be 
more widespread, with nuclear aggregates forming in the cortex (Gutekunst et 
al. 1999) as well as the striatum rapidly during the disease progression (Vonsattel 
and DiFiglia 1998; Nance and Myers 2001).  
1.6. Animal Models of Huntington’s Disease 
Since the discovery of the mutant gene which causes HD (MacDonald et al. 
1993), a vast range of animal models of HD have now been developed which 
include non-mammalian organisms such as; Caenorhabditis elegans (Faber et 
al. 1999; Parker et al. 2001), Drosophila melanogaster (Jackson et al. 1998; 
Warrick et al. 1998; Lee et al. 2004) and Danio rerio (Karlovich et al. 1998; 
Schiffer et al. 2007). In addition numerous mammalian models of HD have been 
developed including; mice (Mangiarini et al. 1996; White et al. 1997; Reddy et 
al. 1998; Schilling et al. 1999; Wheeler et al. 1999; Yamamoto et al. 2000; 
Laforet et al. 2001; Lin et al. 2001; Menalled et al. 2003; Slow et al. 2003; Slow 
et al. 2005; Gray et al. 2008; Menalled et al. 2012; Cheng et al. 2013), rats (de 
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Almeida et al. 2002; von Hörsten et al. 2003; Yu-Taeger et al. 2012), pigs (Yang 
et al. 2010), sheep (Jacobsen et al. 2010) and monkeys (Palfi et al. 2007; Yang 
et al. 2008). Each of these animal models of HD has its own particular merits for 
modelling different aspects of the disease, however the focus of this thesis is on 
murine models of HD, of which there are great number.  
1.6.1. Lesion Rodent Models of Huntington’s Disease 
The first mouse models of HD were lesions models, where mice were given 
excitotoxic lesions of the striatum (Coyle and Schwarcz 1976; Sanberg et al. 
1989; Borlongan et al. 1995) to investigate the functional role of the striatum in 
HD. Lesion models were generated by administration of either kainic (Coyle and 
Schwarcz 1976; Sanberg et al. 1978), ibotenic (Schwarcz et al. 1979) or 
quinolinic (Schwarcz et al. 1983) acids into the striatum, thus causing the 
apoptotic death of cells within the striatum (DiFiglia 1990).  
Arguably the most valid rodent lesion models were lesioned with quinolinic acid 
(QA) which caused the relatively specific apoptotic cell death of medium spiny 
neurons (MSNs) within the striatum with comparatively little effect on the giant 
cholinergic interneurons of the striatum (Schwarcz et al. 1983; Beal et al. 1988). 
Furthermore, the motor abnormalities demonstrated in late stage HD patients 
were replicated in these lesion models (Schwarcz et al. 1983; Beal et al. 1988; 
Ma et al. 2012). Classical lesion models of HD have substantially increased our 
understanding into the role of the corticostriatal pathway and the striatum in HD; 
they produce a rapid behavioural phenotype which allows the efficient validation 
of both novel behavioural tests and potential therapeutics. Although elegant in 
their nature, lesion models do not produce consistent results that accurately 
reflect the genetic basis and thus the progressive and gradual nature of HD, as 
seen in human patients. 
1.6.2. Genetic Mouse Models of Huntington’s Disease 
Once the mHTT gene that causes HD had been identified (MacDonald et al. 
1993) attempts to create genetic models of HD that mimicked the human 
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condition in terms of expressing mHTT in the appropriate proteomic and 
genomic context were undertaken. The first mouse models created to investigate 
the effect of HTT in HD were knock-out models which demonstrated embryonic 
lethality (Duyao et al. 1995; Nasir et al. 1995). These results indicated the 
importance of the wild type huntingtin protein (Htt)  in early embryonic 
development (Reiner et al. 2003) although they did not increase our 
understanding of how mutant huntingtin protein (mHtt) causes HD. Therefore, 
in order to assess the effect of HTT in HD, it was necessary to further manipulate 
the huntingtin gene to produce more genetically modified animals which are 
more reflective of the human condition. Although a large number of transgenic 
mouse models of HD have been created, comparatively few transgenic rat 
models of HD have been produced (Table 1.1.). 
1.6.2.1 Rat Models of Huntington’s Disease 
The first rat model of HD was produced using lenitviral vectors that coded for 
the partial amino acid sequences of either HTT or mHTT (including a range of 
CAG repeat sizes) which were driven by endogenous rat promoters.  The 
lentiviral vectors were injected bilaterally into the striatum of the adult rat (de 
Almeida et al. 2002). Ubiquitinated mHHT aggregates were first seen 1 week 
after the lentiviral vector injection; these progressively worsened over a 12 week 
period. In addition, decreased dopamine expression and cell death were shown 
within the rat striatum over the course of the 12 week study. The molecular and 
histological analysis of the lentiviral vector model of HD demonstrated that 
many hallmarks of HD were present.  However, the rapid nature and appearance 
of the neuropathology including aggregate formation shown in this viral model 
is not fully reflective of the progressive nature of the human disease. Therefore, 
genetically modified rat models which express the transgene for HD were 
produced to perhaps more accurately replicate the progressive nature of the 
disease.  
A transgenic rat model of HD (tgHD) was successfully created that contained 
the human mutation with 51 CAG repeats (von Hörsten et al. 2003). This model 
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demonstrated cognitive impairments of spatial memory on the radial arm maze 
at 10 months of age, decreased anxiety in the elevated plus maze from 2 months 
of age and motor dysfunction on the rotarod at 10 months of age (von Hörsten 
et al. 2003). In addition, neuropathology was indicative of HD including; striatal 
shrinkage and enlarged lateral ventricles at 8 months of age (von Hörsten et al. 
2003). Others have also shown early cognitive dysfunction in a range of tasks 
including operant choice reaction time tasks, spatial operant reversal and object 
recognition and recall tasks (Cao et al. 2006; Fink et al. 2012; Zeef et al. 2012a; 
Zeef et al. 2012b) and motor deficits including hyperkinetic behavior (Zeef et 
al. 2012b) and abnormal locomotor activity in open field (Cao et al. 2006). 
However, variable results have been obtained in this model, with only subtle but 
progressive cognitive deficits demonstrated in female rats on response accuracy 
and response time in the operant serial implicit learning task (SILT) (Brooks et 
al. 2009). In addition, another study using both male and female rats showed 
only modest motor deficits on the rotarod and inconsistent cognitive 
impairments on the water T-maze test of reversal learning (Fielding et al. 2012). 
However, these apparent differences demonstrated in the behaviour of TgHD rat 
may be attributable to sex differences which have been highlighted previously 
(Bode et al. 2008). 
Another transgenic rat model, the BACHD rat, was originally developed by Yu-
Taeger et al, as a model of HD. The model was generated using a human 
bacterial artificial chromosome (BAC) that contained the full length mHTT with 
a 97 CAG/CAA repeat length, under the control of the associated human 
regulatory elements. The first description of the BACHD rat described a HD like 
phenotype with early and progressive motor deficits on the rotarod from 1 month 
of age, alterations in gait at 14 months of age and a clasping phenotype which 
was evident from 3 weeks of age (Yu-Taeger et al. 2012). In addition, altered 
anxiety like behaviour was observed in the elevated plus maze from 4 months of 
age and progressive mHTT aggregate formation was seen in both the cortex and 
striatum (Yu-Taeger et al. 2012). Hyperactivity was demonstrated in open field 
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at 1 month of age followed by hypoactivity from 4 months of age. Rotarod 
deficits were present at 2 months of age and additional gait abnormalities were 
observed at 12 months of age (Yu-Taeger et al. 2012). However, weight, novel 
object recognition and acoustic startle response were unchanged at all ages in 
comparison to wild type animals (Yah-se et al. 2013b). Additional cognitive 
testing on the BACHD rat indicated a lower freezing response upon re-exposure 
to foot shock, which may be indicative of problems with associative learning 
(Yah-se et al. 2013a). Reversal learning deficits were shown in a cross maze task 
at 6 months of age and deficits in contextualised fear conditioning were evident 
from 4 months of age (Yah-se et al. 2013a). Therefore, in comparison to the 
transgenic rat models of HD described, the vast range of transgenic mouse 
models of HD that are available appear to produce more reproducible results. 
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Table 1.1. Rat Models of Huntington’s Disease - There is a range of HD rat models available for the study of HD. Initially virus vectors were used in the production of rat 
models and then genetically modified rat models were created. *CMV= cytomegalovirus, #PGK = phosphoglycerate kinase.   
Rat 
Model 
CAG repeat 
length 
Background Construct Promoter Life span Motor deficits 
Cognitive 
deficits 
Neuropathology 
Lenti-viral 
(de Almeida 
et al. 2002) 
44, 66 and 82 Wistar 
Lentiviral- mediated 
delivery of mHTT injected 
into the striatum, under 
control of endogenous 
mouse promoter. 
Mouse 
PGK# and 
CMV* 
Unknown – 
study conducted 
up until 12 
weeks of age. 
Not reported Not reported 
Aggregate formation 1 week 
after injection, reduction in 
dopamine levels and cell 
death (de Almeida et al. 
2002). 
tgHD 
(von 
Hörsten et 
al. 2003) 
51 Sprague Dawley 
Rat cDNA fragment under 
control of the rat 
endogenous promoter. 
Rat 
huntingtin 
24 months 
Rotarod (von Hörsten et al. 2003). 
Open field (Cao et al. 2006). 
Hyperkinetic locomotor activity 
(Zeef et al. 2012b). 
SILT (Brooks et al. 2009) 
Spatial memory (von 
Hörsten et al. 2003). 
Decreased anxiety 
(von Hörsten et al. 
2003). 
Choice reaction time 
task (Cao et al. 2006). 
mHtt aggregates and 
inclusions at 18months of 
age (de Almeida et al. 
2002). 
BACHD 
(Yu-Taeger 
et al. 2012) 
97 CAG/CAA Sprague Dawley 
Replacement of exon 1 
with human BAC full 
length mHTT sequence 
including 97 CAG/CAA 
repeats under control of 
associated human 
regulatory elements 
Human 
huntingtin 
Unknown – 
characterised up 
until 72 weeks of 
age 
Rotarod, gait abnormalities, 
hypoactivity and clasping (Yu-
Taeger et al. 2012; Yah-se et al. 
2013b). 
 
Anxiety alterations 
(Yu-Taeger et al. 
2012). 
Associative learning 
and reversal learning 
problems (Yah-se et 
al. 2013a) 
Wide distribution of 
aggregate formation 
throughout the brain at 12 
months (Yu-Taeger et al. 
2012) 
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1.6.2.2. Transgenic Mouse Models of Huntington’s Disease 
The first genetically modified mouse models of HD produced were transgenic 
models, which contained either the full length or a fragment of exon 1 of human 
HTT randomly integrated into the murine genome (Menalled and Chesselet 
2002). A range of transgenic mouse models of HD have now been created (Table 
1.2.), which demonstrate different genetic constructs and manipulations, thus 
producing different behavioural and neuropathological phenotypes. 
The first successfully generated transgenic mouse models of HD were termed 
the R6 lines, which included R6/0, R6/T, R6/1, R6/2, and R6/5 (Mangiarini et 
al. 1996). These lines carried a fragment of mHTT exon 1 randomly integrated 
into the murine genome, thus endogenous and mutant proteins were both 
expressed. Of the five R6 lines originally generated (Mangiarini et al. 1996) the 
R6/1 and R6/2 lines have been most widely studied and utilised in HD research 
(Mangiarini et al. 1996; Carter et al. 1999; Hurlbert et al. 1999; Lione et al. 
1999; Bolivar et al. 2004; Mazarakis et al. 2005; Stack et al. 2005; Lazic et al. 
2007; Hodges et al. 2008; Brooks et al. 2012f). 
The R6/1 transgenic mouse model (Mangiarini et al. 1996) produces a subtle 
phenotype, relative to the R6/2 model, due to the comparatively shorter CAG 
repeat length (~115 rather the ~145 of the R6/2). Although symptoms still 
develop relatively early including; motor deficits on rotarod by 8 weeks of age 
(Brooks et al. 2012g), hypoactive locomotor activity (Hodges et al. 2008), 
clasping (Naver et al. 2003), alterations in gait and deficits in coordination as 
demonstrated on balance beam (Brooks et al. 2012f). Acoustic startle response 
pre-pulse reactivity deficits have been reported at 12 weeks of age, (Brooks et 
al. 2012g) as has, weight loss by 12 weeks of age (Brooks et al. 2012f). 
Cognitive deficits have previously been demonstrated in; reference memory in 
the Morris water maze (Brooks et al. 2012f), tests of exploratory behaviour 
(Bolivar et al. 2004; Hodges et al. 2008) and  tests of sensory discrimination 
(Mazarakis et al. 2005). 
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The R6/2 mouse model has been extensively studied and demonstrates a severe 
and aggressive phenotype with motor deficits detectable as early as 5 weeks of 
age (Mangiarini et al. 1996; Carter et al. 1999; Stack et al. 2005). Cognitive 
deficits are also demonstrated in reversal learning in the water T-maze and fear 
conditioning tasks (Lione et al. 1999). Other developmental abnormalities 
quickly develop including; weight loss, diabetes (Hurlbert et al. 1999), increased 
metabolism (van der Burg et al. 2008) and seizures, resulting in an early death 
which typically occurs by 12 weeks of age (Mangiarini et al. 1996). A detailed 
study used MRI to correlate motor symptoms in the R6/2 mouse, with regional 
brain volume loss. MRI measurements indicated that rather than striatal atrophy, 
lack of striatal growth occurred from 8 weeks of age (Rattray et al. 2013).  
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Table 1.2. Transgenic Mouse Models of Huntington’s Disease  # The YAC128 is the most commonly used of this mouse line although others exist with shorter repeat lengths 
(Hodgeson et al)., NII = neuronal nuclear inclusions, *CMV= cytomegalovirus. 
Mouse Model 
CAG 
repeat 
length 
Background Construct Promoter 
Life 
span 
Motor deficits Cognitive deficits Neuropathology 
R6/1 
(Mangiarini et al. 
1996) 
116 CBA x C57BL/6J 
mHTT fragment 
including exon 1 and 
part of the first intron 
integrated into mouse 
genome. 
Human 
huntingtin 
30-40 
weeks 
Rotarod (Brooks et al. 
2012f), hyperactivity then  
hypoactivity, clasping, 
rearing and gait. 
(Naver et al. 2003). 
Exploratory behaviour (Bolivar 
et al. 2004), olfactory 
abnormalities (Lazic et al. 
2007) elevated plus-maze 
(Naver et al. 2003), sensory 
discrimination (Mazarakis et 
al. 2005) 
NII’s from 8 weeks of age 
(Hansson et al. 2001) 
R6/2 
(Mangiarini et al. 
1996) 
144 CBA x C57BL/6J 
mHTT fragment 
including exon 1 and 
part of the first intron 
integrated into mouse 
genome. 
Human 
huntingtin 
10-12 
weeks 
Rotarod, grip strength, 
clasping, weight loss, 
tremor, seizures and open 
field deficits. 
(Carter et al. 1999; 
Hurlbert et al. 1999; Stack 
et al. 2005; Cowin et al. 
2012; Rattray et al. 2013) 
Water T-maze, fear 
conditioning, visual cliff 
avoidance 
(Lione et al. 1999) 
Fear conditioning (Cowin et al. 
2012) 
Reduced brain weight (Davies 
et al. 1997) 
Reduced striatal volume 
(Hansson et al. 1999) 
NII’s at from 4 weeks of age 
(Morton et al. 2000; Meade et 
al. 2002) 
Age related loss of regional 
brain volumes (Rattray et al. 
2013)  
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Mouse Model 
CAG 
repeat 
length 
Background Construct Promoter 
Life 
span 
Motor deficits Cognitive deficits Neuropathology 
N171-82Q 
(Schilling et al. 
1999) 
82 
C3H/HEJX 
C57Bl/6J 
mHTT fragment 
(longer than R6 lines) 
including exon 1 and 
part of the first intron 
integrated into mouse 
genome. 
Mouse prion 
protein 
20-40 
weeks 
Rotarod deficits (Klivenyi 
et al. 2006). 
Morris water maze deficits in 
latency to find platform (Potter 
et al. 2010) 
NII’s at 11 months 
(Schilling et al. 1999) 
YAC128# 
(Slow et al. 2003). 
 
128 FVB/N 
Complete mHTT gene 
integrated into mouse 
genome. 
Human 
huntingtin 
Up to 27 
months 
Motor abnormalities on 
rotarod and open field 
(Menalled et al. 2003; Van 
Raamsdonk et al. 2005). 
Water T-maze set shifting 
procedure (Brooks et al. 
2012e). 
Depressive like behaviour 
(Pouladi et al. 2009) operant 
deficits in SILT (Brooks et al. 
2012h). 
Decreased brain weight and 
striatal volume from 9 months, 
decrease in cortical volume 
from 12 months. Diffuse mHTT 
staining at 12 months but no 
inclusions (Slow et al. 2003). 
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Mouse Model 
CAG 
repeat 
length 
Background Construct Promoter Life span Motor deficits Cognitive deficits Neuropathology 
Hu97/18 (Southwell et al. 
2013) 
97 FVB/N 
Fully humanised 
transgene, one 
transgene is 
expanded and 
the other is wild 
type therefore 
the model is 
heterozygous. 
Human 
huntingtin 
gene 
Unknown – 
study 
conducted 
until 12 
months of 
age. 
Motor deficits on Rotarod 
from 2 months of age 
(although this is not 
demonstrated 
longitudinally). Decrease in 
repetitive movements and 
jumping from 2 months of 
age.(Southwell et al. 2013). 
 
Motor learning deficit in 
Rotarod. 
Spatial learning deficits in 
novel object recognition. 
Anxiety in open field and 
elevated plus maze and 
depressive like behaviour 
in forced swim task. 
(Southwell et al. 2013) 
Reduced cortical and 
striatal volume at 12 
months of age. (Southwell 
et al. 2013). 
Progressive synaptic 
dysfunction and altered 
plasticity from 9 months of 
age (Kolodziejczyk et al. 
2014) 
Ubi-G-HTT84Q (Cheng et 
al., 2013) 
84 FVB/N 
N-terminal 
fragment of 
mHTT fused to 
EGFP 
Human 
ubiquitin 
promoter 
Study 
conducted 
until 13 
months – 
terminated 
due to ill 
health 
Clasping from 8.5 months, 
gait and rotarod deficits at 
13 months (Cheng et al., 
2013).  
None reported 
NII’s at 12 months of age 
(Cheng et al, 2013) 
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Another transgenic mouse model of HD, the YAC (yeast artificial chromosome) 
mouse model expresses the full length mHTT gene, therefore the mHTT is under 
the control of human regulatory elements. A variety of YAC models have been 
created with different CAG repeat lengths (Hodgson et al. 1999), although the 
most widely utilised model is the YAC128, containing 128 CAG trinucleotide 
repeats (Slow et al. 2003). The YAC128 model has been shown to have cognitive 
deficits in set shifting strategy and changing between rules (Van Raamsdonk et 
al. 2005; Brooks et al. 2012e) as well as reversal learning deficits in the water 
T-maze (Van Raamsdonk et al. 2005) and a depressive like behaviour in the 
forced swim test (Pouladi et al. 2009). Abnormalities of motor ability including 
hypoactivity (Menalled et al. 2003; Van Raamsdonk et al. 2005) and a decreased 
latency to fall from the rotarod (Menalled et al. 2003; Van Raamsdonk et al. 
2005; Pouladi et al. 2012) have also been demonstrated at 8 weeks of age. Less 
pre-pulse inhibition in response to acoustic startle at 52 weeks of age has also 
been observed (Van Raamsdonk et al. 2005). Although, others have reported no 
significant differences in pre-pulse inhibition testing (Menalled et al. 2003), 
although these observed differences may well be due to differences in 
background strain.  
Although a range of deficits including; motor, cognitive and psychiatric have 
been described in the YAC128 mouse model, some longitudinal studies have 
suggested that behavioural deficits do not worsen over time (Menalled et al. 
2003; Van Raamsdonk et al. 2005) The YAC128 model has a relatively long life 
span of 108 weeks (Slow et al. 2003). The behavioural differences observed may 
be attributable to differences in background strain. A behavioural 
characterisation of the YAC128 mouse model across different background 
strains has shown that although YAC128 mice on all background strains 
(FVB/N, 129 and C57BL/6) develop motor and cognitive deficits significant 
differences in the degree of deficit are observed in YAC128 mice of different 
background strains on rotarod and open field tests as well as differences in 
weight and total striatal volume (Van Raamsdonk et al. 2007). 
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The N171-82Q transgenic mouse model (Schilling et al. 1999) contains a 
truncated mHTT gene which encodes the first 171 amino acids of the mutant 
protein; this model has a similar life span as the R6/1 model and develops similar 
motor deficits on the rotarod at 12 weeks of age (Schilling et al. 1999; Klivenyi 
et al. 2006). Although motor impairments have been demonstrated, cognitive 
deficits within this mouse model have not been widely reported. But, decreased 
latency to locate the platform in a Morris water maze has been shown (Potter et 
al. 2010), which is reflective of episodic memory deficits. However, the N171-
82Q mouse model has been used in a range of studies investigating possible 
therapeutic treatments for HD (Andreassen et al. 2001; Schilling et al. 2001; 
Gardian et al. 2005; Duan et al. 2008). 
The BACHD (bacterial artificial chromosome) mouse model (Gray et al. 2008) 
is a conditional model of HD which, similar to the BACHD rat model described 
earlier (Yu-Taeger et al. 2012), contains 97 trinucleotide repeats of both CAG 
and CAA. Motor deficits have been demonstrated on the accelerating rotarod as 
early as 8 weeks of age (Pouladi et al. 2012; Yah-se et al. 2013c) as have deficits 
in motor coordination (Abada et al. 2013). In addition, cognitive deficits in set 
shifting, fear conditioning (Abada et al. 2013) and startle response (Pouladi et 
al. 2012) have been described. Furthermore, a depressive like behaviour has 
been shown in the forced swim test (Pouladi et al. 2012) as has anxiety like 
behaviour in a zero maze test. The BACHD mouse model has a life span of up 
to 72 weeks (Gray et al. 2008). In addition, this mouse model demonstrates a 
clear obese phenotype from as early on as 2 months of age (Gray et al. 2008), 
which may contribute to the observed phenotypic differences. An obese 
phenotype is not evident in HD patients. Therefore, this unusual obese 
phenotype may have an inadvertent effect on task performance. Kudwa et al, 
elegantly studied the obese phenotype of BACHD mice and the effect that this 
had on behavioural tasks using food restricted and non-restricted BACHD mice. 
They found that increased body weight accounts for some, but not all, of the 
observed HD like behaviour in BACHD mice, specifically the hypoactive 
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phenotype observed in open field testing (Kudwa et al. 2013). Therefore, the 
obese phenotype observed in the BACHD mouse may inadvertently inflate the 
degree of difference observed between BACHD mice and controls in 
behavioural tests.  
In addition to the transgenic mouse lines described above, which have been 
extensively characterised, a number of additional HD mouse lines have been 
described in the literature, although the volume of research conducted on these 
mouse lines is comparatively limited.  
The short stop model of HD was serendipitously discovered while generating 
YAC128 mice (Slow et al. 2005). This specific mouse line was discovered to 
have a truncation 3’ of the CAG repeat tract and therefore it expressed a 
shortened fragment of the HTT gene, resulting from a premature stop codon. 
Progressive formation of NII’s was found from 3 months of age in the striatum, 
cortex and hippocampus of these animals. Behaviorally, no rotarod deficits were 
demonstrated at 12 months of age. Furthermore, short stop mice did not exhibit 
neuronal degeneration, as there were no differences in overall brain weight, 
striatal volume or overall number of neurons, at 12 or 18 months of age. In 
addition, short stop mice were shown to be resistant to NMDA-induced 
excitotoxicity, when they were given bilateral striatal injections of the NMDA 
receptor agonist QA (Slow et al. 2005). Therefore, despite the formation of NII’s 
from as early as 3 months of age, this mouse line does not present with the 
behavioural problems or neurodegeneration which is demonstrated in HD.  
The HD48 and HD89 mouse lines (Reddy et al. 1998) contain the full length 
human mHTT under the control of the endogenous cytomegalovirus (CMV) 
promoter. Motor deficits including alterations in clasping and hyperkinetic 
followed by hypokinetic behaviour have been described (Reddy et al. 1999). In 
addition, NII’s have also been demonstrated in the striatum (Reddy et al. 1999). 
Both the HD46 and HD100 mouse lines originally described by Laforet et al. 
2001, expressed the N-terminal fragment of mHTT under the control of 
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endogenous neuronal specific endolase. These animals demonstrated 
progressive motor deficits on rotarod, deficits in clasping behavior, alterations 
in gait and locomotor activity from 3 months of age (Laforet et al. 2001). NII’s 
were found predominantly in the striatum and also in cortical layers 2/3, 5 and 
6, diffuse staining was also significantly greater in the striatum in comparison to 
the cortex. Alterations in the electrophysiology of striatal neurons were evident 
with NMDA current densities significantly larger in transgenic animals in 
comparison to wild type animals (Laforet et al. 2001). 
The HD94-Tet regulated mouse model of HD expresses 94 CAG repeats under 
the control of a CamkIIa tetracycline regulated promoter (Yamamoto et al. 
2000). Motor problems including hind limb clasping at 8 weeks of age and a full 
body clasp at 28 weeks of age have been described and in addition, a hypoactive 
phenotype in open field was noted at 36 weeks of age (Yamamoto et al. 2000). 
NII formation in the striatum has been demonstrated from 8 weeks of age, as 
have a decrease in striatal volume and an increase in ventricle size (Yamamoto 
et al. 2000).  
The Hu97/18 mouse line, generated by Southwell and colleagues (2013), is the 
first transgenic mouse model of HD that possesses both HTT genes that are fully 
humanised. The mutation is heterozygous and therefore the model carries one 
mHTT gene containing 97 CAG repeats and another HTT gene with 18 CAG 
repeats (Southwell et al. 2013). Hu97/18 mice demonstrated increased body 
weight in comparison to Hu18/18 animals from 4 months, a similar finding to 
that observed in BACHD mice (Gray et al. 2008). No significant difference was 
demonstrated in latency to fall from the rotarod in Hu97/18 mice in comparison 
to Hu18/18 mice, over a 12 month time period, although the ability to initially 
learn the task at 2 months of age was significantly impaired (Southwell et al. 
2013) . Locomotor activity was the same in both genotypes over a 12 month 
period, although Hu97/18 mice were observed performing increased repetitive 
movements and decreased jumping at both 2 and 4 months of age. Increased 
anxiety was demonstrated by fewer entries into the centre of the field in 
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comparison to Hu18/18 animals at 3 months of age, and by less time spent in the 
arms of the elevated plus maze and 3 and 6 months of age (Southwell et al. 
2013). A depressive behavior was also observed at 12 months of age in the forced 
swim test. Finally, cognitive deficits in spatial learning were demonstrated in a 
novel object recognition task at 6 and 9 months of age and object recognition 
deficits at 9 months of age. Reduced striatal and cortical volumes were both 
demonstrated, although there was a trend in reduction of DARPP-32 staining in 
the corpus callosum, it did not reach significance (Southwell et al. 2013).    
The Ubi-G-HTT84Q mouse model of HD is a newly generated mouse model 
which contains GFP fused with exon 1 of human mHTT with 84 CAG repeats, 
under the control of the human ubiquitin promoter (Cheng et al. 2013). Clasping 
behavior was observed from 8.5 months of age, as was decreased latency to fall 
from the rotarod and gait abnormalities were evident at 13 months of age (Cheng 
et al. 2013). In addition, NII’s were observed in the striatum and cortex at 12 
months of age (Cheng et al. 2013).  
Transgenic HD mouse models have been used in the development and validation 
of a range of behavioral tasks and therapeutic studies due to their rapidly 
progressing and relatively severe phenotype. However the rapid disease 
progression demonstrated in transgenic mouse lines does not accurately mimic 
the human condition. In addition, the random integration of the mHTT gene into 
the murine genome means that both endogenous and mutant huntingtin genes are 
expressed, which is not the case in the human condition. In order to overcome 
these issues with transgenic mouse lines, numerous genetically modified knock-
in mouse models have been created in which the mutant gene is specifically 
targeted into the murine genome. 
1.6.2.3. Knock-in Mouse Models of Huntington’s Disease 
After the successful results gained from transgenic mouse models of HD, knock-
in mouse models were developed (Table 1.3.) in an attempt to more accurately 
represent the human disease. Knock-in models contain the mutant gene targeted 
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into the endogenous mouse Htt, therefore the mutant protein is expressed in its 
appropriate proteomic and genomic context. The generation of knock-in rodent 
models of HD has largely been limited to mice due to the extensive mouse 
genetic toolbox which is available; whereas the development of a similar genetic 
toolbox for rats has been slower, with only recent advances in germline 
competent rat ES cell lines (Buehr et al. 2008; Li et al. 2008) and zinc finger 
nucleases (Geurts et al. 2010; Cui et al. 2011; Huang et al. 2011) which are 
required for complex genetic manipulations.  
A large range of knock-in mouse models have now been created (Menalled 
2005). The behavioural results observed in knock-in mouse models initially 
proved disappointing as they did not show the aggressive and overt motor 
deficits first detected in the R6/2 transgenic model (Mangiarini et al. 1996). 
However, additional testing revealed knock-in models typically develop subtle 
early behavioural phenotypes which gradually worsen (White et al. 1997; 
Wheeler et al. 1999; Menalled et al. 2003; Heng et al. 2010). Early behavioural 
abnormalities have now been demonstrated across a range of knock-in models 
(Table 1.3) (Van Raamsdonk et al. 2005; Trueman et al. 2007; Trueman et al. 
2012e) and are thought to resemble the pre-symptomatic stages of HD. The 
severity of both motor and cognitive symptoms generally correlates with the 
number of CAG repeats contained within the mouse model (Lin et al. 2001). 
The HdhQ50 mouse model originally described by White et al., 1997 contained a 
chimeric insertion of 48 CAG repeats into the endogenous mouse HTT gene, 
which are under the control of the endogenous mouse promoter. However, no 
overt behavioural abnormalities have been described in motor, cognitive or 
psychiatric tasks in comparison to wild type animals.  
The Hdh71 and Hdh94 mouse lines were generated by Menalled et al., (2000). 
Both mouse lines contains a targeted chimeric insertion of either 71 or 94 CAG 
repeats into exon 1, of the mouse HTT gene. No abnormal phenotype was 
observed in the either of the mouse lines in clasping or weight loss at 3 months 
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of age (Menalled et al. 2000). No cognitive deficits have yet been reported. 
Immunohistochemistry for substance P and enkephalin was performed but 
reductions were only found in Hdh94 animals at 8 months of age (Menalled et al. 
2000). 
The HdhQ92 mouse model originally created by Wheeler and colleagues 
(Wheeler et al. 1999) has been extensively studied by Trueman et al in 
homozygous (HdhQ92/Q92) animals. This mouse model has a range of cognitive 
deficits on 9-hole box operant tests, including deficits in the serial implicit 
learning task (SILT), that probes learning and attention, as young as 16 weeks 
of age (Trueman et al. 2007), although the observed deficit is not progressive 
with age (Trueman et al. 2008b). Deficits were observed in the five choice serial 
reaction time task (5-CSRTT), in measures of attention and reaction time, at 16 
weeks of age (Trueman et al. 2012b). Further deficits were observed in the 
delayed alternation operant task, a test of working memory, at 20 weeks of age 
(Trueman et al. 2012e) and the progressive ratio operant task of motivation 
(Trueman et al. 2009b) at 108 weeks of age. In addition, cognitive impairments 
of spatial working memory have also been demonstrated in non-operant tasks 
including the Morris water maze (Brooks et al. 2012c) from 16 weeks of age. 
Motor impairments have been demonstrated in the HdhQ92 mouse line in a range 
of tests including; increased locomotor activity in open field, decreased latency 
to fall from the rotarod, reduced grip strength and prepulse inhibition in acoustic 
startle from 16 weeks of age (Trueman et al. 2009b; Brooks et al. 2012c). 
Immunohistological analysis revealed very specific neuropathology with dense 
NII formation in the striatum, the piriform cortex and the olfactory tubercle at 4 
months of age which progressively worsened over time (Bayram-Weston et al. 
2012b).   
The HdhQ111 mouse model is the subject of this thesis. The original HdhQ111 
mouse model of HD was generated on a CD1 background and contained a 
chimeric genetic alteration which targeted the human polyglutamine expansion 
into the endogenous murine Htt gene. This resulted in the majority of exon 1 and 
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part of intron 1 being replaced with human DNA containing ~111 CAG repeats, 
under the control of the endogenous murine promoter (Wheeler et al. 1999) as 
shown in Figure 1.4.  
 
Figure 1.4. Schematic representation of the genetic construct contained within 
the HdhQ111 mouse model. Mouse endogenous gene is indicated in green and the 
inserted human construct is indicated in blue, it contains the whole of exon 1 and part 
of the first intron. Adapted from Wheeler et al., 1999.  
 
Early behavioural data from HdhQ111 mice on a CD1 background revealed only 
subtle differences in gait at 24 months of age (Wheeler et al. 2002b), although 
these results were demonstrated in both homozygous (HdhQ111/Q111) and 
heterozygous animals (HdhQ111/+). Furthermore, decreased latency to fall from 
the rotarod at 100 weeks of age and weight loss beginning at 28 weeks of age 
have also been demonstrated (Menalled et al. 2009). However, no significant 
differences were observed in comparison to wild type animals in terms of; 
locomotor activity, grip strength, rear climbing, gait, light-dark choice test or 
prepulse inhibition (Menalled et al. 2009). Anxiety like behaviour has been 
demonstrated in only male HdhQ111 mice on a CD1 background in a range of 
tests including; splash test, forced swim test, open field and novelty suppressed 
feeding at 13 weeks of age (Orvoen et al. 2012). NII’s have been demonstrated 
in the striatum of HdhQ111 animals at 10 months of age (Wheeler et al., 2000). 
Some limited studies have been performed in HdhQ111 mice on a C57BL/6J 
background. Long terms memory deficits were observed in novel object 
recognition and in spatial memory in the Morris water maze task, however this 
study only used male animals (Giralt et al. 2012). 
The first description of the HdhQ140 mouse line demonstrated initial hyperactivity 
in locomotor activity analysis and increased rearing, followed by hypoactivity 
by 16 weeks of age and gait abnormalities at 52 weeks of age (Menalled et al. 
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2003). Since the original description of the HdhQ140 mouse line Hickey et al., 
2008 extended the characterisation of the mouse line demonstrating a range of 
motor abnormalities including; reduced climbing, decreased latency to fall from 
the rotarod and reduced running wheel performance from 6 weeks of age. In 
addition, increased anxiety was shown in a light dark box, as was an increase in 
fear conditioning response from 16 weeks of age (Hickey et al. 2008). 
Furthermore, Rising et al, (2001) confirmed that motor deficits were seen in this 
mouse model in increased rearing frequency and decreased latency to fall from 
the rotarod, although these deficits were not progressive over time. NII’s were 
demonstrated in both the striatum and cortex from 6 months of age which 
progressively worsened over time (Rising et al. 2011).  
The original characterisation of the HdhQ150 mouse line showed motor and gait 
abnormalities from 25 weeks of age as well as reactive gliosis and intranuclear 
inclusion formation in the striatum, indicative of HD pathology in human 
patients (Lin et al. 2001). Further studies on this mouse line have confirmed a 
HD phenotype. Woodman et al., 2007 used a modified SHIRPA (Smith Kline 
Beecham Harwell Imperial College Royal London 
Hospital phenotype assessment) test to assess the behavioural phenotype of 
HdhQ150 mice up to 72 weeks of age. Animals appeared normal until 60 weeks 
of age when poor grooming, increased anxiety, aggression and irritability were 
observed. At 88 weeks of age HdhQ150 animals exhibited no fear response and 
were unkempt, in comparison to wild type littermates, the authors compare the 
phenotype of these animals to transgenic R6/1 mice at 36 weeks of age. 
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Table 1.3. Knock-in Mouse Models of Huntington’s disease. *This mouse line will be the subject of this thesis, NII’s = neuronal nuclear 
inclusions. 
Mouse Model 
CAG repeat 
length 
Background Construct Promoter Life span Motor Deficits Cognitive Deficits Neuropathology 
HdhQ50 
(White et al. 1997) 
48 129/CD1 
Chimeric 
human/mouse exon 
1 inserted into the 
murine Htt gene. 
Endogenous 
mouse 
mHTT 
Normal 
No observed 
deficits (White et 
al. 1997) 
None reported 
No abnormalities 
reported  
Hdh71 
(Menalled et al. 2000) 
71 129SvXC57BL/6J 
Chimeric 
human/mouse exon 
1 inserted into the 
murine Htt gene. 
Endogenous 
mouse 
mHTT 
Normal 
None observed 
(Menalled et al. 
2000) 
None reported 
No significant 
differences reported 
(Menalled et al. 2000) 
HdhQ92 
(Wheeler et al. 1999) 
90 129/CD1 
Chimeric 
human/mouse exon 
1 inserted into the 
murine Htt gene. 
Endogenous 
mouse 
mHTT 
Normal 
Rotarod and open 
field 
(Trueman et al. 
2009b). 
Operant: Delayed alternation 
(Trueman et al. 2012e), and 
SILT (Trueman et al. 2007, 
2008b). 
Progressive NII 
formation from 4 
months of age in the 
striatum and olfactory 
tubercle (Bayram-
Weston et al. 2012). 
NII formation from 12 
months of age 
(Wheeler et al. 2000) 
Hdh94 
(Menalled et al. 2000) 
94 129SvXC57BL/6J 
Chimeric 
human/mouse exon 
1 inserted into the 
murine Htt gene 
Endogenous 
mouse 
mHTT 
Normal 
None found 
(Menalled et al. 
2000) 
None reported 
Reduced enkephalin 
mRNA at 8 monthsof 
age (Menalled et al. 
2000).  
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Mouse Model 
CAG 
repeat 
length 
Background Construct Promoter 
Life 
span 
Motor Deficits Cognitive Deficits Neuropathology 
HdhQ111 
(Wheeler et al. 1999)* 
 
109 129/CD1 
Chimeric 
human/mouse exon 
1 inserted into the 
murine Htt gene. 
Endogenous 
mouse 
mHTT 
Normal 
Mild reduction in startle 
(Menalled et al. 2009) 
Increase in anxiety reported on a CD1 
background  (Orvoen et al. 2012). 
Long term memory deficits (Giralt et al. 
2012) 
NII’s from 10 months of 
age (Wheeler et al. 2000) 
HdhQ140 (Menalled et al. 
2003) 
140 C57/BL6 
Chimeric 
human/mouse exon 
1 inserted into the 
murine Htt gene. 
Endogenous 
mouse 
mHTT 
Normal 
Rotarod, open field and 
wheeling running (Hickey et 
al. 2008) 
Decrease in rearing, 
decreased latency to fall on 
rotarod. (Rising et al. 2011) 
Fear conditioning and anxiety (Hickey et 
al. 2008). 
 
 
NII’s in striatum from 6 
months of age (Rising et 
al. 2011) 
HdhQ150 
(Lin et al. 2001) 
150 C57/BL6 
Replacement of 
endogenous mouse 
CAG repeats with 
human CAG 
repeats. 
Endogenous 
mouse 
mHTT 
Normal 
Grip strength (Woodman et 
al. 2007) 
Rotarod and grip strength  
(Brooks et al. 2012d) 
Pre pulse inhibition 
Water maze task (Brooks et al. 2012d) 
Set shifting deficits (Brooks et al. 2006) 
NIIs from 25 weeks of age 
(Lin et al. 2001) 
HdhQ175  
(Menalled et al. 2012) 
188 C57/BL6 
Chimeric 
human/mouse exon 
1 inserted into the 
murine Htt gene 
 
Endogenous 
mouse 
mHTT 90 weeks 
Pre-seizure activity, body 
tremor, abnormal gait, limb 
splay (Heikkinen et al. 
2012), piloerection 
(Menalled et al. 2012), 
Rotarod, weight and gait 
deficits (Smith et al. 2014) 
Two- choice swim test (Heikkinen et al. 
2012).  
Circadian rhythm deficits (Loh et al. 2013). 
Decreased spontaneous alternation (Smith 
et al. 2014) 
Hyperexcitability in MSNs 
and attenuated glutamate 
transmission (Heikkinen et 
al. 2012). 
Axonal and synaptic 
protein alterations (Smith 
et al. 2014) 
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Mouse Model 
CAG 
repeat 
length 
Background Construct Promoter Life span Motor Deficits Cognitive Deficits Neuropathology 
HdhQ200 (Heng et al. 2010) 200 C57/BL6 
Replacement 
of endogenous 
mouse CAG 
repeats with 
human CAG 
repeats. 
Endogenous 
mouse mHTT 
Unknown – 
study 
conducted until 
80 weeks. 
Weight loss from 40 weeks, 
imbalance and co-
ordination deficits at 50 
weeks, gait deficits at 60 
weeks, hypoactivity, thin, 
grip deficits and poorly 
groomed at 80 weeks of 
age (Heng, 2010). 
None reported 
mHTT aggregate 
formation at 9 weeks of 
age, NII’s by 20 weeks 
(Heng et al. 2010) 
Hdh6/72 
(Shelbourne et al. 1999) 
72 C57/BL6/129 
CAG repeat 
insertion into 
exon 1 of 
endogenous 
mouse gene 
Endogenous 
mouse mHTT 
Normal None reported 
Increased aggression in the 
resident intruder task at 9-12 
months of age (Shelbourne et al. 
1999). 
Smaller brain weights at 
4-6 months of age. No 
other immunochemical 
changes observed 
(Shelbourne et al. 1999).  
Hdh4/80 
(Shelbourne et al. 1999) 
80 C57/BL6/129 
CAG repeat 
insertion into 
exon 1 of 
endogenous 
mouse gene 
Endogenous 
mouse mHTT 
Normal None reported 
Increased aggression in the 
resident intruder task at 9-12 
months of age (Shelbourne et al. 
1999). 
Smaller brain weights at 
4-6 months of age. No 
other immunochemical 
changes observed 
(Shelbourne et al. 1999). 
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In addition, Woodman et al. (2007) demonstrated motor abnormalities 
including; rotarod deficits at 72 weeks and grip strength deficits at 24 weeks of 
age in HdhQ150 animals. Furthermore, homozygous HdhQ150 animals showed 
cognitive impairments in spatial learning and navigation in the Morris water 
maze task at 16 weeks of age, abnormalities in acoustic startle and prepulse 
inhibition tests at 24 weeks of age, weight loss from 61 weeks of age and rotarod 
impairments from 84 weeks of age (Brooks et al. 2012d; Brooks et al. 2012g). 
Molecular investigations regarding the neurobiology of the HdhQ150 mouse line 
demonstrated an inverse correlation between soluble and aggregate mHtt 
fragments in the striatum from 3 to 8 months of age, after this time period the 
pool of soluble mHtt fragments remained constant (Marcellin et al. 2012). 
Furthermore, Young et al, demonstrated that HdhQ150 mice exhibited wide 
spread NII formation in the striatum, olfactory bulb, hippocampus and 
cerebellum, extra-nuclear aggregate formation was increased in the dentate 
gyrus and decreased levels of DARPP-32 were also shown (Young et al. 2013).  
The HdhQ175 (zQ175) mouse line has recently been developed and characterised 
(Menalled et al. 2012), this line demonstrates behavioural deficits in 
heterozygous animals from 4 weeks of age, including; hypoactivity in open field 
testing as young as 8 weeks of age, increased rearing at 8 weeks of age, decreased 
latency to fall from the rotarod at 30 weeks of age, and weight loss at 52 weeks 
of age. Behavioural deficits were found to be significantly greater in 
homozygous animals than in heterozygous animals when compared to wild type, 
in; reduced grip strength, decreased climbing ability, reduced cognitive ability 
in a discrimination reference memory two-choice swim task and overall 
decreased life span (Menalled et al. 2012). Additional testing on the zQ175  
mouse line performed by Heikkinen et al. (2012), confirmed the behavioural 
deficits previously demonstrated by Menalled et al. 2012 and extended the 
characterisation to include electrophysiological, morphological, volumetric, 
magnetic resonance imaging (MRI) and magnetic resonance spectroscopy 
(MRS) data. Similar deficits were demonstrated in both studies in open field 
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demonstrating reduced activity at 16 weeks of age, increased rearing frequency 
at 8 weeks of age (Heikkinen et al. 2012). In addition, electrophysiology data 
demonstrated hyperexcitability in the MSNs of zQ175 animals, attenuated 
glutamate transmission was also shown and MRI analysis revealed decreased 
whole brain, cortical and striatal volumes in comparison to wild type animals 
(Heikkinen et al. 2012).  
More, recently work on the zQ175 mouse line (Smith et al. 2014) has 
demonstrated altered gait at 1 month of age, decreased grooming and rotarod 
deficits at 6 months of age, decreases in spontaneous alternation and nest 
building capacity at 16 months of age and a failure to gain weight beginning at 
12 months of age (Smith et al. 2014). Molecular analyses revealed NIIs in the 
striatum which progressed from 6 months of age. In addition, selective neuronal 
vulnerability was demonstrated in the striatum and cortex, with decreased 
cortical and striatal volumes shown at 12 months of age. Finally, levels of the 
synaptic protein dynein were decreased in the striatum of zQ175 animals at 6 
months of age, cytoskeletal and axonal transport changes were seen at 12 months 
of age (Smith et al. 2014).   
HdhQ200 animals demonstrated perhaps the most severe neuropathology of all the 
knock-in mouse lines, with aggregate formation as young as 9 weeks of age, NII 
formation by 20 weeks of age and motor deficits at 50 weeks of age. (Heng et 
al. 2005). The severity of the phenotype is due at least in part to the length of the 
CAG repeat, which is under the control of the endogenous mouse promoter. 
Both Hdh4/80 and Hdh6/72 mouse lines were generated by Shelbourne et al. 1999. 
The knock in mouse lines generated contained 80 and 72 CAG repeats 
respectively, specifically targeted into exon 1 of the mouse endogenous HTT 
gene, under the control of the mouse endogenous promoter. Both groups of 
knock-in animals demonstrated significantly smaller brain weights at 4-6 months 
of age. Although no other abnormal immunohistochemical changes were found 
in terms of neuropathology. Increased aggression was demonstrated in male 
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knock-in animals in comparison to wild type animals, at 9 -12 months of age in 
the resident intruder task (Shelbourne et al. 1999). No motor abnormalities have 
yet been reported in these mouse lines. 
A large number of knock-in mouse models which recapitulate many of the 
symptoms of HD are available for use in scientific research (Table 1.3). 
However, these have been generated using different genetic constructs and on 
different background strains, which produce altered HD phenotypes. Therefore, 
in order to evaluate which mouse models to use in future research studies, the 
longitudinal phenotype of each mouse model must be characterised, considered 
and evaluated against other mouse models to determine which mouse model is 
the most appropriate for use.   
Previous work in the HdhQ92 mouse model demonstrated relatively selective 
neuropathology and robust but subtle behavioural changes in homozygous 
animals (Wheeler et al. 2000a; Trueman et al. 2007, 2008a; Trueman et al. 
2009a; Brooks et al. 2012b; Trueman et al. 2012a; Trueman et al. 2012d). The 
HdhQ111 mouse model contains a similar genetic construct to the HdhQ92 mouse 
model, although the CAG repeat length is expanded. Therefore, the HdhQ111 
mouse model was chosen as the subject of this thesis based on previous work in 
the HdhQ92 model and because a longitudinal behavioural analysis is yet to be 
performed in HdhQ111 animals. HdhQ111 animals were bred on to a C57BL/6J 
background as this background strain in more responsive to operant testing 
(unpublished data). In addition, the use of a C57BL/6 background strain allows 
comparison with other HD mouse models bred onto the same background.  
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1.7. Thesis Aims 
This thesis has the following aims;  
1) To understand the development of neuropathological and behavioural 
change in the HdhQ111 mouse model of HD. 
2) To determine the range and severity of phenotypic changes in the 
HdhQ111 mouse model and how these relate to other mouse models of 
HD and the human condition.   
3) To develop and test novel behavioural tasks for use in mouse models 
of neurological diseases, including HD. 
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Chapter 2 : Materials and Methods 
 
2.1. Animal Husbandry and Legislation  
For all experiments animals were group housed, although in some instances male 
animals had to be separated and singly housed to prevent fighting. All 
experiments were conducted in adult mice, the exact age of the mice used in 
testing is stated in the Materials and Methods section of each chapter. All animals 
were maintained on a 12 hour light/dark circadian schedule (06.00 hours lights 
on, 18.00 hours lights off), in a temperature controlled environment (21ºC ± 2ºC). 
Animals were given ad-libitum access to food and water unless otherwise stated. 
Animals were housed with one chew stick and cardboard tube per cage. Animals 
were weighed and health checked weekly, except when under food or water 
restriction, where daily health checks and weighing was required. All 
experiments were conducted in accordance with the United Kingdom Animals 
Scientific Procedures Act (ASPA) 1986. From 1st January 2013, the European 
Union (E.U.) Directive 2010/63/EU was implemented into UK law by an update 
of ASPA 1986. 
In the instances that C57BL/6J animals were used (for the experiments outlined 
in Chapter 7), these were obtained commercially, from Charles River (Margate, 
Kent, U.K.), at 6-8 weeks of age and tail marked with permanent marker to allow 
identification. HdhQ111 knock-in mice were originally obtained from Jax® (Bar 
Harbour, Maine, U.S.A.) and bred inhouse on a C57BL/6J background, typically 
using HdhQ111/+ and wild type pairings. After a minimum of 10 generations 
C57BL/6J animals were used to re-establish the colony and reduce the level of 
genetic variance. Animals were genotyped using standard PCR methods (see 
2.1.1). The number of CAG repeats present in the breeding colony had expanded 
since the original description (Wheeler et al. 2000a). HdhQ111/+ animals 
trinucleotide repeat length ranged from 125-145 CAG repeats (typically 
containing an average of 138 CAG repeats) on the affected allele. The CAG 
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repeat length in wild type animals and in the unaffected allele of HdhQ111/+ 
animals, was typically 7 CAG repeats. Litters were weaned, ear notched for 
identification purposes and tail tipped for genotyping. 
2.1.1. Genotyping  
Upon weaning, all HdhQ111 animals were tail tipped for genotyping purposes. 
Ethyl chloride anaesthetic spray (Vidant Pharma Ltd, Surrey, U.K.) was applied 
to the tip of the tail before removing a 1mm section. The tail was then cauterised 
with a silver nitrate pen and samples were collected in Eppendorf tubes. All 
samples were then shipped on dry ice to Laragen Inc. (Culver City, California, 
U.S.A). All genotyping was performed by Laragen Inc. using probe based qPCR 
to generate the length of the CAG repeat on both chromosomes and therefore the 
genotype of each individual animal.  
2.2. Behavioural Techniques 
2.2.1. Rotarod 
Rotarod testing was used to provide an overall assessment of motor co-
ordination and balance. Animals received 5 days of training on a rotarod 
apparatus (Ugo Basile, Model Number 47600, Varese, Italy), as shown in Figure 
2.1. Day 1 consisted of training with the rod accelerating from 5 revolutions per 
minute (rpm) to 24rpm. Training days 2 to 5 consisted of training with the rod 
accelerating from 5rpm to 44rpm. During the training period animals were put 
back onto the accelerating rod if they fell from the apparatus. Training sessions 
lasted a maximum of 300 seconds (5 minutes) each and were completed on 
consecutive days. Animals were then tested on the apparatus which consisted of 
2 trials (accelerating from 5rpm to 44rpm in a single session). The latency to fall 
from the rod was recorded for each trial following the activation of a button 
situated below the rotarod. The values from both trials were averaged to provide 
the rotarod latency statistic. If the mouse remained on the accelerating beam for 
whole 5 minute testing period, they were removed at the end of the testing 
session and given a score of 300 seconds.    
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Figure 2.1. Photograph of the rotarod apparatus used in behavioural testing. 
The rotarod was manufactured by Ugo Basile S.R.I. 47600, VA, Italy.  
2.2.2. Grip Strength 
Grip strength testing was used to determine motor function and the strength of 
the fore limbs and hind limbs. Animals were placed on a mesh grid (30cm x 
30cm) which had a wooden border. For testing, towels were placed under the 
apparatus to provide a comfortable landing surface. The grid was then inverted 
30cm above the bench by placing 4 wooden posts under the border of the grid, 
such that the mouse was suspended upside down on the under surface (Figure 
2.2). Latency to fall from the grid was recorded; the maximum time allowed per 
trial was 60 seconds. Each animal was tested twice on the same day, the times 
were averaged to provide the grip strength statistic.  
 
 
 
 
 
Figure 2.2. Photograph of the inverted grid used in grip strength behavioural testing. 
Photograph of the grip strength grid apparatus (30cm x 30cm) suspended on the wooden border 
of the grid using 4 posts such that the grid is raised 30cm above the bench. For testing, towels 
were placed underneath the apparatus.  
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2.2.3. Balance Beam 
Animals were tested on a balance beam apparatus (1m in length, 17º angle of 
ascent, with a 1.5cm to 0.5cm taper across the width) to determine motor co-
ordination and balance, as shown in Figure 2.3A. Animals were trained on the 
apparatus to encourage traversing of the beam to the ‘house’ box located at the 
high end. Training day 1 consisted of placing the mouse on the beam initially 
close to the ‘house’ box and then increasing the distances away from the ‘house 
box’ until the animal was at the start area of the beam. The mouse was then 
placed facing away from the ‘house’ box at the end of the beam (to allow turn 
time to be measured as a measure of motor coordination) and encouraged to turn 
around and fully traverse the beam, as shown in Figure 2.3B. The second day of 
training consisted of 2 trials where the animal was placed facing away from the 
‘house’ box and needed to turn around and traverse the beam to enter the ‘house’ 
box at the top. Testing was conducted by 2 consecutive trials which were 
videotaped to enable analysis. The animal was placed at the far end of the 
balance beam facing away from the ‘house’ box; the time taken to turn around 
and the time taken to traverse the beam were recorded. Between each trial mice 
were given 1 hour to recover before the next trial. While traversing the beam 
foot slips for the front and hind legs on each side were recorded, one side was 
live scored and the other video recorded to allow bilateral analysis. 
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Figure 2.3. Schematic representation of the balance beam apparatus used for testing and 
the associated training schedule. A. The balance beam apparatus was constructed from wood 
painted black, with a goal ‘house’ located at the top of the beam. 1m of the beam was used for 
testing, the beam was 17º from horizontal and towels were used to provide cushioning at the base 
on the apparatus. B. During training animals were initially placed at position 1 and encouraged 
to traverse the beam and enter the house located at the top. Mice were subsequently placed further 
down the beam (positions 2, 3, 4 and 5) and similarly encouraged to run along the beam to enter 
the house at the top. 
2.2.4. Spontaneous Automated Locomotor Activity 
Animals were placed in a clear Perspex cage (dimensions 40cm x 24cm x 18cm) 
on a metal rack through which 3 infrared beams were able to pass, crossing the 
base of each cage, as shown in Figure 2.4. Locomotor activity was recorded, via 
non-perseverative infrared beam breaks, for a total of 32 hours on MED-PC® 
(version 4) software (Vermont, USA) to determine changes circadian cycle 
mediated activity levels. Animals were allowed ad-libitum access to both food 
and water which were placed at opposite ends of the clear Perspex cage. Lamps 
were placed into the testing room and set on a timer to ensure that animals were 
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maintained on their standard 12 hour light/dark cycle, lights on at 06.00 hours 
and lights off at 18.00 hours.   
 
 
 
 
 
 
 
 
 
2.2.5. Sucrose Consumption 
Sucrose consumption was measured as an indicator of motivation and physical 
ability to consume a palatable reward. Sucrose consumption testing was 
conducted for 8 hours during the light phase from 09.00 hours to 17.00 hours. 
Animals were singly housed and placed in a standard cage (dimensions 45cm x 
20cm x 15cm) with ad-libitum access to water and access to 4 grams of sucrose 
pellets (TestDiet®, Minnesota, U.S.A.) placed in a plastic dish in the centre of 
the cage. At 17.00 hours the quantity of sucrose consumed was recorded, as was 
the body weight of the animal. Animals were then returned to their home cages. 
Sucrose consumption testing occurred for a total of 4 consecutive days.   
2.2.6. Food Consumption 
Animals were singly housed in a standard cage (dimensions 45cm x 20cm x 
15cm) and allowed ad-libitum access to both food and water for a 16 hour 
overnight period. The quantity of food consumed overnight was recorded the 
following morning as a measure of motivation and physical ability to consume 
food. Food consumption testing occurred for a total of 4 consecutive days. 
Figure 2.4. Photograph of automated locomotor activity cage.   
Each clear Perspex cage (dimensions 40cm x 24cm x 18cm) was placed on a metal rack through 
which 3 infrared beams were able to pass. Ad-libitum food and water was provided at opposite 
ends of the cage. Locomotor activity was recorded, via infrared beam breaks, for a total of 32 
hours on MED-PC® software (Vermont, USA).  
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2.2.6. Gait Analysis 
Measurement of gait analysis was conducted to determine any development in 
gait abnormalities, using a clear Perspex corridor apparatus (65cm x 5cm x 15 
cm) which was lined with a pre-cut piece of white paper, as shown in Figure 
2.5A. Animals were trained to run to the enclosed darkened box at the end of the 
corridor by placing the mouse at the far end of the corridor and encouraging them 
to move towards the goal box at the end. Training was conducted twice for each 
mouse until the animal readily ran to the end box without encouragement.  
For testing, the paws of the animal were painted with non-toxic paint (TTS paint, 
Nottinghamshire, UK); red was used for the front paws and blue for the hind 
paws. The animal was then placed at the near end of the apparatus and ran to the 
enclosed goal box at the far end of the apparatus, leaving a print of associated 
foot prints on the paper at the base of the apparatus. The mouse was then placed 
into a water bath to wash and groom before being returned to the home cage. The 
paper print (Figure 2.5B) was then allowed to air dry to enable analysis (Figure 
2.5C) of; stride length, width and overlap for both the front and hind paws of 
each animal. For each animal, this was calculated using 4 paw prints (Figure 
2.5C), this allowed 3 values to be calculated for each measurement (stride length, 
stride width and overlap) which were then averaged to provide gait 
measurements.  
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2.3. Operant Techniques 
2.3.1. 9-hole Operant Box Apparatus 
Operant testing was conducted in a total of 16 9-hole operant boxes (Campden 
Instruments, Loughborough, UK), measuring 14cm x 13.5cm x 13.5cm, 
controlled by a BehaviourNet Controller BNC MKII operating system (Campden 
Figure 2.5. Gait analysis apparatus and representative images of the results obtained. 
A. A photograph of the gait corridor apparatus used in gait analysis. B. Representative image of 
the results obtained from gait analysis. C. Schematic illustration of gait analysis measurements 
of stride length, stride width and stride overlap. 
Chapter 2                                                                      Materials and Methods  
 
 52  
 
Instruments, Loughborough, UK). Each operant box (Figure 2.6A) constituted a 
sound attenuating chamber which enclosed the 9-hole box made of aluminium 
on all sides with a clear Perspex lid. Each box contained a litter tray beneath the 
metal grid floor. The rear wall of each chamber was curved and contained a 
horizontal array of nine holes (11mm in diameter, placed 2mm apart and 15mm 
above floor level) numbered 1-9 from left to right.  
Each hole contained photocell infrared beams which were localised at the front 
of each hole to detect nose pokes. At the rear of each hole a white light emitting 
device (LED) acted as the target visual stimulus. Only holes 1, 3, 5, 7 and 9 were 
used in any given test presented in this Thesis; consequently black plastic film 
was placed in the light array to block unused holes (2, 4, 6 and 8) to prevent their 
use. A peristaltic pump delivered liquid reinforcement in the form of strawberry 
milk (Yazoo®, Campina Ltd, Horsham, UK) to a reward magazine at the front 
of the box, located opposite the 9-hole array (Figure 2.6). The reward size 
delivered into the magazine differed depending on the operant task, as stated in 
the results chapter. However, typically a 5µl reward was delivered, which 
required a 100 millisecond pump duration. 
Reward delivery to the magazine was signalled by an LED located above the 
magazine and nose entry into the magazine was detected by an infrared beam 
located across the opening of the magazine. ‘House lights’ were also located on 
the side walls of the operant chamber, which illuminated to signal the end of a 
trial or time out intervals (TOI) within trials. Background noises were provided 
by an extractor fan and computer operating system. Each of the 9-hole operant 
boxes was modified to include a Skinner-like responding set up located opposite 
the 9-hole array (Figure 2.6B). As stated, for operant tasks either the 9-hole or 
the Skinner-like configuration was used.  
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Figure 2.6. A. Overall picture of the mouse operant boxes used including the 9-hole and ‘Skinner-like’ set 
ups. B. Schematic of the operant box apparatus including both the 9-hole and ‘Skinner-like’ set ups. In the 
9-hole set up the back response wall contained 9 stimulus lights, 5 of which were used in operant testing. 
Holes 1, 3, 5, 7 and 9 contained stimulus lights and photocell detectors to detect nose pokes via breaking 
of an infrared beam. Holes 2, 4, 6 and 8 were covered with well blanks. In the ‘Skinner-like’ set up 2 
response holes were located either side of the reward magazine. Each nose poke contained a stimulus light 
and an infrared beam to detect nose poke responses.   
2.3.2. Skinner-like Modified Operant Box Apparatus 
The 16 9-hole operant boxes described above in 2.3.1. were modified to include 
additional Skinner-like nose poke response holes located either side of the 
reward magazine (Figure 2.6B). Each response hole measured 11mm in diameter 
and contained photocell infrared beams localised at the front to detect nose pokes 
and a white LED at the rear to act as a visual target. When the Skinner-like 
operant configuration was not in use the response holes were covered using black 
plastic inserts to prevent unwanted responding.  
2.3.3. Water Restriction Regime 
1 week prior to the beginning of operant testing gradual water restriction was 
introduced and animals were habituated to strawberry milk reward (Yazoo®, 
Campina Ltd, Horsham, UK) within their home cages, to prevent any neophobic 
response. Water restriction was introduced such that the time animals went 
without water was gradually increased daily for 1 week. Once fully water 
restricted animals were maintained on a restriction schedule of 3 hours access to 
water, which was given daily in their home cages for 5 days a week for the 
duration of operant testing. Animals were allowed ad-libitum access to water, 
Chapter 2                                                                      Materials and Methods  
 
 54  
 
from Friday afternoon until Sunday afternoon to meet with licencing 
requirements provided by the Home Office.  
2.3.4. 9-hole Box Operant Tests 
To summarise the range of operant tests used in this Thesis, the primary purpose 
of each of operant test is shown below in Table 2.1. Although it should be noted 
that although the operant tests have a primary purpose there are also secondary 
measures which are discussed in more detail in the relevant chapters.    
Table 2.1. Summary of operant tests used.   
Operant Test Primary cognitive function designed to probe 
Fixed ratio (FR) Acquisition and amenability in responding 
Progressive ratio (PR) Motivation 
5-choice serial reaction time ask 
(5-CSRTT) 
Attention 
Serial implicit learning task (SILT) Implicit learning 
Delayed matching and non- matching to 
position (DMTP/DNMTP) 
Working memory and reversal learning 
2.3.4.1. 9-hole Box Training  
At approximately 10 weeks of age mice were introduced to the 9-hole operant 
box apparatus. Initial training in responding into the magazine began with the 
non-contingent delivery of 150µl of strawberry milk into the magazine and 
illumination of the magazine light, for 1 day. Reward retrieval was detected via 
infrared beam breaks, which were triggered following nose entry and withdrawal 
from the magazine. After successful reward retrieval the magazine light was 
extinguished. The process was repeated until the 20 minute session time had 
elapsed. 
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After 1 day of magazine training, mice were taught to nose poke into the stimulus 
LED lights on a simple fixed ratio (FR1) schedule of reinforcement, for each 
trial, the central hole in the array of the operant box was illuminated. To obtain 
reward, mice were required to respond to the stimulus light in the central hole of 
the array via a single nose poke response. A correct nose poke in response to the 
stimulus light triggered the centre light to extinguish and the simultaneous 
illumination of the magazine light and delivery of a 5µl strawberry milkshake 
reward into the magazine. Upon withdrawal of the animal’s nose from the 
magazine, the next trial was initiated with the illumination of the centre light. In 
order to promote learning, the centre light was painted with strawberry milk to 
encourage nose poking into the illuminated hole. Mice were trained on this 
programme until they had achieved over 100 pokes into the centre hole within 
the 20 min time period without additional painting of the centre hole with 
strawberry milk.  
2.3.4.2. Fixed Ratio (FR) Testing 
Fixed ratio (FR) operant testing was conducted after the 9-hole training described 
above in 2.4.1. The purpose of this test was to investigate the acquisition and 
amenability to respond when varying sizes of reward were used. Mice were 
required to poke into the central hole of the array, in response to illumination, to 
obtain reward. The operant programme utilised varying reward sizes of 2.5µl, 
5.0µl and 7.5µl of strawberry milk, which were delivered into the reward 
magazine. Animals were reinforced with 5.0µl of reward for the first 3 days of 
testing, then 2.5µl of reward for the next 3 days, before finally rewarding animals 
with 7.5µl of reward for the final 3 days. The number of pokes into both the 
central hole and magazine was recorded in response to reward size, over a 45 
minute session time.   
2.3.4.3. Progressive Ratio (PR) Testing 
The progressive ratio (PR) operant task tested the motivation of mice in terms of 
how many nose poke presses they were prepared to make to obtain a given level 
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of reward before ceasing to respond. The PR schedule of reinforcement required 
progressively more nose poke responses, to be made on each successive trial, 
into the illuminated central hole of the array for successive rewards. The number 
of responses required to obtain a reward increased by 3 additional responses 
every 3 trials. The first trial required 1 response for 1 reward, the next 3 trials 
required 3 responses for 1 reward, and the next 3 trials required 6 responses for 
1 reward etc. There was no upper limit to the number of trials that could be 
initiated. The motivation of the animals to a obtain reward was recorded by 
measuring how quickly they stopped responding for a pre-defined period of time 
(30 seconds), termed the “break point”. The overall ratio attained within the 
session was also recorded as a measure of motivation. Reward sizes of 2.5µl, 5µl 
and 7.5µl were used on separate days in PR testing. A 2.5µl reward size was used 
for the first 3 days of testing, the 7.5µl reward size was used for the next 3 days 
of testing and the 5.0µl reward size was used in the final 3 days of testing. Each 
session lasted for 60 minutes. 
2.3.4.4. 5-Choice Serial Reaction Time Task (5-CSRTT) Testing 
In the 5-Choice Serial Reaction Time Task (5-CSRTT) animals were trained to 
respond, via nose poking, to a stimulus light which was presented randomly 
across the 5 hole light array (Figure 2.6.), in order to receive a 5µl reward. The 
purpose of this task was to investigate attentional performance and spatial 
awareness. Three different stimulus lengths were used (10, 2 and 0.5 seconds), 
which increased the difficulty and attentional load of the task. For the first 10 
days of testing a 10 second stimulus length was presented. A stimulus length of 
2 seconds was then used for the next 5 days and a stimulus length of 0.5 seconds 
was used for the final 5 days of testing. Therefore, the attentional load of the task 
increased with decreasing stimulus length. If a response was not made within the 
stimulus length time, or the subsequent 10 seconds after the presentation of the 
stimulus (termed a ‘limited hold’) the light was extinguished and a ‘time out’ 
period of 10 seconds was initiated by illumination of the house light. The process 
was repeated until the 30 minute session time had elapsed. 
Chapter 2                                                                      Materials and Methods  
 
 57  
 
2.3.4.5. Serial Implicit Learning Task (SILT) Testing 
For the Serial Implicit Learning Task (SILT) animals were trained to respond to 
a 2-step sequence of stimulus lights in order to receive a reward. A continuous 
stimulus light was randomly presented in 1 of the 5 holes across the array (as in 
the 5-CSRTT). Then, a correct response to the first stimulus light (S1) resulted 
in the simultaneous extinguishing of this continuous light stimulus and 
illumination of a second light (S2). A correct response to S2 resulted in delivery 
of a 5µl reward into the magazine. A predictable stimulus sequence (hole 7 was 
always illuminated after hole 3) was embedded among other unpredictable 
sequences in order to probe implicit learning. The programme was repeated until 
the 30 minute session time had elapsed. The latency to respond accurately to S1 
and S2 on each trial was recorded, subdivided according to the S1 holes and S2 
step sizes, and whether the S2 choice was predictable.  
2.3.4.6. Delayed Matching and Non-Matching to Position (DNMTP and 
DMTP) Tasks 
The delayed matching to position and delayed non-matching to position (DMTP 
and DNMTP) operant tasks, were designed to test working memory and reversal 
learning in mice. The development of the DMTP and DNMTP operant tasks is 
the focus of Chapter 7 and thus a more in depth description of the task is given 
there.  
The DMTP and DNMTP tasks were conducted in both the 9-hole operant 
apparatus (as described in Chapter 2, section 2.3.1.) and a modified ‘Skinner-
like’ operant apparatus (as described in Chapter 2, section 2.3.2). However, the 
responses required were the same in each manipulation of the task. The animal 
was required to nose poke into a continuously illuminated stimulus; the animal 
was then re-centralised, via nose poking, before being presented with 2 stimulus 
lights that were illuminated simultaneously. The animal was then required to 
match the response with either the stimulus light that it previously responded into 
(the DMTP task) or in the reversal of the task, the stimulus light which it had not 
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previously responded to (the DNMTP task), to obtain a 5µl strawberry milk 
reward. The testing procedure was repeated until the 30 min session time had 
elapsed.  
2.4. Histological Techniques 
2.4.1. Tissue Preparation 
Animals were culled via cervical dislocation and the whole brain dissected from 
the skull. The whole brain was divided into sagittal hemispheres using a razor 
blade. The right hemisphere was micro-dissected into constituent brain regions, 
snap frozen in liquid nitrogen and stored at -80°C, for subsequent gene 
expression analysis (undertaken by colleagues and not reported in this thesis). 
The left hemisphere was post fixed in 4% paraformaldehyde (PFA) at room 
temperature for 24 hours on a shaker and then transferred into 25% sucrose in 
phosphate buffered saline (PBS) solution for subsequent immunohistochemical 
analysis. For a full list of solutions and recipes see the Appendix.    
2.4.2. Immunohistochemistry of Free Floating Sections  
The left hemisphere of each brain (see tissue preparation 2.4.1. above) was 
frozen on a sliding sledge freezing microtome (Leitz, Wetzlar), cut coronally into 
a 1 in 12 series of 40µm sections and collected into 48 well plates (Thermo, 
Fisher Scientific) which contained an anti-freeze solution of di-sodium hydrogen 
orthophosphate. Sections were stored at -20°C until required.  A 1 in 12 series of 
sections was selected from the 48 well plate and placed into a single well of a 25 
well immunohistochemistry basket. The sections were washed in tris-buffered 
saline (TBS) to remove residual antifreeze, then endogenous peroxidase activity 
was quenched for 5 minutes using 10% H2O2 (VWR, West Sussex, UK) and 
methanol (Sigma-Aldrich, Dorset, UK) before further TBS washes were applied. 
Sections were blocked in 3% serum in Triton-X tris-buffered saline (TXTBS) for 
1 hour to block non-specific binding sites. Sections were incubated in a solution 
of TXTBS, 1% serum and primary antibody, overnight at room temperature. For 
the primary antibody concentrations used for each antibody see Table 2.2.  
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Table 2.2. Primary antibody information summary. 
Primary 
Antibody 
Used to stain 
Concentratio
n Used 
Species 
Raised in 
Blocking 
serum 
Supplier and Reference 
DARPP-32 Medium spiny 
neurons 
1: 30000 Mouse Horse 
Cornell University 
(AB_2314285) 
(Ouimet et al. 1984) 
Neu-N Neurons  1: 2000 Mouse Horse 
Millipore (MAB 377) 
 (Mullen et al. 1992) 
S830 
Mutant 
huntingtin 
1: 25000 Sheep Horse 
Gift from Gillian Bates 
(King’s College London). 
(Sathasivam et al. 2001) 
Following overnight incubation in primary antibody, sections were washed in 
TBS before incubation in biotinylated secondary antibody at a concentration of 
1:200 for all stains for 2 hours at room temperature. Sections were then washed 
in TBS and incubated in an ABC kit (Vector Laboratories Ltd, Peterborough, 
Cambridgeshire), using a 1 in 200 dilution of both solutions A and B for 2 hours. 
The specific secondary antibodies used are specified in the methods section of 
each experimental chapter, although a summary of the secondary antibodies used 
in this Thesis is shown below in Table 2.3.  
Table 2.3. Secondary antibody information summary 
Secondary Antibody Supplier 
Biotinylated Horse Anti-Mouse IgG Antibody, rat adsorbed* Vector (BA2001) 
Biotinylated Horse Anti-Goat IgG Antibody* Vector (BA9500) 
* All secondary antibodies were used at a 1: 200 concentration.  
Sections were washed in TRIS non-saline (TNS) before visualisation of the 
tissue bound antibody using the chromogen 3-3’-diaminobenzadine (DAB) 
supplied from DAKO. A 1:5 concentration of DAB in TNS was initiated by the 
addition of a 0.25% of H2O2. The reaction was allowed to develop until the stain 
could be clearly seen under the microscope. To stop the reaction sections were 
washed in TBS before being mounted on to double subbed 1% gelatinised slides 
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(Thermo Scientific, Menzel Gläser). Slides were allowed to air dry before 
dehydration in an industrial methylated spirit (IMS) alcohol ladder of increasing 
concentrations (70%, 95% and 100%) and were then cleared in 100% xylene. All 
slides were then cover slipped using distyrene plasticizer and xylene (DPX) 
(Thermo Scientific, Raymond Lamb, Leicestershire, UK) mountant and allowed 
to dry before subsequent analysis.   
2.4.3. Cresyl Violet Staining.  
Cresyl violet (CV) staining was used to gain an overall visualisation of cellular 
morphology by staining Nissl substance in the cytoplasm of neurons and glia.  A 
1 in 12 series of sections was selected from the 48 well plate and mounted onto 
glass slides double subbed with 1% gelatine and allowed to air dry. Once dry, 
slides were placed for 5 minutes in each of the following solutions: 70% IMS, 
95% IMS, 100% IMS, 50/50 chloroform alcohol, 95% IMS, 70% IMS, distilled 
water, cresyl violet solution and distilled water. Sections were then dehydrated 
in 70% and 95% IMS for 5 minutes each, then destained by gentle agitation in 
acid alcohol solution for up to 5 minutes until an appropriate level of staining 
required was obtained. Additional dehydration in 100% IMS was performed, 
before clearing in xylene and cover slipping using DPX mountant.  
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2.5. Stereological Analysis and Image Acquisition 
Stereological quantification was conducted using Visiopharm Integrator System 
(VIS, version 4.4.6.9) software on an Olympus Canada Inc. Q-Imaging 
Microscope. For each slide striatal sections were outlined under a 1.25X 
objective lens. Defined striatal sections were then sampled in a systematically 
automated fashion and cells were counted using oil under the 100X objective 
lens. The counting frame size used was 285µm2. A representative image of the 
counting frame used is shown below in Figure 2.7. Cells that are within the 
counting frame and touching either of the green lines were included in the count, 
whereas cells that touched either of the red lines were excluded.    
Figure 2.7. Representative image of stereological analysis conducted in Visiopharm Integrator 
System (VIS) software. The 285µm2 counting frame can be seen in the centre of the image, as a square 
with a red and green border. Cells that were clearly within the counting frame and not touching the red lines 
were counted (2 cells in this image labelled with the letter ‘A’). If a cell touched the red line within the 
counting frame it was excluded. The striatal border of this section can be seen to the right of the image as 
the green dashed line.  
 
The number of animals used in each stereological analysis differed depending 
on the experiment, therefore the precise number of animals used is provided in 
each experimental chapter. The total number of cells (C) in each striatal section 
was calculated using the following formula:  
C = Ʃc x (ƩA x (Ʃn x a)) x f 
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Where:  
C = estimated total number of cells  
Ʃc = total number of cells counted 
ƩA = sum of all striatal areas  
Ʃn = total number of frames allocated to the included striatal area 
a = area of sampling user grid (285µm2) 
f = frequency of sectioning  
An Abercrombie correction factor was then applied to the total number of 
calculated cells using the following formula (Abercrombie 1946):  
aC = C x (ST /(ST+D) 
Where:  
aC = Abercrombie corrected cell count 
C = estimated total number of cells 
ST = section thickness 
D = cell diameter.   
Representative images of the stained sections were acquired using a Leica 
Microsystems Ltd microscope (Heerbrugg, Switzerland, Model CH-9435) and 
Leica Application Suite (LAS, version 3.8) software.  
2.6. Statistical Analysis  
All statistical analyses were performed in IBM SPSS Statistic 20 software for 
windows. Repeated measures analysis of variance (ANOVA) tests followed by 
simple effects analysis were conducted for the majority of behavioural tests. 
Although, the exact statistical analysis performed in each case is stated in the 
relevant methods section for each experimental chapter. Where significance was 
found post-hoc tests with Bonferroni corrections were applied to identify the 
locus of effects and their interaction(s). The critical significance level used 
throughout was α= 0.05. 
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Chapter 3 : A longitudinal histological 
characterisation of the HdhQ111 mouse model of 
Huntington’s disease. 
3.1. Introduction  
An early neuropathological hallmark of HD is the selective loss of GABAergic 
medium spiny neurons (MSNs) within the striatum (Deng et al. 2004; Starr et 
al. 2008), with the relative sparing of other neuronal populations (Ferrante et al. 
1985; Ferrante et al. 1987a; Ferrante et al. 1987b; Reiner et al. 1988). As MSNs 
are the major striatal afferents from the neocortex and the thalamus, the loss of 
these projections causes cortical atrophy which has also been shown to be a 
neuropathological feature of HD (Suzanne et al. 1988; Halliday et al. 1998; 
Rosas et al. 2002).  
Another characteristic neuropathological hallmark of HD is the presence of 
protein aggregates and the progressive formation of inclusions of mutant 
huntingtin (mHTT), which can be both intranuclear and extranuclear (Vonsattel 
et al. 1985; DiFiglia et al. 1997; Gutekunst et al. 1999; Sieradzan et al. 1999). 
The precise cause of the formation of neuronal intranuclear inclusions (NIIs) is 
still under debate. While many studies have indicated that inclusion formation is 
a toxic mechanism (Li et al., 2001; Lee et al, 2004; Miller et al.,2010); others 
have shown mHTT to be pro-apoptotic, leading to the degradation of inclusions 
(Saudou et al., 1998; Ho et al., 2001; Huang et al., 1998). Therefore, the 
formation of NIIs may be a neuroprotective mechanism (Saudou et al. 1998; 
Guidetti et al. 2001; Zhou et al. 2001; Arrasate et al., 2004, Mitra et al., 2009), 
at least in the first instance. Nevertheless, at the very least the presence of NIIs 
is a neuronal abnormality which is a characteristic neuropathological hallmark 
of HD, and has previously been shown in both transgenic (Davies et al. 1997; 
Schilling et al. 1999; Morton et al. 2000; Hansson et al. 2001; Meade et al. 2002; 
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Bayram-Weston et al. 2012c, d; Cheng et al. 2013) and knock-in (Wheeler et al. 
2000b; Lin et al. 2001; Menalled et al. 2003; Heng et al. 2010; Rising et al. 
2011; Bayram-Weston et al. 2012a; Bayram-Weston et al. 2012e) HD mouse 
models.     
HD was previously thought to be a relatively focused disease of the striatum, 
causing both a gross reduction in striatal volume and enlargement of the lateral 
ventricles (Vonsattel et al. 1985; Aylward et al. 2004). Although, recent 
advances in in vivo imaging technology have demonstrated more widespread 
atrophy, which can affect: the cerebrum, total white matter, cerebral cortex, 
caudate, putamen, globus pallidus, amygdala, hippocampus, brainstem, and 
cerebellum (Thieben et al. 2002; Rosas et al. 2003; Reading et al. 2005; Henley 
et al. 2006; Rosas et al. 2008; Henley et al. 2009; Tabrizi et al. 2009; Hobbs et 
al. 2010; Tabrizi et al. 2011), often in the mid to early stages of the disease.     
To determine the validity of the HdhQ111 mouse model in recapitulating the 
neuropathological features of the human disease, immunohistochemical stains 
were conducted longitudinally to determine any neuropathological changes 
which occurred during the disease progression.   
3.2. Aims  
The aim was to characterise the development of neuropathology in the HdhQ111 
mouse model of HD, longitudinally over 18 months using histological and 
stereological techniques, and to determine its face and predictive validity as a 
model of HD.   
3.3. Materials and Methods  
3.3.1. Animals 
Animals were group housed and allowed ad-libitum access to both food and 
water. Animals were housed with a single cardboard tube and wooden chew stick 
per cage to provide modest enrichment. All animals were maintained on a 12 
hour light:dark circadian schedule (06.00 hours lights on, 18.00 hours lights off), 
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in a temperature controlled environment (21ºC ± 2ºC). Animals were weaned, 
genotyped and ear notched for identification purposes at 4 weeks of age (as 
described in Chapter 2) and allowed to age to the required time point before 
being humanely euthanised. 
A total of 48 mice (24 HdhQ111/+) were used in this histological characterisation, 
a total of n = 4 for each genotype and age. HdhQ111/+ animals contained an 
average CAG repeat length of 138, which ranged from 132 to 142 CAG repeats. 
3.3.2. Tissue Preparation 
Animals were allowed to age to the required time point and were then culled via 
cervical dislocation and the whole brain dissected from the skull. The tissue was 
prepared as previously described in section 2.4.1. of Chapter 2. 
3.3.3. Immunohistochemical Staining of Sections  
Immunohistochemical staining was conducted utilising DARPP-32, Neu-N and 
S830 primary antibodies, as previously described in section 2.4.2 of Chapter 2.  
3.3.4. Cresyl Violet Staining 
Cresyl violet staining was conducted as previously described in section 2.4.3. of 
Chapter 2. 
3.3.5. Stereological Quantification and Image Acquisition 
Stereological quantification and image acquisition was conducted as previously 
described in section 2.5 of Chapter 2.  
3.3.6. Statistical Analysis 
All statistical analyses were performed in IBM SPSS Statistic 20 software. 
Repeated measures analysis of variance (ANOVA) tests followed by simple 
effects analysis were conducted for the majority of analyses. For s830 staining 
One-way ANOVAs were performed. Where significance was found post-hoc 
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tests with Bonferroni corrections were applied. The critical significance level 
used throughout was α = 0.05. 
3.4. Results 
3.4.1. Cresyl Violet Results  
The total number of CV stained cells within the striatum did not differ between 
HdhQ111/+ and wild type animals (Genotype; F1,6 = 0.006, p = n.s.), nor did the 
number of CV stained cells change as animals aged (Age; F5,30 = 2.13, p = n.s). 
There was also no significant interaction effect (Age x Genotype; F5,30 = 0.508, 
p = n.s.) as can be seen in Figure 3.1.  
 
Figure 3.1. Cresyl violet (CV) longitudinal stereological results for HdhQ111/+ animals. HdhQ111/+ 
animals showed no statistically significant difference in the number of CV stained cells in comparison to 
wild type animals. Error bars represent ± standard error of the mean. N=4 in all cases.    
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The striatal volume, as measured by CV staining, showed that HdhQ111/+ animals 
demonstrated significant striatal atrophy in comparison to wild type animals 
(Genotype; F1,6 = 11.98, p<0.01). Although this difference was not progressive 
as animals aged (Age x Genotype; F5, 30 = 7.14, p = n.s.), a significant decrease 
in striatal volume was observed (Age; F5,30 = 7.14, p <0.001) as shown in Figure 
3.2.  
Figure 3.2. Striatal volume results for HdhQ111/+ animals. HdhQ111/+ animals showed significantly 
decreased striatal volumes in comparison to wild type animals, although this was not shown to be 
progressive as animals aged. Error bars represent ± standard error of the mean. N=4 in all cases. Statistical 
significance considers all ages ** p <0.01.     
 
3.4.2. Neu-N Results 
The number of Neu-N stained cells within striatum did not significantly differ 
between HdhQ111/+ and wild type animals (Genotype; F1,6 = 1.25, p = n.s.), 
although the number of Neu-N stained cells did significantly decrease as animals 
aged (Age; F5,30 = 7.24, p <0.001). Despite this, there was no significant 
interaction effect (Age x Genotype; F5,30 = 0.93, p = n.s.), as shown in Figure 
3.3.   
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Figure 3.3. Neu-N longitudinal results of stereological analysis for HdhQ111/+ animals. HdhQ111/+ 
animals showed no statistically significant difference in the number of Neu-N stained cells in comparison 
to wild type animals. Although the number of cells significantly decreased as animals aged. Error bars 
represent ± standard error of the mean. N=4 in all cases. 
3.4.3. DARPP-32 Results 
A photographic representation of the differences in DARPP-32 staining in the 
striatum of wild type and HdhQ111/+ animals is shown below in Figure 3.4. The 
number of DARPP-32 stained cells within the striatum decreased as animals 
aged (Age; F5,30  = 23.7, p <0.001). HdhQ111/+ animals had significantly fewer 
DARPP-32 stained cells within the striatum than wild type animals (Genotype; 
F1,6 = 1.93, p <0.001), although this was not progressive as animals aged (Age x 
Genotype; F 5, 30 = 1.93, p = n.s.), as shown in Figure 3.5. 
Chapter 3                                                               Histological Characterisation 
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Representative light microscope images of DARPP-32 staining in the striatum of both 
wild type and HdhQ111/+ animals over time. Scale bars represent 50µm throughout and all photos were 
obtained using X40 magnification objective lens.  
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Figure 3.5. DARPP-32 longitudinal results of stereological analysis for HdhQ111/+ animals. The number 
of DARPP-32 positive cells significantly decreased as animals aged. HdhQ111/+ animals had significantly 
fewer DARPP-32 positive cells than wild type animals, although this was not shown to be progressive over 
time. Error bars represent ± standard error of the mean. N=4 in all cases. Statistical significance is presented 
considering all ages of testing *** p<0.001.   
 
3.4.4. S830 Results 
Representative light microscope images of the progression of S830 
immunoreactivity within the HdhQ111/+ mouse striatum are shown below in 
Figure 3.6. All staining was negative in wild type animals. NIIs can clearly be 
seen from 6 months of age and form progressively until they are prevalent by 18 
months of age. 
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Figure 3.6. Representative light microscope images of S830 staining in the striatum of HdhQ111/+ 
animals over time. Images on the left were taken at X40 and images on the right were taken at X100. 
Scale bars represent 50µm throughout. 
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The total number of cells affected by mHtt, as determined by stereological 
quantification of S830 staining, demonstrated that significantly more striatal 
cells were affected by mHtt as animals aged (Age; F5,15 = 5.05, p <0.01), as 
shown in Figure 3.7.   
Figure 3.7. Total cells affected by S830 staining in HdhQ111/+ animals longitudinally. The number of 
cells affected by S830 staining significantly increased as animals aged. Error bars represent ± standard error 
of the mean. N=4 in all cases. Statistical significance is presented considering all ages of testing ** p<0.01.   
Diffuse mHtt staining and overt mHtt inclusion staining were measured relative 
to each other. Diffuse mHtt staining was demonstrated in the striatum of 
HdhQ111/+ animals at 3 months of age and decreased as animals aged (Age; F5,30 
= 6.70, p <0.001). No diffuse mHtt staining was present in HdhQ111/+ animals at 
18 months of age (Figure 3.8). Overt mHtt inclusions began to appear in the 
striatum at 6 months of age and were prevalent by 18 months of age (Figure 3.8). 
As animals aged, the number of cells affected by mHtt diffuse staining 
significantly decreased and the number of cells affected by overt mHtt inclusions 
significantly increased (Staining x Age; F5,30 = 30.85, p<0.001), as shown in 
Figure 3.8.   
 
 
Chapter 3                                                               Histological Characterisation 
73 
 
Figure 3.8. Cells affected by diffuse mHtt staining and mHtt inclusions longitudinally in HdhQ111/+ 
animals. The number of cells affected by diffuse mHtt staining significantly decreased as animals aged 
and the number of cells affected by overt mHtt inclusions significantly increased as animals aged. Error 
bars represent ± standard error of the mean. N=4 in all cases. 
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Furthermore, measurement of mHtt inclusion width in the striatum of HdhQ111/+ 
animals demonstrated that mHtt inclusions became significantly wider as 
animals aged (Figure 3.9).   
 
Figure 3.9. mHtt inclusion width measured longitudinally in HdhQ111/+ animals. The width of mHtt 
inclusions significantly increased as animals aged. Error bars represent ± standard error of the mean. N=4 
in all cases. Statistical significance is presented considering all ages of testing *** p<0.01.   
Stereological quantification of s830 mHtt inclusion staining was restricted to the 
striatum. Although, overt mHtt inclusions were also seen in other brain regions, 
including; the olfactory tubercle, piriform cortex, motor cortex, hippocampus 
and cerebellum. Although these observations were not quantified, overt mHtt 
inclusions were widespread throughout the brain of HdhQ111/+ animals by 18 
months of age.  
3.5. Discussion 
The HdhQ111/+ mouse model of HD demonstrated striatal atrophy, as measured 
by cresyl violet staining and loss of DARPP-32 staining, which may be 
indicative of a loss of MSNs. Diffuse mHtt staining was seen from 3 month of 
age and was present in small amounts as animals aged until 18 months of age, 
where it was no longer evident. NIIs were shown to progressively develop from 
6 months of age and were prevalent throughout the striatum at 18 months of age. 
This observation is in accordance with literature in other mouse models of HD 
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which shows mHtt aggregates progressively reduce as overt mHtt inclusions are 
formed (Davies et al. 1997; Wheeler et al. 2000b; Bayram-Weston et al. 2012b, 
c).  
A significant reduction in the number of DARPP-32 positive cells in the striatum 
was shown in HdhQ111/+ animals, which may be indicative of a loss of MSNs, 
which is a hallmark of HD pathology (Deng et al. 2004; Starr et al. 2008). 
Studies of MSN degradation in HD mice are limited, in comparison to the 
number of studies regarding mHtt aggregate and inclusion formation; although 
our findings are in accordance with other studies in transgenic (Bibb et al. 2000; 
van Dellen et al. 2000) and knock-in mouse models (Hickey et al. 2008) which 
demonstrated a loss of DARPP-32 positive MSNs in the striatum of HD mice. 
No significant interaction effect between Age x Genotype was demonstrated for 
MSN loss, thus it cannot be considered to be progressive over time, as it was in 
previous studies. However, the lack of significant interaction is likely to be due 
to the small sample size considered in the statistical analysis. An in depth 
discussion regarding the effects of sample size on the statistical analysis is given 
in the General Discussion in Chapter 8.   
Despite a reduction in the number of DARPP-32 stained cells in HdhQ111/+ 
animals, there was no significant difference in the number of cresyl violet stained 
cells in the striatum. In order to further explore the neuropathology in the 
HdhQ111/+ mouse model, in future studies, ‘glial-like’ nuclei could be quantified 
in the cresyl violet stain to determine if any gliosis occurs alongside striatal 
shrinkage. 
In comparison to previous studies of the neuropathology in the HdhQ111 mouse 
model (Wheeler et al. 2000b; Wheeler et al. 2002a), which demonstrated 
inclusion formation from 10 months of age, our findings demonstrate the 
appearance of NIIs 4 months earlier, at 6 months of age. However, previous 
characterisations of NIIs in HdhQ111 animals were conducted using a CD1 
background strain and a C57BL6/J background strain was used here. The mouse 
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background strain is known to be an important factor in the disease progression 
of HD and has previously been shown to modify the phenotype observed in the 
YAC128 model (Van Raamsdonk et al. 2007) and the HdhQ111 model (Lloret et 
al. 2006). Lloret et al., concluded that NIIs develop most rapidly on the C57BL/6 
background, which is supported by the results obtained here. Furthermore, it is 
important to consider that previous characterisations of the NIIs in the HdhQ111 
mouse model have used the EM48 antibody (Wheeler et al. 2000b; Wheeler et 
al. 2002a), rather than the S830 antibody that was used here.  
The HdhQ92 mouse model, which is most genetically similar to the HdhQ111 
mouse model, also demonstrates a different neuropathological phenotype when 
different genetic background strains are used. When HdhQ92 animals were bred 
on a CD1 background strain, they demonstrated NII formation from ~12 months 
of age (Wheeler et al. 2000b), whereas when bred on a C57BL/6J background, 
NIIs were present from 6 months of age (Bayram-Weston et al. 2012b). 
Therefore, when our findings are compared to HdhQ92 animals on the same 
background strain (Bayram-Weston et al. 2012b) they demonstrate a similar 
neuropathological profile with NIIs present in the striatum from 6 months of age. 
Although NII formation in other brain regions was not quantified, it seems that 
HdhQ111 animals demonstrate a similar pattern of NII formation in the olfactory 
tubercle and piriform cortex as that previously described in HdhQ92 animals. 
Although, it should be noted that the neuropathological analysis of HdhQ92 
animals on a C57BL6/J background was conducted in homozygous animals, 
rather than the heterozygous animals used here, therefore there does not seem to 
be a dosage effect in terms of comparative neuropathology. HdhQ111/+ mice 
demonstrated striatal atrophy, which has not previously been shown in the 
HdhQ92 mouse model, therefore it could be the case that the large polyglutamine 
repeat length evokes a more rapid striatal volume reduction in HD mice.      
Comparison of our findings to the results obtained in HdhQ140 and HdhQ150 
animals (Lin et al. 2001; Rising et al. 2011) demonstrates a similar appearance 
of NIIs at 6 months of age. Due to the genetic expansion of the polyglutamine 
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repeat length, the HdhQ111 animals used here had an average of 138 CAG repeats. 
Therefore, it is perhaps unsurprising that our HdhQ111 animals demonstrated a 
similar neuropathological phenotype as that previously observed in HdhQ140 and 
HdhQ150 animals, due to the similar CAG repeat length. However, when our 
findings are compared to those observed in the zQ175 mouse model (Carty et al. 
2015), NIIs were visible 2 months later in zQ175 mice in comparison to 
HdhQ111/+ mice. Therefore, it could be concluded that the appearance of NIIs 
inversely correlates with polyglutamine repeat length.  
In comparison transgenic mouse models of HD such as the R6/1 (Hansson et al. 
1999; Bayram-Weston et al. 2012c) and R6/2 (Morton et al. 2000; Meade et al. 
2002) models, which first develop NIIs at 8 and 4 weeks of age respectively; 
HdhQ111/+ animals show a more slowly progressive and less severe 
neuropathology in terms of striatal volume reduction and NII formation. 
However, in comparison to other transgenic models such as the N171-82Q 
(Schilling et al. 1999) and the Ubi-G-HTT84Q (Cheng et al. 2013) models, 
HdhQ111/+ animals demonstrate a comparatively earlier appearance of NIIs which 
are more progressive and less severe throughout the life of the animal.  
The aim of this neuropathological characterisation was to initially determine if 
the HdhQ111/+ mouse model replicated the neuropathology of the human 
condition. Therefore, due to time restrictions, in the first instance, stereological 
quantifications were restricted to the striatum. However, in future analyses it 
would be interesting to consider the neuropathology demonstrated in other brain 
areas. Particularly as HD is increasingly being recognised as a disease that 
affects the whole brain, including cortical atrophy (Rosas et al. 2002; Rosas et 
al. 2003; Tabrizi et al. 2009; Tabrizi et al. 2011) and because mHTT inclusions 
were seen in other brain regions such as the olfactory tubercle and the piriform 
cortex. Furthermore, additional characterisations of the neuropathology in 
HdhQ111 mice may wish to consider performing immunohistochemical analysis 
for measures of factors which are required for normal neuronal functions such 
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as; tyrosine hydroxylase (TH), brain derived neurotrophic factor (BDNF), 
dopamine 1 (D1) and dopamine 2 (D2) receptors.  
In conclusion, the HdhQ111/+ mouse model displays a progressive 
neuropathological phenotype, with a decrease in striatal volume and evidence of 
MSN cell loss. Diffuse mHtt staining was demonstrated from 3 months of age 
and was apparent until 15 months of age. Overt NIIs were observed from 6 
months of age and were prevalent by 18 months of age. NIIs were also 
distributed more widely throughout the brain by 18 months of age, although this 
was not quantified. The neuropathological phenotype observed in HdhQ111/+ mice 
is therefore less severe than that observed in other transgenic mouse models and 
resembles the neuropathology seen in adult onset human HD patients.  
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Chapter 4 : A longitudinal motor characterisation 
of the HdhQ111 mouse model of Huntington’s 
disease. 
4.1. Introduction 
The presentation of overt motor symptoms, has been shown to occur during the 
disease progression of HD in both the human condition (Hefter et al. 1987a; 
Kremer and Group 1996) and in knock-in mouse models (Hickey et al. 2008; 
Trueman et al. 2009b; Heng et al. 2010; Brooks et al. 2012d; Smith et al. 2014). 
A clinical diagnosis of manifest HD is currently based on the total motor score 
(TMS) of the Unified Huntington’s Disease Rating Scale (UHDRS), because 
there is a lack of sensitive cognitive assessments available to diagnose manifest 
HD. Therefore, in order to determine whether the HdhQ111 mouse model 
accurately reflects the human condition of HD, it is important to determine if 
and when motor symptoms develop.  
A behavioural test battery of motor function was applied longitudinally to 
determine the time course of symptom development in the HdhQ111 mouse model 
of HD. The accelerating rotarod was used to assess motor co-ordination, as it has 
previously been used extensively to classify motor dysfunction in a range of HD 
mouse lines (Laforet et al. 2001; Hickey et al. 2008; Trueman et al. 2009b; Heng 
et al. 2010; Rising et al. 2011; Brooks et al. 2012d, c; Brooks et al. 2012f; Cheng 
et al. 2013; Southwell et al. 2013; Smith et al. 2014). A balance beam apparatus 
was used to determine abnormalities in co-ordinated movement and balance, 
which have been demonstrated in HD patients (Johnson et al. 2000) and mouse 
models (Heng et al. 2007; Brooks et al. 2012d, c; Brooks et al. 2012f). In 
addition, a further test of motor function utilising an inverted lid to test grip 
strength was used, as this has been used previously to determine motor function 
and strength in HD mice (Menalled et al. 2009; Brooks et al. 2012c, d).  
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Spontaneous locomotor activity testing was included in the motor test battery to 
investigate changes in both general locomotor activity levels and disruption to 
circadian rhythms. Circadian rhythm disruptions predominantly manifest as 
sleep disturbances in HD patients (Wiegand et al. 1991; Videnovic et al. 2009; 
Aziz et al. 2010) and have also been described in HD mouse models (Hefter et 
al. 1987a; Carter et al. 1999; Morton et al. 2005; Menalled et al. 2009; Wulff et 
al. 2010). Gait abnormalities have been shown in HD patients (Koller and 
Trimble 1985; Hausdorff et al. 1998; Reynolds Jr et al. 1999; Delval et al. 2006; 
Grimbergen et al. 2008; Rao et al. 2008) and HD mouse models (Lin et al. 2001), 
including the HdhQ111 mouse model (Menalled et al. 2009). Thus, gait analysis 
was included in the motor test battery to determine any gait abnormalities. 
Finally, consumption tests were included to determine if animals were able to 
consume food adequately. Difficulties in swallowing, are evident in the later 
stages of the human disease (Leopold and Kagel 1985; Hunt and Walker 1989; 
Kagel and Leopold 1992), thus reducing the ability to consume food.  
In addition to overt motor symptoms, weight loss is common in HD patients 
(Kremer and Roos 1992; Stoy and McKay 2000; Van Raamsdonk et al. 2006), 
even in the early stages of the disease (Djousse et al. 2002). Although the precise 
reasons for weight loss in HD remains unclear it is likely that both the underlying 
metabolic dysfunction (Koroshetz et al. 1997; Mochel et al. 2007b) and the 
chorea and movement abnormalities associated with the disease both contribute 
to the weight loss observed. Decreases in body weight as HD progresses have 
also been described in a range of both transgenic and knock-in mouse models 
(Carter et al. 1999; Brooks et al. 2012d, c; Brooks et al. 2012f), including the 
HdhQ111 mouse line (Oroven et al., 2012). However, the BACHD transgenic 
mouse line demonstrates an increase in body weight during HD disease 
progression (Gray et al. 2008). Therefore, it was necessary to determine the body 
weight progression of the HdhQ111 animals to compare and contrast any weight 
changes seen to further determine how accurately the HdhQ111 mouse model 
accurately reflects the human condition. Furthermore, weight loss was used to 
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determine the health and wellbeing of animals, a 20% weight loss of free feeding 
body weight was used to define a humane endpoint in experimental procedures. 
4.2. Aims 
To characterise the developmental time course, severity and nature of the motor 
phenotype in the HdhQ111 mouse model of HD, using a longitudinal battery of 
motor tests.  
4.3. Materials and Methods.   
4.3.1. Animals. 
A total of 56 age matched mice were used (36 HdhQ111/+ animals, with a CAG 
repeat length range 131-143 and an average of 138 CAG repeats). Of the 36 
HdhQ111/+ mice, 16 were male and 21 were female. Of the 20 wild type mice 10 
were female and 10 were male. Animals were housed in pairs or threes, although 
some animals had to be separated and singly housed to prevent fighting. Testing 
occurred during the light phase from 12.00 hours to 18.00 hours. A female 
HdhQ111/+ animal was culled at 12 months of age, and 2 male animals (1 WT and 
1 HdhQ111/+) were culled at 16 months of age due to health issues unrelated to 
HD.  
4.3.2. Behavioural Methods 
The behavioural methods used in this experimental chapter have been described 
fully in the Materials and Methods sections of Chapter 2, therefore only a brief 
summary of each method is given below.  
Animals were tested at 3 monthly intervals in a behavioural test battery that 
included: locomotor activity, rotarod, grip strength and balance beam. In 
addition, at six monthly intervals additional tests of food and sucrose 
consumption and gait analysis, were added into the test battery, as shown in 
Figure 4.1. 
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Figure 4.1. Longitudinal hand testing time scale. 
Animals were tested in the longitudinal testing battery every 3 months. Rotarod, balance beam, grip strength 
and locomotor activity testing occurred every 3 months, from 3 months of age until 18 months of age. 
Additional tests of gait analysis, food consumption and sucrose consumption were completed at the 6 
month, 12 month and 18 month time points.  
 
4.3.2.1. Weight Progression 
Animals were weighed monthly between 15.00 hours and 16.00 hours. 
4.3.2.2. Spontaneous Locomotor Activity 
Spontaneous locomotor activity was recorded for a total of 32 hours on MED-
PC® software (Med Associates, Vermont, USA). Animals were maintained on 
a 12 hour light/dark cycle from 06.00 hours to 18.00 hours. Animals were 
allowed ad-libitum access to both powdered food and water, which were placed 
at opposite ends of the activity box.  
4.3.2.3. Rotarod 
Animals received 5 days of training on a rotarod apparatus, training sessions 
lasted a maximum of 300 seconds each and were completed on consecutive days. 
Testing consisted of 2 trials (accelerating from 5rpm to 44rpm), the latency to 
fall from the beam was recorded for each trial. If the mouse remained on the 
accelerating beam for the 5 minute testing period, they were removed and given 
a score of 300 seconds.  
4.3.2.4. Grip Strength 
Animals were placed on a mesh grid which was inverted such that the mouse 
was upside down on the under surface of the grid. Latency to fall was recorded, 
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the maximum time allowed per trial was 60 seconds. Each animal was tested 
twice. 
4.3.2.5. Balance Beam 
Animals were trained on the balance beam apparatus to encourage traversing of 
the beam to the goal box located at the elevated high end of the beam. Testing 
consisted of 2 separate trials which were videotaped to enable analysis. The 
animal was placed at the far end of the balance beam; the time taken to turn 
around and traverse the beam to reach the goal box located at the top were 
recorded. While traversing the beam foot slips of the front and hind legs on each 
side were recorded, one side was live scored and the other video recorded to 
enable future analysis. 
4.3.2.6. Sucrose Consumption 
Animals were singly housed with ad-libitum access to water and 4 grams of 
sucrose pellets placed in a dish at the centre of the cage. Sucrose consumption 
was measured for 8 hours during the light phase from 09.00 to 17.00 hours. At 
17.00 hours the quantity of remaining sucrose and the animals were weighed. 
Sucrose consumption testing occurred for a total of 4 consecutive days.   
4.3.2.7. Food Consumption 
Animals were singly housed in a standard cage and allowed ad-libitum access to 
both food and water for a 16 hour overnight period (17.00 hours to 09.00 hours). 
The quantity of food consumed overnight and the weight of the animal was 
recorded the following morning. Food consumption testing occurred for a total 
of 4 consecutive days. 
4.3.2.8. Gait Analysis 
Animals were tested using a clear Perspex corridor apparatus lined with a pre-
cut piece of white paper. Animals were trained to run to the enclosed darkened 
box at the end of the corridor. For testing, the paws of the animal were painted 
with non-toxic paint. The animal was placed at the far end of the apparatus and 
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ran to the enclosed goal box at the far end, leaving a print at the base of the 
apparatus. Stride length, stride width and overlap were then analysed over 3 
consecutive strides. Each animal was tested once.  
4.3.3. Statistical Analysis 
Statistical analyses were conducted in IBM SPSS 20 Statistics Software. 
Typically, three way split plot analyses with ANOVA were used with repeated 
measures of age and between subject measures of genotype and sex, followed 
by simple effects analysis. Where significance was found post-hoc tests with 
Bonferroni corrections were performed. In the cases where missing values were 
present, due to animals needing to be culled for health reasons, missing data were 
estimated by an unbiased iterative interpolation procedure within the IBM SPSS 
statistical analysis.  The critical significance level used throughout was α = 0.05. 
4.4. Motor Characterisation Results 
4.4.1. Weight Progression Results 
Male animals were significantly heavier than their female counterparts 
throughout the 18 months of testing (Sex; F1,52 = 248.05, p<0.001). Wild type 
and HdhQ111/+ animals demonstrated similar body weights at the earlier testing 
time points, however HdhQ111/+ animals subsequently lost body weight in 
comparison to their wild type littermates, as demonstrated by the divergence of 
the wild type and HdhQ111/+ weight curves for both sexes similarly (Age x 
Genotype; F16,832 = 6.98, p<0.001). Post-hoc tests confirmed that the significant 
difference in body weight began at 11 months of age (p<0.05) (as shown in 
Figure 4.2.), and was subsequently shown at 12 months (p<0.01), 13 months 
(p<0.01), 14 months (p<0.05), 15 months (p<0.01), 16 months (p<0.001), 17 
months (p<0.001) and 18 months (p<0.001) of age.  
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Figure 4.2. Weight progression of HdhQ111/+ animals.  
Mice were weighed at 2 months of age and subsequently every month. The data represents the mean weight 
of HdhQ111/+ and wild type animals averaged to provide the data point. The data represents a total 56 animals, 
36 HdhQ111/+ animals (20 female and 16 male) and 20 wild type animals (10 female and 10 male). Error bars 
represent ± standard error of the mean. Significant differences are stated for males and females combined 
* p<0.05, **p<0.01, ***p<0.001. 
4.4.2. Spontaneous Locomotor Activity Results 
Spontaneous locomotor activity was tested longitudinally in HdhQ111/+ animals 
(Figure 4.3.). Animals displayed decreased levels of locomotor activity as they 
aged (Age; F5,255 = 24.42, p<0.001). Furthermore, a significant effect of time of 
day was observed (Time; F24,1224 = 116.65, p<0.001), with animals generally 
becoming more active in the dark phase (18.00 hours to 06.00 hours) than in the 
light phase (Figure 4.3.). However no significant differences were observed in 
locomotor activity between HdhQ111/+ and wild type animals (Genotype; F1,52 = 
0.002, p = n.s.). 
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Figure 4.3. Spontaneous locomotor activity longitudinal results for HdhQ111/+ animals. 
Results are shown as an average over 24 hours (from 15.00 hours to 15.00 hours) at each time point. The 
data represents a total 56 animals, 36 HdhQ111/+ animals (20 female and 16 male) and 20 wild type animals 
(10 female and 10 male). A main effect of time was demonstrated at each age, with animals generally more 
active in the dark phase (18.00 hours to 06.00 hours). No significant differences were demonstrated between 
genotypes at any age. Error bars represent ± standard error of the mean. 
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4.4.3. Grip Strength Results 
HdhQ111/+ animals displayed no impairments in grip strength performance, in 
comparison to wild type animals (Genotype; F1,52 = 1.39, p = n.s.) (Figure 4.4.). 
As animals aged their latency to fall from the grid increased (Age; F5,260 = 3.83, 
p=0.002). Interestingly, male animals performed significantly worse on the grip 
strength test than female animals (Sex; F1,52 = 6.68, p=0.013, data not shown). 
Although this sex difference was shown for both HdhQ111/+ and wild type animals 
(Genotype x Sex: F1,52 = 0.58,  p = n.s.). 
 
Figure 4.4. Grip strength for HdhQ111/+ animals over 18 months. 
Mice were tested at 3 months of age and subsequently every 3 months. The average latency to fall represents 
an average of 2 trials for HdhQ111/+ and wild type animals at each time point. The data represents a total 56 
animals, 36 HdhQ111/+ animals (20 female and 16 male) and 20 wild type animals (10 female and 10 male). 
Grip strength results demonstrated no significant differences between HdhQ111/+ or wild type animals at any 
time points. Error bars represent ± standard error of the mean. 
4.4.4. Rotarod Results 
Rotarod performance over the 18 months of testing demonstrated that HdhQ111/+ 
animals displayed a decreased latency to fall from the rotarod in comparison to 
wild type animals (Genotype; F1,52 = 5.83, p<0.05) (Figure 4.5.). A highly 
significant effect of age was seen, with animals displaying a decreased latency 
to fall from the rotarod as they aged (Age; F5,260 = 15.98, p<0.001). There was a 
trend for HdhQ111/+ animals to have a decreased latency to fall from the rotarod 
as they aged, at 12 months, 15 months and 18 months of age in comparison to 
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wild type animals, but this effect failed to meet significance (Age x Genotype; 
F5,260 = 1.35, p = n.s.). Interestingly male animals performed significantly worse 
than female animals throughout rotarod testing (Sex; F1,52 = 10.46, p<0.01, data 
not shown). 
 
Figure 4.5. Rotarod performance in HdhQ111/+ animals over 18 months. 
The data represents a total 56 animals, 36 HdhQ111/+ animals (20 female and 16 male) and 20 wild type 
animals (10 female and 10 male). Data are shown as an average of 2 trials. Error bars represent ± standard 
error of the mean. * p<0.05.  
4.4.5. Balance Beam Results 
HdhQ111/+ animals were significantly impaired in numerous aspects of balance 
beam performance in comparison to wild type animals (Figure 4.6.). As shown 
in Figure 4.6A, latency to turn on the balance beam was progressively slower as 
animals aged (Age; F5,260 = 13.82, p<0.001). Although HdhQ111/+ animals did not 
differ from wild type animals at younger ages, they were progressively slower 
to turn than wild type controls (Figure 4.6A, Age x Genotype; F5,260 = 3.376, 
p<0.01), from 9 months of age (p<0.05) and subsequently at 12 months (p<0.05), 
15 months (p<0.01) and 18 months of age (p<0.01). Interestingly, female 
animals were shown to turn on the beam significantly faster than male animals 
(Sex; F1,52 = 5.40, p<0.05, data not shown). 
Male animals were slower to traverse the balance beam than female animals 
(Sex; F1,52 = 13.78, p<0.001). Although HdhQ111/+ animals did not differ in 
traverse time from wild type animals at the earliest ages, they were progressively 
slower to traverse the balance beam than wild type animals as they aged (Age x 
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Genotype; F1,52 = 15.29, p<0.001), at 9 months (p<0.01), 15 months (p<0.001) 
and 18 months of age (p<0.001), as shown in Figure 4.6B.  
Measurement of foot slips made while traversing the balance beam (Figure 4.6C) 
demonstrated that the number of foot slips made by HdhQ111/+ animals did not 
differ from wild type animals at younger ages. However, HdhQ111/+ animals made 
progressively more foot slips than wild type animals as they aged (Age x 
Genotype; F5,260 = 40.56, p<0.001) from 12 months of age (p<0.001) and 
subsequently at 15 months (p<0.001) and 18 months of age (p<0.001). 
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Figure 4.6. Balance beam performance in HdhQ111/+ animals over 18 months. 
A. Time to turn on the balance beam demonstrated HdhQ111/+ animals were significantly slower to turn on 
the beam than wild type animals, from 9 months of age. B. Traverse time on the balance beam showed 
HdhQ111/+ animals were significantly slower to traverse the beam than wild type animals from 9 months of 
age. C. Total number of foot slips made while crossing the beam demonstrated HdhQ111/+ animals made 
significantly more foot slips from 12 months of age. The data represents a total 56 animals, 36 HdhQ111/+ 
animals (20 female and 16 male) and 20 wild type animals (10 female and 10 male). Error bars represent ± 
standard error of the mean. * p<0.05, ** p<0.01, *** p<0.001.  
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4.4.6. Sucrose Consumption Results 
Sucrose consumption did not differ between HdhQ111/+ and wild type animals 
(Figure 4.7., Genotype; F1,52 = 2.50, p = n.s.). However, it was shown that the 
quantity of sucrose consumed decreased as animals aged (Age; F2,104 = 228.78, 
p<0.001). Furthermore, no sex differences in sucrose consumption were seen 
(Sex; F1,52 = 5.82, p = n.s.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Sucrose consumption in HdhQ111/+ animals over 18 months. 
The data represents a total 56 animals, 36 HdhQ111/+ animals (20 female and 16 male) and 20 wild type 
animals (10 female and 10 male). The data shown is an average of the 4 days of testing. Error bars represent 
± standard error of the mean. 
4.4.7. Food Consumption Results 
The quantity of food consumed did not differ between HdhQ111/+ and wild type 
animals (Figure 4.8, Genotype; F1,52 = 2.70, p = n.s.). However, animals 
consumed significantly more food as they aged (Age; F2,104 = 40.14, p<0.001), 
despite this no significant interaction effect was demonstrated (Age x Genotype; 
F2,104 = 0.198, p = n.s.). Furthermore, male animals consumed significantly more 
food than female animals (Sex; F1,52 = 6.55, p<0.05). Interestingly female 
HdhQ111/+ animals consumed significantly less food than female wild type 
animals (Genotype x Sex; F1,52 = 7.79, p<0.05, data not shown).   
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Figure 4.8. Food consumption of standard laboratory chow in HdhQ111/+ animals over 18 months. The 
data represents a total 56 animals, 36 HdhQ111/+ animals (20 female and 16 male) and 20 wild type animals 
(10 female and 10 male). The data shown is an average from 4 days of testing. Error bars represent standard 
± error of the mean.  
 
4.4.8. Gait Analysis Results 
HdhQ111/+ animals did not show any impairments in gait performance in 
comparison to wild type animals in stride length (Genotype; F1,52 = 0.04, p = 
n.s.), stride width (Genotype; F1,52 = 0.02, p = n.s.) or stride overlap (Genotype; 
F1,52 = 0.02, p = n.s.), as shown in Figure 4.9. However, as animals aged, their 
stride length decreased (Age; F2,104 = 15.37, p<0.001) (Figure 4.9A), as did their 
stride overlap (Age; F2,104 = 4.36, p<0.05) (Figure 4.9C). However, no significant 
effect of age was seen in stride width (Age; F1,52 = 3.61, p = n.s.) (Figure 4.9B). 
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Figure 4.9. Gait analysis results for HdhQ111/+ animals over 18 months.  
No significant differences were observed between HdhQ111/+ and wild type animals in any measure of gait 
analysis. The data represents a total 56 animals, 36 HdhQ111/+ animals (20 female and 16 male) and 20 wild 
type animals (10 female and 10 male). Error bars represent ± standard error of the mean.  
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4.5. Discussion 
The results of the longitudinal motor characterisation of HdhQ111/+ animals 
presented in this chapter demonstrate that significant motor deficits occur in 
HdhQ111/+ animals, as measured in balance beam performance from 9 months of 
age and a decreased latency to fall from the rotarod from 12 months of age. 
HdhQ111/+ animals also had a significantly lighter body weight than wild type 
animals from 11 months of age.  
The observed weight differences replicate previous findings in other mouse 
models of HD, which shows progressive weight loss as disease burden increases 
(Carter et al. 1999; Brooks et al. 2012d, c; Brooks et al. 2012f). Although, the 
observed onset of weight loss differs for each specific mouse strain. 
Furthermore, the progressive weight loss demonstrated in HdhQ111/+ animals is 
reflective of the weight loss shown in the human condition (Kremer and Roos 
1992; Stoy and McKay 2000; Djousse et al. 2002; Aziz et al. 2008). Although 
the underlying reasons for the associated weight loss are still unknown, the lack 
of observable chorea in HdhQ111/+ mice, despite weight loss, may be indicative 
of an underlying metabolic problem which causes the observed weight loss. This 
suggestion has been explored in human HD patients (Mazziotta et al. 1987; 
Browne et al. 1997; Koroshetz et al. 1997) and in other mouse strains (Duan et 
al. 2003a; Tsang et al. 2006; Weydt et al. 2006; van der Burg et al. 2008), 
although, it is yet to be confirmed in the HdhQ111 mouse model of HD. 
Furthermore, the results obtained on several of the motor tests can be sensitive 
to the confounding effects of body weight. The effect, if any that the weight 
changes had on the motor read outs presented here is uncertain. Although, if 
weight were to influence the motor results obtained, it may be that heavier 
animals, which are in this case wild type animals, are likely to be disadvantaged 
in certain tasks such as the rotarod, in comparison to HdhQ111/+ animals, which is 
not the case in the observed results. However, it could also be argued that a 
decreased body weight may be advantageous in other motor tests such as the 
balance beam. If this was the case, HdhQ111/+ animals would not show a deficit 
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in comparison to wild type animals, which is not the case in the observed results, 
as balance beam deficits are shown in HdhQ111/+ animals despite significant 
weight loss in comparison to wild type animals.      
Significant motor deficits were seen in HdhQ111/+ animals in turn time and 
traverse time on the balance beam apparatus from 9 months of age, thus 
suggesting an inability to initiate movement and subsequently move along the 
beam. Furthermore, the increased number of foot slips that HdhQ111/+ animals 
made while crossing the balance beam compared to wild type animals, at 12, 15 
and 18 months of age, are indicative of progressive impairments in motor co-
ordination and balance. Sex differences were demonstrated, with female animals 
generally displaying a more rapid time to turn and traverse the beam, although 
these differences between sexes were not consistently produced over time and 
their level of significance was not as high as that of the genotype differences. 
Problems with balance are important to consider in people who are affected by 
HD, as this can lead to an increased risk of falls (Busse et al. 2009) and thus, a 
reduced quality of life (Helder et al. 2001; Ready et al. 2008; Ho et al. 2009).  
Further motor deficits were demonstrated in HdhQ111/+ animals in rotarod 
performance, as HdhQ111/+ animals displayed a decreased latency to fall from the 
rotarod in comparison to wild type animals. These deficits in rotarod 
performance are again indicative of problems with co-ordinated motor 
movement in HdhQ111/+ animals. Significant gender differences were observed in 
rotarod performance, with female animals performing significantly better on the 
rotarod than male animals. These gender differences may be attributable to 
differences in weight between male and female animals which were shown at all 
of the testing time points. This suggestion has previously been described in other 
outbred mouse strains (McFadyen et al. 2003).  
Although HdhQ111/+ animals displayed significant deficits in balance beam 
traverse time from 9 months of age, no significant deficits were seen in 
spontaneous locomotor activity. Therefore, it may be the case that when these 
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animals are free to move in the locomotor activity cages no significant 
differences in activity are observed. Whereas, when HdhQ111/+ animals are 
challenged to initiate movement and traverse a beam or accelerate on a rotarod, 
they find the task significantly harder than wild type animals. Therefore, the lack 
of observable deficits in spontaneous locomotor activity suggests that the deficits 
seen in both rotarod and balance beam are indeed indicative of a specific 
involvement in motor co-ordination and balance. 
Spontaneous locomotor activity was studied in the HdhQ111/+ mouse model of HD 
because significant alternations in circadian rhythm have been previously 
reported in HD patients (Wiegand et al. 1991; Videnovic et al. 2009; Aziz et al. 
2010; Wulff et al. 2010); however, such differences were not observed in this 
case in the HdhQ111/+ mouse model. Furthermore, overall, animals displayed 
decreased activity as they aged, although this may be the result of the natural 
aging process it may also be attributable to habituation effects. As animals were 
tested in the motor test battery every 3 months, they were required to be tested a 
total of 6 times within the testing battery. Therefore, it could be the case that 
animals became increasingly habituated to the locomotor activity boxes and thus 
moved less during testing. This is suggested in particular by the large decline in 
locomotor activity between the first and second tests, at 3 months of age and 6 
months of age respectively, before other motor deficits were apparent. 
Furthermore, this suggestion may also be valid for the other motor tasks. 
Because the same animals were used repeatedly in the longitudinal testing 
paradigm, this meant that animals received repeated testing on the motor tasks 
at a young age; therefore this exposure and testing on the motor tests at a young 
age may affect future motor test read outs. To prevent this occurring in future 
longitudinal motor characterisations, a new group of animals could be tested at 
each time point, although this would have considerable ethical, financial and 
logistical implications. A full discussion of the experimental design used in 
longitudinal testing is given in the General Discussion in Chapter 8. 
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The lack of genotype differences in grip strength is perhaps unsurprising due to 
the relatively insensitive nature of the behavioural test, with the majority of 
animals performing close to the 60 second ceiling in the protocol. This grip 
strength test is highly likely to be influenced by differences in body weight, with 
heavier animals falling from the grid more rapidly than lighter animals. 
However, if this were to be the case it is likely to disadvantage wild type animals 
rather than HdhQ111/+ animals. Furthermore, the time that each grip strength trial 
was conducted for (60 seconds) is in accordance with the relevant licencing 
requirements to minimise pain, suffering, distress and lasting harm to animals. 
However, this may not be long enough to draw out any genotype differences. It 
is therefore plausible that extending the test duration to 2 or 3 minutes may 
increase the sensitivity of the task, but this is yet to be investigated. Therefore, 
the grip strength behavioural test, which in this case utilised an inverted grid, 
may not be a sensitive test measure. Attempts to use mechanical grip strength 
metres (Van Riezen and Boersma 1969) have been used successfully in 
observing deficits in grip strength in other genetically modified mouse models 
(Barnéoud et al. 1997; Glynn et al. 2005) and in the R6/2 mouse model of HD 
(Hickey et al. 2005). Although, typically mechanical grip strength meters only 
test forelimb grip strength, and it can be difficult to motivate mice to sustain 
clinging onto the bar of the grip strength meter.  
Sucrose and food consumption measures demonstrated no significant differences 
between HdhQ111/+ and wild type animals. These measures were included in the 
testing battery to probe motivation and physical ability to consume palatable and 
less palatable food stuffs. Although problems with food consumption including 
dysphagia have been shown in HD patients (Leopold and Kagel 1985; Hunt and 
Walker 1989; Kagel and Leopold 1992), these symptoms often occur in the later 
stages of the disease and therefore the behavioural phenotype of the HdhQ111/+ 
mouse model may be too subtle to demonstrate significant behavioural 
differences in these measures.    
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Gait abnormalities have previously been observed in both HdhQ111/+ and 
HdhQ111/Q111 mice at 24 months of age (Wheeler et al. 2002a), although these 
animals were bred on a CD1 background strain, which is different to the 
background strain of the animals used here. No gait abnormalities were observed 
in the HdhQ111/+ animals in this case, although the characterisation was only 
conducted until 18 months of age, therefore it may be the case that such 
abnormalities would have developed if the characterisation were to be extended 
to 24 months of age. However, significant motor abnormalities were 
demonstrated in other motor tests and thus for practical, financial and welfare 
reasons it was pre-planned to end the motor characterisation at 18 months of age.  
Gender differences were demonstrated in some of the motor tasks, with female 
animals often performing better than male animals. Typically, this was an 
independent influence on the behavioural results and there were no interactions 
demonstrated between sex and genotype. The gender differences between male 
and female animals do not appear to be stable within the behavioural results of 
the motor tests. Therefore, gender differences could be attributable to the 
oestrous cycle of female animals. Although it is plausible to use a single sex of 
animals in behavioural testing, HD is a disease which affects both genders 
equally (Wexler 2004) and thus both genders were used in behavioural testing 
to reflect this. Gender differences have previously been observed in the HdhQ111 
mouse line, with male animals demonstrating increased anxiety (Oroven et al., 
2012). However Oroven et al., used HdhQ111/Q111 animals and therefore an 
anxious phenotype may not be observed in HdhQ111/+ mice. Anxiety 
measurements were not conducted in this particular study and may have been 
demonstrated if anxiety was to be investigated.  
The longitudinal motor characterisation presented here, demonstrated a gradual 
decrease in body weight in HdhQ111/+ animals, with respect to their wild type 
littermates. The emergence of motor deficits in balance beam performance from 
9 months of age, and in rotarod performance in HdhQ111/+ animals, demonstrates 
subtle and progressive motor deficits which resemble the early stages of motor 
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dysfunction in HD, as the deficits are specific in nature and lack the gross 
dyskinesia observed in late stage HD patients.   
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Chapter 5 : Longitudinal operant testing to probe 
cognitive dysfunction in the HdhQ111 mouse model 
of Huntington’s disease. 
5.1. Introduction 
In the previous chapter, motor dysfunction was demonstrated in HdhQ111/+ mice 
in both balance beam and in rotarod performance measures. However, 
behavioural deficits that are present prior to the onset of motor dysfunction have 
been shown in HD patients. Specific deficits can include; lack of motivation, 
depression, apathy, anxiety and reduced ability to switch tasks, have been 
demonstrated in human HD patients prior to the presentation of profound motor 
dysfunction (Diamond et al. 1992; Kirkwood et al. 2000; Aron et al. 2003; 
Lemiere et al. 2004; Duff et al. 2007; Robins Wahlin et al. 2007; Paulsen et al. 
2008b). Behavioural deficits have further been demonstrated in a range of 
knock-in HD mouse models, these include specific deficits in; motivation, 
attention, extra dimensional set-shifting and working memory (Lione et al. 1999; 
Van Raamsdonk et al. 2005; Brooks et al. 2006; Trueman et al. 2007, 2008b; 
Brooks et al. 2012d, c; Brooks et al. 2012e; Brooks et al. 2012f; Giralt et al. 
2012; Trueman et al. 2012b; Trueman et al. 2012e). Cognitive and behavioural 
dysfunctions such as these, have been shown to significantly affect the daily 
activities of people with HD, often reducing independence, causing isolation and 
reducing overall quality of life (Helder et al. 2001; Ready et al. 2008; Ho et al. 
2009). Therefore, cognitive dysfunctions are a core early symptom of HD and in 
order to assess whether a mouse model of HD is valid and replicative of the 
human condition a longitudinal characterisation of the development of any 
associated cognitive deficits is necessary.  
Cognitive deficits have previously been investigated in mouse models of HD 
using swimming tests including the Morris water maze (Lione et al. 1999; Van 
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Raamsdonk et al. 2005; Brooks et al. 2012a; Brooks et al. 2012c, d; Brooks et 
al. 2012f) and the water T-maze apparatus (Van Raamsdonk et al. 2005; Brooks 
et al. 2012a; Brooks et al. 2012e). However, in comparison to these swimming 
tests, operant testing allows more a sensitive, unbiased, rapid and automated way 
of testing for specific cognitive deficits. Operant testing has previously been 
utilised in numerous HD mouse models to determine cognitive dysfunction in a 
range of operant tasks, often in the absence of motor symptoms (Balci et al. 
2009; Brooks et al. 2012e; Brooks et al. 2012h; Oakeshott et al. 2012; Trueman 
et al. 2012b; Trueman et al. 2012e). Therefore, we sought to determine the 
cognitive phenotype of the HdhQ111 mouse model of HD utilising a longitudinal 
operant test battery which was designed to probe specific and discrete cognitive 
functions. 
There is evidence for the use of the frontal striatal system, which is known to be 
affected in HD, in cognitive learning (Poldrack et al. 1999) which may affect the 
ability of people with HD to learn new cognitive tasks. HD patients have 
previously been shown to be unable to acquire certain tasks (Heindel et al. 1988) 
due to deficits particularly in procedural learning (Knopman and Nissen 1991). 
Therefore, the ability of HdhQ111/+ animals to initially learn and then 
subsequently reacquire the task of ‘nose poking’ was explored using a standard 
fixed ratio (FR1) schedule.  
Once animals had successfully acquired the ‘nose poke’ response, they were 
tested on an FR1 schedule which utilised different reward sizes. Thus, perception 
of the value of the different reward sizes was tested. Motivation and apathetic 
behaviours in responding were explored utilising a progressive ratio (PR) 
operant task which required animals to respond to a light stimulus an increasing 
number of times to obtain a reward. This measured the motivation and 
willingness of animals to maintain responding for a reward when the level of 
responding required to achieve this reward successively increased. Exploration 
of motivational problems in HdhQ111/+ animals was probed as alterations in 
motivation have previously been described in the PR task in other mouse models 
Chapter 5                                              Longitudinal Operant Characterisation 
102 
 
of HD (Oakeshott et al. 2012) and in HD patients (Burns et al. 1990; Paulsen et 
al. 2001b; Thompson et al. 2002b). In addition, different reward sizes were 
utilised to explore perception of value in responding to reward and flexibility in 
responding to the different reward sizes.  
The five choice serial reaction time task (5-CSRTT) was designed to probe 
attentional function and spatial awareness, as deficits in executive functions, 
including spatial perception and attentional sharing have previously been 
demonstrated in HD patients (Sprengelmeyer et al. 1995; Claus and Mohr 1996; 
Lawrence et al. 1998b; Murphy et al. 2000; Lemiere et al. 2004; Finke et al. 
2006; Delval et al. 2008; Thompson et al. 2010). These specific cognitive 
deficits have been shown to significantly affect everyday activities, increasing 
the risk of falls and reducing quality of life for people with HD (Helder et al. 
2001; Ready et al. 2008). The stimulus length was decreased in the 5-CSRTT to 
increase the attentional load of the task. Animals were therefore required to pay 
attention to the stimulus lights, utilising spatial awareness and attention in order 
to respond accurately, particularly when the shorter stimulus lengths were 
applied.  
The serial implicit learning task (SILT) was designed as an extension of the 5-
CSRTT, it therefore required an additional response (a total of two responses) to 
obtain a reward. This task was included in the test battery to probe attention and 
spatial awareness, as the 5CSRTT does but, in addition, to test implicit learning. 
Previous attempts to explore implicit learning deficits in HD patients have 
demonstrated mixed results; while some have shown clear implicit learning 
impairments, prior to the onset of motor symptoms (Knopman and Nissen 1991; 
Willingham and Koroshetz 1993; Ghilardi et al. 2008), others have concluded 
that implicit learning is unaffected in the HD patient population (Bylsma et al. 
1991; Brown et al. 2001). Therefore, a SILT operant task was included in the 
operant test battery to investigate if any deficits in implicit learning were 
observed in the HdhQ111/+ mouse model of HD.  
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The operant test battery used in this experiment therefore comprised; initial 
stimulus response training, acquisition and maintenance of a simple fixed ratio 
1 schedule (FR1), progressive ratio (PR) to determine intrinsic levels of 
motivation, the five choice serial reaction time task (5CSRTT) to probe 
attentional dysfunction and the serial implicit learning task (SILT) to determine 
attentional function and implicit learning. The inclusion of these operant tasks 
within the test battery was necessary to determine cognitive deficits associated 
with the HdhQ111 mouse model of HD.  
5.2. Aims 
To determine the face and predictive validity of the HdhQ111 mouse model of HD 
by characterising the nature, severity and time course of cognitive deficits using 
an operant test battery.  
5.3. Materials and Methods 
5.3.1. Animals 
A total of 16 animals, 7 HdhQ111/+ (4 female and 7 male) and 9 wild type (5 
female and 4 male) were used. HdhQ111/+ animals contained an average of 137 
CAG repeats, which ranged from 122 repeats to 142 repeats. A female HdhQ111/+ 
animal became ill at approximately 13 months of age, this animal was humanely 
euthanised. For further details regarding animal husbandry see section 2.1 of 
Chapter 2.  
Operant testing occurred between 08.00 and 12.00 hours, 5 days per week. 1 
week prior to operant testing animals were gradually water restricted and 
habituated to strawberry milkshake (Yazoo® Campina Ltd, Horsham, UK) in 
their home cages. For the duration of operant testing animals were restricted to 
3 hours of access to water per day, given after behavioural testing between the 
hours of 14.00 hours and 17.00 hours. Throughout the experiments animals were 
allowed ad-libitum access to standard laboratory chow food.   
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The operant testing battery took approximately 3 months to complete at each age 
of testing (Figure 5.1). Therefore, the time point stated (6, 12 or 18 months of 
age) represents the mid-point in each phase of testing, with mice reaching the 
stated age of testing typically during the 5-CSRTT test.   
5.3.2. 9-hole Operant Box Apparatus 
A full description of the 9-hole operant boxes used in behavioural testing is given 
in section 2.3.1. of Chapter 2. It should be noted that only holes; 1, 3, 5, 7 and 9 
were used in any given test presented in this experimental chapter. Consequently 
black plastic film was placed in the light array to block unused holes (2, 4, 6 and 
8) to prevent their use. 
5.3.3. 9-hole Operant Box Testing  
An operant test battery was conducted longitudinally, as shown in Figure 5.1, at 
6 months, 12 months and 18 months of age. A full description of the operant 
tests used is given in section 2.3.4. of Chapter 2, however a brief description is 
also given below.   
At 10 weeks of age mice were introduced to the 9-hole operant chambers. 
Magazine training began with the non-contingent delivery of 150µl of 
strawberry milk into the magazine and illumination of the magazine light, for 1 
day. Reward retrieval was detected by nose entry then withdrawal from the 
magazine, which broke the infrared beam across the magazine. After successful 
reward retrieval the magazine light was extinguished. The process was repeated 
until the 20 minute session time had elapsed. 
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Figure 5.1. Schematic representation of operant testing timeline. Animals were tested in the operant battery at 6 monthly intervals at 6 months, 12 months and 18 months of 
age. Due to the time it took to complete the operant battery animals began testing one and a half months prior to testing for that time point, animals finished testing one and a half 
months after the required time point.  
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After magazine training, mice were taught to nose poke on a simple FR1 
schedule of reinforcement which required illumination of the central hole in the 
array of the 9-hole operant box. To obtain reward, mice were required to respond 
to the stimulus light in hole 5 via a single nose poke. A correct nose poke in 
response to the stimulus light triggered the extinguishing of the centre light and 
simultaneous illumination of the magazine light and delivery of 5µl of reward 
into the magazine. Upon withdrawal of the animal’s nose from the magazine, the 
next trial was initiated with the illumination of the central light. In order to 
promote learning the central light was painted with strawberry milk to encourage 
nose poking into the illuminated hole. Mice were trained on this program until 
they had achieved over 100 pokes into the central hole within the 20 minute 
session without encouragement from painting of the holes.  
5.3.3.1. Fixed Ratio (FR) Testing 
FR testing was conducted after FR1 training (described above). The purpose of 
this test was to test investigate the amenability of responding to the delivery of 
varying reward sizes. Mice were required to poke into the central hole of the 
array, in response to illumination, to obtain reward. The program utilised varying 
reward sizes of 2.5µl, 5.0µl and 7.5µl, which were delivered into the magazine. 
Animals were reinforced with 5.0µl of reward for the first 3 days of testing, 2.5µl 
of reward for the next 3 days, before finally rewarding animals with 7.5µl of 
reward for the final 3 days of testing. The number of pokes into the central hole 
was recorded in response to reward size, over the 45 minute session time.   
5.3.3.2. Progressive Ratio (PR) Testing 
PR task tested the motivation of the mice to obtain reward. The PR schedule of 
reinforcement required an increasing number of nose poke responses, into the 
illuminated central hole of the array to obtain successive rewards. The number 
of responses required to obtain reward increased by 3 after the repetition of each 
ratio (responses required per reward; 1, 1, 1, 3, 3, 3, 6, 6, 6, 9, 9, 9 etc). The 
motivation of the animals to obtain reward was recorded as the ratio attained 
after a 60 minute session and by measuring the response ratio attained before a 
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defined period of non-responding (30 seconds), this time period was termed a 
break point. The ratio attained by each animal at each break point was recorded. 
Each session lasted for 1 hour. 
5.3.3.3. 5-Choice Serial Reaction Time Task (5-CSRTT) Testing 
In the 5-CSRTT animals were trained to respond, via nose poking, to a stimulus 
light which was presented randomly across the 5 hole array, in order to receive 
a reward. The task was modified from those previously described in rats (Cole 
and Robbins 1989) to be conducted in mice. The purpose of this task was to 
investigate spatial awareness and attentional performance. The use of 3 different 
stimulus lengths (10 seconds, 2 seconds and 0.5 seconds) increased the difficulty 
and attentional load of the task. The stimulus length used became increasing 
shorter over the testing period. For the first 10 days of testing a 10 second 
stimulus length was presented, a stimulus length of 2 seconds was used for the 
next 5 days and a stimulus length of 0.5 seconds was used for the final 5 five 
days. If a response was not made within 10 seconds after the presentation of the 
stimulus (termed a ‘limited hold’), the light was extinguished (termed a ‘limited 
hold’) and a time-out period of 10 seconds was initiated by illumination of the 
house light. The process was repeated until the 30 minute session time had 
elapsed. 
5.3.3.4. Serial Implicit Learning Task (SILT) Testing 
For SILT testing animals were trained to respond to a 2-step sequence of lights 
in order to receive a reward. A continuous stimulus light was randomly presented 
in one of the 5 holes across the array. A correct response to the first stimulus 
light (S1) resulted in the simultaneous extinguishing of this light and 
illumination of a second light (S2). A correct response to S2 resulted in delivery 
of a 5µl reward into the magazine. A predictable stimulus sequence (hole 7 was 
always illuminated after hole 3) was embedded among other unpredictable 
sequences in order to probe implicit learning. The test was repeated until the 30 
minute session time had elapsed. 
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5.3.4. Statistical Analysis 
Statistical analyses were conducted in IBM SPSS Statistic 20 software. Repeated 
measures ANOVAs, were conducted, followed by simple effects analysis. 
Where significance was found post-hoc analyses with Bonferroni corrections 
were performed. In the cases where missing values were present, data were 
estimated by an unbiased iterative interpolation procedure within the statistical 
analysis. The critical significance level used throughout was α= 0.05. 
5.4. Results 
5.4.1. Training Results 
All animals were trained on a simple FR1 schedule. Initial, training was 
conducted for 13 days to allow animals to learn and acquire the nose poke 
response. At subsequent testing ages, animals were required to complete FR1 
training again for 8 days at each testing age to reacquire nose poke responding 
after a rest period in testing.   
During initial training in the nose poke response, animals were trained for a total 
of 13 days until the levels of responding had plateaued. No significant 
differences in performance were demonstrated between wild type and HdhQ111/+ 
animals (Genotype; F1,12 = 0.51, p = n.s.) or between sexes (Sex; F1,12 = 1.95, p 
= n.s.) (Figure 5.2). However, all animals made an increasing number of nose 
poke responses over subsequent days (Time; F12,144 = 24.15, p<0.001), as they 
successfully acquired the nose poke response.  
Animals were re-trained on the FR1 schedule for 8 days at 12 months of age for 
the second testing age. HdhQ111/+ animals were able to reacquire the nose poke 
response to the same degree as wild type animals (Genotype; F1,12 = 3.01, p = 
n.s.). No significant sex differences were observed (Sex; F1,12 = 1.26, p = n.s.). 
But, as was seen at the earlier time point, a significant overall effect of time was 
demonstrated (Time; F7,84 = 44.67, p<0.001), with the overall number of 
responses increasing on subsequent days as shown in Figure 5.2., as animals 
reacquired the nose poke response.   
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At the final 18 month age of testing, animals were placed on the training schedule 
for 8 days. HdhQ111/+ animals were unable to make as many nose poke responses 
as wild type animals over the 8 days of training (Genotype; F1,12 = 5.85, p<0.05). 
Thus indicating that HdhQ111/+ animals were now unable to reacquire the nose 
poke response in the same way that wild type animals were able to do so. There 
was a trend for female animals to make more responses than male animals at 18 
months of age, although this trend failed to meet significance (Sex; F1,12 = 4.650, 
p = 0.052). A significant overall effect of time was also seen, as animals learnt 
to reacquire the nose poke response on subsequent days of training (Time; F7,48 
= 4.217, p<0.05). 
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Figure 5.2. Longitudinal Operant Training Results for HdhQ111/+ animals. Nose poke training raining at 6 months of age revealed no genotype or sex differences but a significant 
main effect of time was seen. Training at 12 months of age demonstrated no significant effect of sex or genotype although a significant main effect of time was seen. Training at 18 
months of age revealed HdhQ111/+ animals made significantly fewer nose poke responses than wild type animals. An overall significant effect of time was seen. Data are shown for 
a total of 16 mice, 7 HdhQ111+ (4 female and 3 male) and 9 wild type (5 female and 4 male). Data are presented as the average number of nose poke responses made by either 
HdhQ111/+ or wild type mice across each day of testing at each age. Error bars represent ± standard error of the mean, * p<0.05. 
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5.4.2. Fixed Ratio Results 
Once all animals had successfully learnt the nose poke response, or reacquired 
the nose poke response (as shown above in 5.5.1.), the program was manipulated 
to investigate the effects of using different reward sizes on responding. Animals 
made significantly more responses at the smaller reward sizes (Reward size; F2,24 
= 105.64, p<0.001). When all testing ages and reward sizes were considered, 
overall HdhQ111/+ animals made significantly fewer responses than wild type 
animals (Genotype; F1,12 = 11.355, p<0.01). Despite a trend for HdhQ111/+ animals 
to make fewer responses than wild type animals as they aged, this trend failed to 
meet significance (Age x Genotype; F2,24 = 3.078, p=0.065). HdhQ111/+ animals 
made significantly fewer responses to the smallest 2.5µl reward in comparison 
to wild type animals when all ages were considered (Genotype x Reward size; 
F2,24 = 11.88, p<0.001), this effect was largely driven by the results seen at the 
18 month time point, as shown in Figure 5.3. 
HdhQ111/+ animals made a similar number of responses as wild type animals at 
each reward size at 6 months of age and 12 months of age, as shown in Figure 
5.3. However, at 18 months of age, HdhQ111/+ animals made fewer responses than 
wild type animals at all reward sizes. Therefore, restricted analysis of the 18 
month time point only, demonstrated that HdhQ111/+ animals made significantly 
fewer responses at all reward sizes in comparison to wild type controls 
(Genotype; F1,12 = 12.65, p<0.01), which was not seen at either of the earlier ages 
(Figure 5.3.). Interestingly, HdhQ111/+ female animals made significantly fewer 
responses than female wild type animals when all testing conditions were 
considered (Sex; F 1,12 =13.57, p<0.01).  
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Figure 5.3. Longitudinal Fixed Ratio (FR) Results for HdhQ111/+ animals. FR results demonstrated a significant overall effect of reward size, with animals responding more for 
smaller reward sizes. HdhQ111/+ animals made significantly fewer responses than wild type animals when all testing conditions were considered. HdhQ111/+ animals made significantly 
fewer responses than wild type animals, which was driven by the result at the 18 month time point. Data are shown for a total of 16 mice, 7 HdhQ111+ (4 female and 3 male) and 9 
wild type (5 female and 4 male). Data are shown as the average number of responses made over 3 days of testing for HdhQ111/+ or wild type animals. Error bars represent ± standard 
error of the mean. Significance considers genotype differences over all ages of testing, ** p<0.01.   
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5.4.3. Progressive Ratio Results 
Animals were able to reach a higher ratio of responding in PR testing when larger 
reward sizes were used in testing (Reward size; F2,24 = 46.53, p<0.001) and 
animals were able to reach higher ratios of responding at higher break points 
(Break point; F5,60 = 116.99, p<0.001), as seen in Figure 5.4. 
HdhQ111/+ animals demonstrated a reduced ratio of attainment in comparison to 
wild type animals (Genotype; F1,12 = 4.26, p<0.05), although this deficit was not 
shown to be progressive over time (Age x Genotype; F2,24 = 0.542, p = n.s.). 
Furthermore, no significant sex differences were demonstrated (Sex; F1,12 = 4.26, 
p = n.s.).  
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Figure 5.4. Longitudinal Progressive Ratio (PR) Results for HdhQ111/+ animals. Animals were able to reach a higher ratio of responding in PR testing when larger reward sizes 
were used in testing and animals were able to reach higher ratios of responding at higher break points. HdhQ111/+ animals demonstrated a reduced ratio of attainment in comparison 
to wild type animals, although this deficit was not shown to be progressive over time. Data are shown for a total of 16 mice, 7 HdhQ111+ (4 female and 3 male) and 9 wild type (5 
female and 4 male). Data are shown as the average number of responses made over 3 days of testing, for each reward size, for HdhQ111/+ or wild type animals. Error bars represent 
± standard error of the mean. Significance considers genotype differences over all ages of testing,* p<0.05.  
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5.4.4. Five Choice Serial Reaction Time Task (5-CSRTT) Results 
Animals initiated significantly fewer trials in the 5-CSRTT when the stimulus 
length was decreased and the attentional load of the task was therefore increased, 
at all testing ages (Figure 5.5: Stimulus length; F2,24 = 118.49, p<0.001).  
HdhQ111/+ animals initiated significantly fewer trials than wild type animals when 
all ages and stimulus lengths were considered (Genotype; F1,12 = 10.14, p<0.01), 
although no significant interaction effect was demonstrated (Age x Genotype; 
F2,24 = 0.43, p = n.s.). However, restricted analysis of the 18 month age 
demonstrated a highly significant difference between genotypes, with HdhQ111/+ 
animals initiating significantly fewer trials than wild type animals at all stimulus 
lengths (Genotype; F1,12 = 8.04, p<0.05).  
 
Figure 5.5. Total trials started in the 5-Choice Serial Reaction Time Task (5-CSRTT) longitudinally 
in HdhQ111/+ animals. Animals initiated significantly fewer trials as the stimulus length was decreased, at 
all ages. HdhQ111/+ animals initiated significantly fewer trials than wild type animals, largely due to the 
magnitude of difference in the number of initiated trials at 18 months of age. Data are shown for a total of 
16 mice, 7 HdhQ111+ (4 female and 3 male) and 9 wild type (5 female and 4 male) and is the average number 
of responses made over 5 days of testing at each stimulus length. Error bars represent ± standard error of 
the mean. Significance considers genotype differences over all ages of testing, ** p<0.01.  
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Decreasing the stimulus length led animals to make significantly less accurate 
responses (Stimulus length; F2,24 = 291.86, p<0.001) when all testing ages were 
considered (Figure 5.6.). Furthermore, animals were significantly more accurate 
in responding into the central hole in comparison to the peripheral holes in all 
testing conditions (Hole; F4,48 = 25.12, p<0.001).  
When all testing ages were included in the analysis, HdhQ111/+ animals were 
significantly less accurate in responding in the 5-CSRTT in comparison to wild 
type animals (Genotype; F1,12 = 5.00, p<0.05), although this deficit was stable 
over time (Age x Genotype; F2,24 = 0.33, p = n.s.). The overall genotype 
difference was largely driven by deficits observed at the shortest 0.5 second 
stimulus length, rather than at the longer stimulus lengths of 10 seconds and 2 
seconds, as shown in Figure 5.6. 
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Figure 5.6. Accuracy in the 5-Choice Serial Reaction Time Task (5-CSRTT) longitudinally in HdhQ111/+ animals. Animals were significantly less accurate in responding at 
shorter stimulus lengths and were significantly more accurate is responding to the central hole in comparison to the peripheral holes. HdhQ111/+ animals were significantly less 
accurate than wild type animals, although no Genotype x Age interaction was demonstrated. Data are shown for a total of 16 mice, 7 HdhQ111+ (4 female and 3 male) and 9 wild 
type (5 female and 4 male) and is the average number of responses made over 5 days of testing at each stimulus length. Error bars represent ± standard error of the mean. Significance 
considers genotype differences over all ages of testing, * p<0.05. 
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Animals were significantly faster to respond in the 5-CSRTT when the stimulus 
length was decreased (Stimulus length; F2,24 = 108.18, p<0.001). This effect was 
due to an increase in response time at the 10 second stimulus length, in 
comparison to the response time at the 2 second and 0.5 second stimulus lengths, 
at all ages of testing (Figure 5.7.). Furthermore, animals were significantly faster 
to respond into the central hole of the array in comparison to the peripheral holes 
in all testing conditions (Hole; F4,48 = 12.01, p<0.001). 
The HdhQ111/+ animals were significantly slower to respond to stimulus in the 5-
CSRTT than wild type animals, when all testing ages were considered, 
(Genotype; F1,12 = 13.19, p<0.01), however no statistically significant interaction 
effect was observed (Age x Genotype; F2,24 = 0.23, p = n.s.). Restricted analysis 
of each age revealed a progressive phenotype; no significant differences in 
response time were observed between HdhQ111/+ and wild type animals 6 months 
of age; (Genotype; F1,12 = 7.56, p = 0.123), but HdhQ111/+ animals were 
significantly slower to respond than wild type animals at 12 months of age 
(Genotype; F1,12 = 8.29, p<0.05) and 18 months of age (Genotype; F1,12 = 12.72, 
p<0.01).  
Interestingly, in female HdhQ111/+ animals the response time was significantly 
slower than in female wild type animals in all experimental conditions 
(Genotype x Sex; F1,12 = 10.80, p<0.01), although no significant differences were 
observed between the response time performance of male animals.   
Chapter 5                                                                                                                                       Longitudinal Operant Characterisation 
119 
 
 
Figure 5.7. Response time in the 5-Choice Serial Reaction Time Task (5-CSRTT) longitudinally in HdhQ111/+ animals. Animals responded faster to the shorter stimulus lengths 
and into the central hole in comparison to peripheral holes. HdhQ111/+ animals were significantly slower to respond to the stimulus than wild type animals. Female HdhQ111/+ animals 
were significantly slower to respond than female wild type animals. Data are shown for a total of 16 mice, 7 HdhQ111+ (4 female and 3 male) and 9 wild type (5 female and 4 male) 
and is the average number of responses made over 5 days of testing at each stimulus length. Error bars represent ± standard error of the mean. Significance considers genotype 
differences over all ages of testing, ** p<0.01. 
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In the 5-CSRTT when the stimulus length was decreased, and the attentional 
load of the task was increased, the number of time outs made by animals 
significantly increased (Stimulus length; F2,24 = 82.54, p<0.001). Furthermore, 
animals made more time outs when responding into the peripheral holes in 
comparison responses made into the central hole (Hole; F4,48 = 6.82, p<0.001), 
as shown in Figure 5.8. The number of time outs made did not differ between 
HdhQ111/+ and wild type animals (Genotype; F1,12 = 3.81, p = n.s.). Despite a trend 
for HdhQ111/+ animals to make more time-out responses than wild type animals 
when restricted analysis was performed at 18 months of age, this failed to meet 
significance (Genotype; F1,12 =1.85, p = n.s.).    
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Figure 5.8. The number of time outs made in the 5-Choice Serial Reaction Time Task (5-CSRTT) longitudinally in HdhQ111/+ animals. Animals made significantly more 
time outs as stimulus length decreased. Animals also made significantly more time outs at the peripheral holes in comparison to the central hole. Data are shown for a total of 16 
mice, 7 HdhQ111+ (4 female and 3 male) and 9 wild type (5 female and 4 male) and is the average number of responses made over 5 days of testing at each stimulus length. Error 
bars represent ± standard error of the mean.  
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5.4.5. Serial Implicit Learning Task (SILT) Results 
SILT analysis comprised of S1 and S2 accuracy and response time measures to 
probe attention and motor function, as well as accuracy and response time 
measures for the predictable sequence (hole 3 - hole 7) as a measure of implicit 
learning.  
Animals were significantly less accurate in S1 responding accuracy in the SILT 
when the stimulus length was decreased from 2 seconds to 0.5 seconds (Stimulus 
length; F1,12 = 6.53, p<0.05), as shown in Figure 5.9. Furthermore, animals were 
more accurate in responding into the central hole rather than the peripheral holes 
(Hole; F4,48 = 19.27, p<0.001). HdhQ111/+ animals made significantly slower 
responses than wild type animals (Genotype; F1,12 = 8.40, p <0.05) and this 
deficit was stable over time (Age x Genotype; F2,24 = 2.66, p = n.s.).  
However, restricted analysis at each testing age confirmed a deficit in S1 
response accuracy in HdhQ111/+ animals in comparison to wild type animals, 
which was not seen at 6 months of age (Genotype; F1,12 = 0.101, p = 0.756) or 
12 months of age (Genotype; F1,12 = 1.109, p = 0.313) but was demonstrated at 
18 months of age; (Genotype; F1,12 = 5.97, p<0.05), with HdhQ111/+ animals 
making significantly less accurate responses in comparison to wild type animals.  
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Figure 5.9. S1 Accuracy Serial Implicit Learning Task (SILT) results for HdhQ111/+ animals 
longitudinally. Animals were more accurate in responding into the central hole at shortest (2 second) 
stimulus length. Data are shown for a total of 16 mice, 7 HdhQ111+ ((4 female and 3 male) and 9 wild type 
(5 female and 4 male) and is the average number of responses made over 5 days of testing at each stimulus 
length. Error bars represent ± standard error of the mean. Significance considers genotype differences over 
all ages of testing, * p<0.05. 
Animals were significantly faster to respond to the S1 stimulus when the 
stimulus length was reduced (Stimulus length; F1,12 = 11.70, p<0.01) when all 
testing ages were considered, as shown in Figure 5.10. Furthermore, animals 
were significantly faster to respond into the central hole rather than the 
peripheral holes (Hole; F4,48 = 11.60, p<0.001), as shown in Figure 5.10. When 
all testing ages were considered, HdhQ111/+ showed an increased S1 response time 
in comparison to wild type animals (Genotype; F1,12 = 8.41, p<0.05), but this 
deficit was not shown to be progressive over time (Genotype x Age; F2,24 = 
0.160, p = n.s.). Restricted analyses to each time point demonstrated that, 
HdhQ111/+ animals displayed similar levels of S1 response time at 6 months of 
age (Genotype; F1,12 = 3.42, p = 0.089) but were significantly impaired in 
responding at 12 months (Genotype; F1,12 = 12.36, p<0.01) and 18 months of age 
(Genotype; F1,12 = 6.55, p<0.05).  
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Figure 5.10. S1 Response Time Serial Implicit Learning Task (SILT) results for HdhQ111/+ animals 
longitudinally. Animals were faster to respond into the central hole at the shorter 0.5 second stimulus 
length. HdhQ111/+ animals were significantly slower to respond across all task manipulations in comparison 
to wild type animals. Data are shown for a total of 16 mice, 7 HdhQ111+ (4 female and 3 male) and 9 wild 
type (5 female and 4 male) and is the average number of responses made over the final 5 days of testing at 
each stimulus length. Error bars represent ± standard error of the mean. Significance considers genotype 
differences over all ages of testing, *p<0.05.  
In the second response required in the SILT task (S2), mice were significantly 
less accurate to respond when the step size of the response was increased (Step; 
F3,36 = 228.22, p<0.001) and when the stimulus length was decreased (Stimulus 
length; F1,12 = 169.19, p<0.001), as shown in Figure 5.11. HdhQ111/+ animals were 
significantly less accurate in S2 responding in comparison to wild type animals 
when all testing ages were considered (Genotype; F1,12 = 14.76, p<0.01), 
although this deficit was not shown to be progressive over time (Age x 
Genotype; F2,24 = 4.31, p = n.s.). Nevertheless, restricted analysis of each testing 
age demonstrated no significant difference between HdhQ111/+ animals and wild 
type animals in S2 response accuracy at 6 months of age (Genotype; F1,12 = 2.09, 
p = 0.174). Although HdhQ111/+ animals demonstrated a significant S2 accuracy 
deficit in comparison to wild type animals at 12 months of age (Genotype; F1,12 
= 11.55, p<0.01) and 18 months of age (Genotype; F1,12 = 18.83, p<0.01). 
Interestingly, female HdhQ111/+ animals were shown to be significantly less 
accurate in comparison to female wild type animals (Genotype x Sex; F1,12 = 
5.61, p<0.05), although this was not shown for male animals.  
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Figure 5.11. S2 Accuracy in Responding in the Serial Implicit Learning Task (SILT) for HdhQ111/+ 
animals longitudinally. Data are shown for a total of 16 mice, 7 HdhQ111+ (4 female and 3 male) and 9 wild 
type (5 female and 4 male) and is the average number of responses made over the final 5 days of testing at 
each stimulus length. Error bars represent ± standard error of the mean. Significance considers genotype 
differences over all ages of testing, ** p<0.01.  
Animals were significantly slower to respond to the S2 stimulus when the step 
size was increased (Step; F3,36 = 42.35, p<0.001) and when the stimulus length 
was decreased (Stimulus length; F1,12 = 33.44, p<0.001), as shown in Figure 5.12. 
HdhQ111/+ animals were shown to be significantly slower to respond to the S2 
stimulus when all ages were considered (Genotype; F1,12 = 6.45, p<0.05), this 
finding was driven by the results obtained using the 2 second stimulus length 
and was consistent over time (Age x Genotype; F2,24 = 0.43, p = n.s.).  
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Figure 5.12. S2 Response Time in the Serial Implicit Learning Task (SILT) in HdhQ111/+ 
animals longitudinally. Animals took significantly longer to respond at the shorter 0.5 second 
stimulus length and as the step size increased. HdhQ111/+ animals were significantly slower to 
respond than wild type animals when all testing conditions were considered. Data are shown for 
a total of 16 mice, 7 HdhQ111+ (4 female and 3 male) and 9 wild type (5 female and 4 male) and 
is the average number of responses made over the final 5 days of testing at each stimulus length. 
Error bars represent ± standard error of the mean. Significance considers genotype differences 
over all ages of testing, * p<0.05.  
 
S2 accuracy in responding to the stimulus was considered in light of the 
predictability of the stimulus, which was designed to probe implicit learning 
(Figure 5.13). Mice were significantly less accurate when the stimulus length 
was decreased (Stimulus length; F1,12 = 247.91, p<0.001). Furthermore, animals 
were significantly more accurate when the stimulus was predictable rather than 
unpredictable (Predictability; F1,12 = 17.04, p<0.01). HdhQ111/+ animals were 
significantly less accurate overall in responding in comparison to wild type 
animals regardless of the predictability of the stimulus (Genotype; F1,12 = 12.61, 
p<0.01). However, the predictability of the stimulus did not confer any 
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significant benefit to either wild type animals or HdhQ111/+ animals (Genotype x 
Predictability; F1,12 = 0.45, p = n.s.), as shown in Figure 5.13.   
 
Figure 5.13. S2 Response Accuracy in the Serial Reaction Time Task (SILT) for predictability of 
stimulus in HdhQ111/+ animals longitudinally. Data are shown for a total of 16 mice, 7 HdhQ111+ (4 female 
and 3 male) and 9 wild type (5 female and 4 male) and is the average number of responses made over the 
final 5 days of testing at each stimulus length. Error bars represent ± standard error of the mean. 
Significance considers genotype differences over all ages of testing, * p<0.05. 
 
The predictability of the S2 stimulus in the SILT did not confer any significant 
benefit to how rapidly animals were able to respond to the stimulus 
(Predictability; F1,12 = 0.27, p = n.s.) (Figure 5.14.). There was considerable 
variation among response times, in some instances, therefore no significant 
effect of stimulus length was seen in this case (Stimulus length; F1,12 = 0.15, p = 
n.s.). Although, HdhQ111/+ animals showed a trend to be significantly slower than 
wild type animals when all testing conditions were considered, this trend failed 
to meet the threshold for statistical significance (Genotype; F1,12 = 4.328, p = 
0.062).      
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Figure 5.14. S2 Response Time in the Serial Implicit Learning Task (SILT) for predictability of 
stimulus in HdhQ111/+ animals longitudinally. Data are shown for a total of 16 mice, 7 HdhQ111+ (4 female 
and 3 male) and 9 wild type (5 female and 4 male) and is the average number of responses made over the 
final 5 days of testing at each stimulus length. Error bars represent ± standard error of the mean.  
5.5. Discussion 
Longitudinal operant testing revealed specific cognitive deficits in HdhQ111/+ 
animals in comparison to wild type animals in FR, PR, 5-CSRTT and SILT in 
the operant test battery. The data demonstrated that HdhQ111/+ animals were most 
significantly impaired in comparison to wild type animals at 18 months of age, 
which was demonstrated with restricted statistical analyses. Our results therefore 
suggest that the HdhQ111/+ mouse demonstrates an insidious and subtle disease 
progression that was not detectable in this operant test battery throughout most 
of the life of the animal.     
Initial training in the nose poke response and subsequent reacquisition of the 
nose poke response demonstrated an inability for HdhQ111/+ animals to initiate as 
many trials as wild type animals at the oldest 18 month time point. This 
observation is also reflected in the results of the 5-CSRTT, with HdhQ111/+ 
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animals initiating significantly fewer trials than wild type animals at 18 months 
of age. Due to the motor deficits demonstrated in the previous chapter, which 
occur from 9 months of age and are prevalent by 12 months of age, the reduction 
in responding may be due to significant motor impairments which are also 
reflected in the response time measures. Therefore, HdhQ111/+ animals may not 
be physically able to initiate a response as rapidly as wild type animals at 18 
months of age and therefore initiate fewer trials within the testing session. This 
suggestion is further confirmed by the response time deficits shown in the 5-
CSRTT task and the SILT at 18 months of age. The operant apparatus is 
extremely sensitive to detecting response time deficits, which are indicative of 
motor dysfunction, therefore it may be the case that operant testing is able to 
detect motor dysfunction more sensitively than the other motor tests used in 
Chapter 4. It may also be the case that the response time deficits observed in 
HdhQ111/+ animals are reflective of an inability to initiate movement. Difficulties 
in the initiation of movement were described in HdhQ111/+ animals progressively 
from 9 months of age on the balance beam in Chapter 4. Although the initiation 
of movement has not yet been thoroughly explored in HD mouse models, people 
with HD have showed a decrease in the initiation of movement from early in the 
disease progression (Bradshaw et al. 1992; Smith et al. 2000).   
Upon the introduction of different reward sizes into the FR1 testing schedule a 
general effect of reward size was seen, with all animals making significantly 
more responses for smaller reward sizes. This effect may be due to animals 
taking a greater time to consume larger rewards, or there may be an effect of 
satiation, with animals becoming satiated when they consume larger rewards. 
However, at the 2.5µl reward size HdhQ111/+ animals responded less than wild 
type animals, this effect was driven by the large difference observed at 18 
months of age, although it was not seen at any other reward size.  This may be 
due to an underlying apathetic phenotype in HdhQ111/+ animals, which means that 
they respond less than wild type animals for smaller rewards. Apathy has been 
shown in HD patients (Burns et al. 1990; van Duijn et al. 2013), although 
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typically this occurs early in the disease progression, often prior to the onset of 
motor dysfunction. Therefore, if apathy were causing the results observed in 
HdhQ111/+ mice, apathy is expressed relatively late in the disease progression in 
comparison to the human condition.  
However, significant differences were observed between HdhQ111/+ animals and 
wild type animals in progressive ratio performance, thus indicating that 
HdhQ111/+ mice are impaired in motivation in comparison to wild type animals. 
These results are comparable to those previously observed in the HdhQ92 
(Trueman et al. 2009b), zQ175 and BAC mouse models (Oakeshott et al. 2012) 
which demonstrated reduced motivation in HD mice in comparison to wild type 
controls at 15 months and 73 weeks respectively. However, previous studies 
utilised food restriction in their PR tasks, and it may be the case that mice are 
comparatively more motivated when placed on food restriction rather than the 
water restriction that was imposed in this experiment. Furthermore, the studies 
cannot be directly compared due to the fact that Oaksehott et al., utilised a 
different version of the PR task which required higher ratios of responding to 
obtain reward and a longer session time. Although, Trueman et al., utilised the 
same version of the PR testing regime, this study used homozygous HdhQ92/Q92 
animals, whereas to replicate the human condition heterozygous HdhQ111/+ 
animals were used here. Furthermore, previous studies conducted the PR task in 
animals at a single time point and not longitudinally and thus, it may be the case 
that if HdhQ111/+ animals were tested solely at 18 months of age they would show 
a motivational deficit in the PR task in comparison to wild type animals. The 
motivational deficits observed in the PR task in the HdhQ111/+ mouse model are 
in accordance with previous studies in the human patient population (Burns et 
al. 1990; Paulsen et al. 2001b; Thompson et al. 2002b), which demonstrate 
motivational problems early in the disease progression of HD, prior to the onset 
of motor symptoms. Thus, although motivational deficits were shown in the 
HdhQ111/+ mouse model they were not progressive over time and were present 
alongside the motor dysfunction shown in Chapter 4.     
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Highly significant effects of stimulus length and response hole location were 
demonstrated in the 5-CSRTT, across all testing conditions. This was 
unsurprising given the attentional load of the task was increased when the 
stimulus length was decreased. The inability for HdhQ111/+ animals to initiate as 
many trials as wild type animals in the 5-CSRTT at 18 months of age at all 
stimulus lengths is indicative of a general inability to complete the task. The 
precise reason for this inability to complete the task could be due to multiple 
underlying cognitive factors, such as depression, apathy or lack of motivation. 
But, given the considerable motor dysfunction that was demonstrated in 
HdhQ111/+ animals at 18 months of age, in the previous chapter, it is perhaps the 
case that animals are simply unable to physically get to the stimulus to make a 
response within the required time.     
HdhQ111/+ animals were able to maintain their response accuracy in the 5-CSRTT 
over consecutive testing ages, despite considerable response time deficits which 
developed as they aged. Therefore, it may be the case that HdhQ111/+ animals are 
able to maintain their accuracy in responding in the 5-CSRTT, at the detriment 
of responding slower to the stimulus. This suggestion is also supported by the 
fact that HdhQ111/+ animals did not demonstrate a significant difference in the 
number of time outs made in comparison to wild type animals. Therefore, 
HdhQ111/+ animals are able to respond to the stimulus and to the same degree of 
accuracy as wild type animals, although it may take them longer to do so.  
A previous study in the HdhQ92 mouse model of HD utilised the 5-CSRTT to 
demonstrate that HdhQ92/Q92 animals had a significant deficit in accuracy in 
responding in the 5-CSRTT when the stimulus was pseudo-randomly generated 
with stimuli of different durations (Trueman et al. 2012c). The experimental 
design employed by Trueman et al., was different from the version of the 5-
CSRTT employed in this study, where the stimulus length was decreased over 
consecutive days. Therefore, the way in which the 5-CSRTT was implemented 
in this experiment, through gradually decreasing the stimulus length during 
testing, may have allowed animals to respond with increasing accuracy. 
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Whereas, if the 5-CSRTT was implemented in HdhQ111/+ mice, as it was by 
Trueman et al., with pseudo-randomly generated stimuli of different durations 
which further increases the attentional load of the task, deficits in attentional 
function may have been observed.  
In the SILT HdhQ111/+ animals were significantly slower in responding to both 
the S1 and S2 stimulus, than wild type animals, thus further reflecting the motor 
deficits previously observed in HdhQ111/+ animals. The S1 accuracy deficits 
demonstrated in HdhQ111/+ animals at 18 months of age were surprising, given 
that these deficits did not exist in the 5-CSRTT. Therefore, it may be the case 
that when the complexity of the operant task is increased and requires two 
responses, animals are unable to maintain the accuracy of responding as was 
shown in the 5-CSRTT. It could also be the case that motor dysfunction prevents 
animals from responding to the S1 SILT stimulus accurately. Although, the 
deficits observed in the SILT task in S2 accuracy among HdhQ111/+ animals may 
also be attributed to motor problems, these deficits may further be explained by 
the eccentricity of response required in this task, which has been previously 
demonstrated in rats with striatal lesions (Lelos et al. 2012).  
In the SILT animals were able to respond with increasing accuracy to the S2 
predictable stimulus, although this benefit was not reflected in S2 response time. 
This demonstrates that both wild type and HdhQ111/+ animals are able to learn the 
implicit learning component of the task. Therefore, it can be concluded that 
HdhQ111/+ animals have no deficit in implicit learning in comparison to wild type 
animals. Generally HdhQ111/+ animals were significantly slower in responding in 
the SILT task, than wild type animals, thus further reflecting the motor deficits 
observed in HdhQ111/+ animals in the previous chapter. Previous studies regarding 
implicit learning in the HD patient population have produced mixed results, with 
some demonstrating deficits in implicit learning in people with HD (Knopman 
and Nissen 1991; Willingham and Koroshetz 1993; Ghilardi et al. 2008), 
whereas others have shown no significant difference in implicit learning between 
people with HD and controls (Bylsma et al. 1991; Brown et al. 2001). Our results 
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support the hypothesis that there are no significant deficits in implicit learning 
performance in the HdhQ111/+ mice in comparison to wild type animals.  
Due to the experimental aim of characterising the HdhQ111/+ mouse model, the 
operant tasks utilised in the operant testing battery were designed to run for a 
pre-determined session time. This experimental design ensured that exposure to 
the operant box was the same among animals. Although, when HdhQ111/+ animals 
began significantly fewer trials than wild type animals, it meant that wild type 
animals were exposed to comparatively more reward and thus practice effects 
may have been demonstrated within the data. Therefore, at the later ages, 
practice effects may be observed in the data due to wild type animals performing 
comparatively more trials than HdhQ111/+ animals on subsequent days.  However, 
because the aim of this study was to characterise the HdhQ111 mouse model, this 
finding could not have been foreseen. Thus future manipulations of these operant 
tasks would be designed such that the animal is required to complete a set 
number of trials during the task to eliminate any possible practice effects among 
testing groups.   
In addition, the longitudinal operant battery was performed such that the same 
animals underwent repeated testing in the operant test battery. Therefore, 
animals were extensively exposed to the operant boxes, and the associated 
responding, obtaining of reward and the associated water restriction for an 
extended period of time. Thus, it may be the case that the extensive training and 
testing from a young age may mask some of the cognitive deficits associated 
with HdhQ111/+ animals. Although the experiment was performed with the aim of 
characterising the cognitive phenotype of the HdhQ111 mouse model of HD, it 
may be that repeated exposure and testing on operant tasks of cognition 
inadvertently modified subsequent operant behaviours. Therefore, in future 
behavioural characterisations, it may be necessary to use a separate testing group 
for each of the experimental time points, to eliminate any such effects, although 
this will have considerable ethical and financial implications. An extensive 
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discussion regarding the possible effects of repeatedly testing the same animals 
in a longitudinal study is presented in the General Discussion in Chapter 8.   
The suggestion of practice effects caused by cognitive training is also clinically 
relevant, as studies in other neurodegenerative disease including Alzheimer’s 
disease (Davis et al. 2001; Farina et al. 2002; Clare et al. 2003) and Parkinson’s 
disease (Sinforiani et al. 2004; Sammer et al. 2006; Milman et al. 2014; Atias et 
al. 2015) have considered cognitive training as a non-pharmacological 
therapeutic intervention. These studies used cognitive training, via repeatedly 
conducting specific cognitive tasks on computer programmes, to improve both 
motor and cognitive disease symptoms. Therefore, these patient studies 
demonstrate that the way that operant testing has been performed in this 
experimental design may mask or even perhaps improve some of the behavioural 
deficits seen in the HdhQ111/+ mouse model of HD. To explore this possibility a 
thorough investigation into the effects of repeatedly testing HdhQ111/+ mice on 
the 5-CSRTT is presented in the following chapter.  
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Chapter 6 : Can pre-training in an operant task 
modify subsequent behaviour and 
neuropathology in the HdhQ111 mouse model of 
Huntington’s disease? 
6.1. Introduction  
In the previous chapter, operant tests were utilised to demonstrate significant 
cognitive deficits in the HdhQ111/+ mouse model of HD, although the observed 
deficits were perhaps not as progressive or severe as was to be expected based 
on previous results in other mouse models of HD (Trueman et al. 2007; Trueman 
et al. 2009a; Brooks et al. 2012h; Trueman et al. 2012c). This led to the 
hypothesis that the experimental design employed in the previous chapter 
(repeatedly conducting the same operant test battery in the same animals) may 
lead to an altered behavioural phenotype, which may not have been observed if 
separate groups of animals had been used for each age of operant behavioural 
testing.  
Attentional deficits were observed in the 5-choice serial reaction time task (5-
CSRTT) in HdhQ111/+ animals at 18 months of age (as seen in Chapter 5). 
However, previous literature in HD patients (Lawrence et al. 1996; Lawrence et 
al. 1998a; Lemiere et al. 2004) and other HD mouse lines (Trueman et al. 2007; 
Trueman et al. 2012c) suggests that problems with attention are a specific early 
deficit within the progression of HD. Therefore, it may be the case that previous 
testing on the 5-CSRTT, at a young age, may improve attentional performance 
in HdhQ111/+ animals when they are subsequently tested in the same task at a later 
age.  
This hypothesis is further supported by human studies which suggest cognitive 
training can improve executive function in healthy individuals as they age (Ball 
et al. 2002; Willis et al. 2006). Furthermore, in the patient population cognitive 
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training studies have been conducted in other neurodegenerative diseases 
including Parkinson’s disease (PD) (Sinforiani et al. 2004; Sammer et al. 2006; 
París et al. 2011; Milman et al. 2014) and Alzheimer’s disease (AD) (Hofmann 
et al. 1996; Davis et al. 2001; Farina et al. 2002; Clare et al. 2003; Clare and 
Woods 2004). These studies have demonstrated that cognitive training, 
specifically focused on tasks of executive function, can improve both cognitive 
and motor outcomes in PD and AD patients. 
6.2. Aims  
To determine if pre-training in an operant task (the 5-CSRTT), at a young age, 
modifies the subsequent behavioural and neuropathological phenotype of 
HdhQ111/+ animals at an older age. 
6.3. Materials and Methods  
6.3.1. Animals 
A total of 43 animals were used in this experiment, which included 21 HdhQ111/+ 
animals (11 female and 10 male) and 22 wild type animals (13 female and 9 
male). Animals were split equally into three testing groups based on sex and 
genotype (see Experimental Design section 6.3.2., Table 6.1). HdhQ111/+ animals 
were genotyped by Laragen Inc (see Chapter 2 section 2.1.1.) and contained an 
average CAG repeat length of 141 repeats, which ranged from 134-149 repeats.  
Animals were housed in mixed genotype and single sex groups and were kept in 
a temperature controlled environment (21°C±1°C) on a 12 hour light dark cycle 
(lights on 06.00 hours, lights off 18.00 hours). Animals were given ad-libitum 
access to standard laboratory chow food, and a water restriction regime was 
imposed for the duration of operant testing.  
6.3.2. Experimental Design 
The animal testing groups used in this experiment are shown below in Table 6.1. 
Operant pre-training commenced in the operant boxes at 4 months of age. The 
operant pre-training given to animals differed depending on the testing group. 
The first group received 15 days of nose poke training and then 20 days of 
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training in an attentional task (the 5-choice serial reaction time task). The second 
group received a comparable total number of days (35 days) of nose poke 
training; however, for the final 20 days an extended nose poke training regime 
was used, as detailed below in 6.3.4.2. The third testing group were cage controls 
and therefore received no exposure to, or training in, the operant boxes; however 
they were handled and water restricted in the same way as the other testing 
groups.  
Table 6.1. Animal testing groups. 
 *An HdhQ111/+ animal in testing group 3 became ill at approximately 8 months of age and was therefore 
culled reducing the number of HdhQ111/+ animals in the testing group to 7. 5-CSRTT refers to the 5-Choice 
Serial Reaction Time Task.  
 
 
Pre-training 
(4 months of age) 
 
Testing 
(12 months of age) 
Group 1  
Attentional pre-training 
(n=14, 7 HdhQ111/+) 
Nose poke training (15 days) 
5-CSRTT training (20 days) 
Nose poke training (15 days) 
5-CSRTT testing (20 days) 
Group 2  
Non-attentional pre-
training 
(n=14, 6 HdhQ111/+) 
Nose poke training (15 days)  
Extended nose poke training 
(20 days) 
Nose poke training (15 days) 
5-CSRTT testing (20 days) 
Group 3  
Control 
(n=15, 8 HdhQ111/+*) 
- 
Nose poke training (15 days) 
5-CSRTT testing (20 days) 
6.3.3. Operant Apparatus 
Operant testing was conducted in 16 9-hole operant boxes as previous described 
in Chapter 2 (section 2.3.1.). For the 5-choice serial reaction time task (5-
CSRTT) utilised in this chapter only the 9-hole operant set up was required and 
thus the response holes required for the ‘Skinner like’ operant set up were 
covered with black plastic for operant testing, as were holes 2,4 ,6 and 8 of the 
9-hole array.    
6.3.4. Operant Pre-training  
One week prior to the beginning of operant pre-training all animals were 
gradually water restricted, to a final restriction of 3 hours of access to water per 
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day. Animals were introduced to Yazoo© strawberry milk reward, by placing 
dishes of strawberry milk into their home cages. Animals then received operant 
pre-training as described below and indicated in Table 6.1. Animals were tested 
in operant boxes 5 days per week and were given ad-libitum access to water from 
Friday evenings until Sunday evenings.  
6.3.4.1. Nose Poke Pre-training 
At 4 months of age the animals in Groups 1 and 2 received 15 days of nose poke 
training (as previously described in section 2.3.4.1. of Chapter 2). Briefly, 
animals were required to learn to poke into the central stimulus light of the 9-
hole array. Once an animal had correctly poked into the illuminated light 
stimulus it was extinguished and 5µl of strawberry milk reward was 
simultaneously delivered into the reward magazine. The programme was 20 
minutes in duration. 
6.3.4.2. Extended Nose Poke Pre-training 
In addition to the nose poke pre-training described above, the animals in testing 
Group 2 received 20 days of extended nose poke training (Table 6.1). The 
extended nose poke training programme was designed as a comparable task to 
the 5-CSRTT (as detailed below), although without the attentional training 
component. Animals were still required to make nose pokes to obtain reward, 
but the location of the response hole differed on subsequent days of pre-training, 
to prevent perseverative responding. The operant programme was designed to 
randomly select a light stimulus which the animal was required to poke into for 
the duration of the 30 minute training session to obtain reward a 5µl strawberry 
milk reward.  
6.3.4.3. 5-Choice Serial Reaction Time Task (5-CSRTT) Pre-training 
After 15 days of nose poke pre-training, the animals in testing Group 1 (see 
6.3.4.1. above and Table 6.1) animals were tested in the 5-choice serial reaction 
time task (5-CSRTT). The details of the 5-CSRTT programme utilised have 
previously been described (see section 2.3.4.4. in Chapter 2).  
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6.3.5. Operant Testing 
Operant testing was conducted in all groups of animals at 12 months of age. 
Animals were gradually water restricted one week prior to operant testing and 
introduced to strawberry milkshake within their home cages. 
6.3.5.1. Nose Poke Testing 
All animals were placed on the nose poke training programme for 15 days, as 
described above in 6.4.3.1.  
6.3.5.2. 5-Choice Serial Reaction Time Task (5-CSRTT) Testing 
After the completion of nose poke training, animals were tested on the 5-CSRTT 
as previously described (see section 2.3.4.4. in Chapter 2). Testing lasted for a 
total of 20 days, for the first 10 days of testing a 10 second stimulus length was 
used. For the next 5 days of testing a 2 second stimulus length was used, and for 
the final 5 days of testing a 0.5 second stimulus length was used.    
6.3.6. Tissue Preparation 
At the end of operant testing animals were culled via cervical dislocation and the 
tissue was prepared as previously described in Chapter 2, section 2.4.1.  
6.3.7. Immunohistochemistry of Free Floating Sections  
Immunohistochemistry was conducted on the left hemisphere of each brain as 
described in Chapter 2, section 2.4.2. The primary antibodies used for 
immunohistochemical staining included; S830, Neu-N and DARPP-32. Cresyl 
violet staining was also conducted as previously described in Chapter 2, section 
2.4.3. 
6.3.8. Stereological Analysis and Image Acquisition 
Stereological analysis and image acquisition was conducted as previously 
described in Chapter 2, section 2.5. 
6.3.9. Statistical Analysis 
Statistical analyses were performed in IBM SPSS Statistic 20 software for 
windows. Repeated measures ANOVA tests followed by simple effects analysis 
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were conducted for behavioural tests. For histological analysis univariate 
ANOVA tests followed by simple effects analysis were conducted. Where 
significance was found post-hoc tests with Bonferroni corrections were applied 
to identify the locus of effects and their interaction(s). The critical significance 
level used throughout was α= 0.05. 
6.4. Results 
6.4.1. Pre-training Results 
The pre-training given to testing Groups 1 and 2  (see Table 6.1) demonstrated 
that both HdhQ111/+ animals and wild type animals were able to acquire and learn 
the nose poke response equally well, initiating approximately 160 nose pokes 
per session, after 15 days of pre-training (Figure 6.1A, Genotype; F1,10 = 8.56, p 
= n.s.). Furthermore, comparison of testing Groups 1 and 2 demonstrated similar 
levels of acquisition in learning the nose poke response (Figure 6.1B, Group; 
F1,10 = 32.56, p = n.s.), with both groups initiating approximately 160 trials per 
session by the end of the 15 days of pre-training.  
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Figure 6.1. Nose poke pre-training results. A. Both HdhQ111/+ and wild type animals demonstrated similar 
acquisition and learning of the nose poke response, performing approximately 160 nose pokes per session 
after 15 days of pre-training B. Both testing groups 1 and 2, which comprised both HdhQ111/+ and wild type 
animals, demonstrated similar acquisition and learning of the nose poke response, performing 
approximately 160 nose pokes per session after 15 days of pre-training. The data in panel A, are shown for 
a total of 28 animals, 13 HdhQ111/+ and 15 wild type. Group 1 contained a total of 14 days animals, 7 of 
which were HdhQ111/+ and group 2 contained 14 animals, 6 of which were HdhQ111/+. Data are shown as an 
average for each day, error bars represent ± standard error of the mean.  
 
Testing Group 2 were given extended 20 days of nose poke training after initial 
nose poke training. Although there was a trend for HdhQ111/+ animals to make 
fewer responses than wild type animals, throughout the 20 days of extended nose 
poke pre-training (Figure 6.2), this trend failed to meet the conventional 
threshold of significance (Genotype; F1,12 = 4.10, p=0.066).  
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Figure 6.2. Extended nose poke pre-training results. There was a trend for HdhQ111/+ animals to make 
fewer nose poke responses than wild type animals during extended nose poke training, although this trend 
failed to meet conventional levels of significance. Data are shown for a total of 14 animals, 6 of which were 
HdhQ111/+. Error bars represent ± standard error of the mean.  
 
Testing Group 1 were given pre-training in the 5-CSRTT after initial nose poke 
training. HdhQ111/+ animals demonstrated similar overall performance in the 5-
CSRTT as wild type animals in all measures of task performance (Figure 6.3). 
HdhQ111/+ animals began a similar number of trials in the 5-CSRTT as wild type 
animals (Genotype: (F1,10 = 0.08, p = n.s.), and there was a clear effect of 
stimulus length, with fewer trials initiated at the shorter stimulus lengths (Figure 
6.3A, Stimulus length: F2,20 = 85.54, p<0.001). HdhQ111/+ animals were as 
accurate in the 5-CSRTT as wild type animals, at all stimulus lengths (Figure 
6.3B, Genotype: F1,10 = 0.02, p = n.s.). Animals became less accurate as stimulus 
length was decreased (Stimulus length: F2,20 = 419.47, p<0.001) and were more 
accurate in responding into the central hole in comparison to the holes further 
away from the centre (Hole: F4,40 = 14.88, p<0.001). HdhQ111/+ animals displayed 
similar response times as wild type animals in the 5-CSRTT (Figure 6.3C, 
Genotype: F1,10 = 0.13, p = n.s.), and reducing the stimulus length decreased the 
response time (Stimulus length; F2,20 = 67.70, p<0.001). Faster responses were 
made towards the central hole of the array in comparison to the holes further 
from the centre (Hole: F4,40 = 6.88, p<0.001). 
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The number of time outs made in the 5-CSRTT was the same in HdhQ111/+ and 
wild type animals, although animals made more time outs when shorter stimulus 
lengths were used, see Figure 6.3D (Stimulus length: F2,20 = 31.34, p<0.001).  
 
Figure 6.3. 5-Choice serial reaction time task (5-CSRTT) pre-training results. A. Total trials started 
did not differ among genotypes although fewer trials were initiated at the shorter stimulus lengths. B. 
Accuracy in responding did not differ between HdhQ111/+ or wild type animals although animals were more 
accurate toward the central hole and at the longest stimulus lengths. C. Response time did not differ between 
HdhQ111/+ and wild type animals although animals responded significantly faster into the central hole and at 
the shortest stimulus lengths. D. The number of time outs made did not differ between HdhQ111/+ and wild 
type animals although more time outs were made at the shorter stimulus lengths. The data represents 14 
animals, 7 of which were HdhQ111/+ animals, which began operant testing at 4 months of age. Data are shown 
as an average of the last 5 days of testing at each stimulus length. Error bars represent ± standard error of 
the mean.     
 
 
 
 
 
 
 
 
Chapter 6                                                                             Operant Pre-training 
144 
 
6.4.2. Testing Results 
6.4.2.1. Operant pre-training alters the ability to acquire the nose poke 
response. 
Animals who had received pre-training in either an operant attentional task 
(Group 1) or an operant non-attentional task (Group 2) were able to re-acquire 
the nose poke response rapidly, performing approximately 150 responses after 
15 days of testing (Figure 6.4.). However, the animals who were naive to the 
operant boxes (Group 3) took significantly longer to acquire the nose poke 
response than those who had previously been trained in the operant boxes 
(Groups 1 and 2) (Group: F2,36 = 14.17, p<0.01). After 15 days of testing the wild 
type animals who were naive to the operant boxes were able to perform 
comparable levels of responses as HdhQ111/+ animals who had previously 
received pre-training, although they were not able to perform as many trials as 
wild type animals who had received pre-training. HdhQ111/+ animals who were 
naive to the operant boxes were noticeably unable to initiate as many trials as 
the animals in the other testing groups. An overall genotype effect was seen 
(Genotype: F1,36 = 17.57, p<0.001), although the interaction between genotype 
and group failed to meet convetional levels of significance (Age x Genotype: 
F1,36 = 2.83, p = n.s.).  
Figure 6.4. Acquisition of a nose poke response at 12 months of age. All animals began testing at 12 
months of age. The data represents a total of 43 animals, which were split into three testing groups, as 
detailed above in Table 6.1. Error bars represent ± standard error of the mean. 
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6.4.2.1. Does operant pre-training in an attentional task modify subsequent 
operant behaviour in the 5-CSRTT? 
Animals who had received pre-training on the 5-CSRTT task at a young age 
initiated significantly more trials in the 5-CSRTT in comparison to animals who 
had not received pre-training in the task (Group: F1,23 = 21.83, p<0.001), as seen 
in Figure 6.5A. HdhQ111/+ animals initiated fewer trials than wild type animals 
(Genotype: F1,23 = 46.58, p<0.001). A highly significant effect of stimulus length 
was seen, with fewer trials were initiated at the shorter 0.5 second stimulus 
length, in comparison to the longer 2 second stimulus length was used in testing 
(Stimulus length: F1,23 = 31.40, p<0.001).   
Despite a trend for HdhQ111/+ animals to demonstrate a greater attentional deficit, 
in response accuracy, than wild type animals when they had not received pre-
training, this trend failed to meet the threshold for conventional levels of 
significance (Genotype: F1,23 = 4.21, p = 0.052). Nevertheless, both wild type 
and HdhQ111/+ animals who had received pre-training in the 5-CSRTT were 
significantly more accurate in responding in the 5-CSRTT than those who had 
not received pre-training (Group: F1,23 = 30.86, p<0.001, Figure 6.5B). 
The group of animals that were pre-trained in the 5-CSRTT demonstrated 
improved response times in comparison to animals who were trained in the task 
at an older age (Group; F1,23 = 37.36, p<0.001). Interestingly, HdhQ111/+ animals 
were significantly improved in response time in the 5-CSRTT, in comparison to 
HdhQ111/+ animals that were not pre-trained on the task (Group x Genotype: F1,23 
= 6.41, p<0.05), as shown in Figure 6.5C. This pattern of results was also 
reflected in the number of time-outs made in the 5-CSRTT (Figure 6.5D). 
Animals who were pre-trained in the 5-CSRTT made significantly fewer time 
outs in comparison to animals who were not pre-trained on the task (Group: F1,23 
= 17.76, p<0.001). HdhQ111/+ animals made significantly fewer time outs in the 
task when they had received pre-training in the 5-CSRTT at a young age, in 
comparison to HdhQ111/+ animals who received training at an older age (Group x 
Genotype: F1,23 = 11.26, p<0.01). 
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Figure 6.5. Attentional pre-training improves subsequent performance in the 5-CSRTT. A. Total trials started, demonstrated that pre-training increases the number of trials started. 
B. Accuracy in responding was higher in the pre-training groups. C. Response time was faster in the pre-trained groups and significantly improved in HdhQ111/+ animals who had pre-
training.  D. Time outs made as a percentage of total responses were decreased in the group that received pre-training and significantly decreased in HdhQ111/+ animals that had received 
pre-training. Data represents a total of 27 animals (Group 1 n=14 (7 WT and 7 HdhQ111/+) and Group 3, n=14 (7 WT and 6 HdhQ111/+)) Data are shown for the final 5 days of testing at the 
2 second and 0.5 second stimulus lengths. Only significant interaction effects are shown. Error bars represent ± standard error of the mean. * p<0.05, ** p<0.01.  
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6.4.2.2. Does pre-training require an attentional component to modify 
subsequent operant behaviour in the 5-CSRTT? 
Animals who had previously received pre-training in an operant task with a non-
attentional component (group 2, see Table 6.1) were able to initiate a similar 
number of trials in the 5-CSRTT as animals who had received pre-training with 
an attentional component (Group: F1,24 = 3.05, p = n.s., see Table 6.1). HdhQ111/+ 
animals initiated fewer trials in the 5-CSRTT than wild type animals (Genotype: 
F1,24 = 21.98, p<0.001) and fewer trials were initiated at the shorter 0.5 second 
stimulus length in comparison to the 2 second stimulus length (Stimulus length: 
F1,24 = 40.94, p<0.001), as shown in Figure 6.6A. Animals who had received 
previous attentional pre-training were significantly more accurate in the 5-
CSRTT in comparison to animals who had received comparable pre-training in 
an non-attentional task (Group: F1,24 = 8.84, p<0.01). Although HdhQ111/+ animals 
were less accurate than wild type animals (Genotype: F1,24 = 18.16, p<0.001), no 
significant interaction was demonstrated (Group x Genotype: F1,24 = 1.29, p = 
n.s., Figure 6.6B).      
Despite a trend for animals who had received pre-training on an attentional task 
to demonstrate faster response times in the 5-CSRTT than animals who had 
received equivalent pre-training in a non-attentional task (Figure 6.6C), this 
trend failed to meet the threshold for statistical significance (Group: F1,24 = 3.61, 
p=0.07). Furthermore, animals that received pre-training in an attentional task 
made significantly fewer time outs in the 5-CSRTT in comparison to animals 
that had received pre-training in a non-attentional task (Group: F1,24 = 13.57, 
p<0.05). HdhQ111/+ animals made more time outs than wild type animals 
(Genotype: F1,24 = 19.84, p<0.001), despite a trend for HdhQ111/+ animals who 
had received pre-training in an attentional task to make fewer time outs than 
HdhQ111/+ animals who had received non-attentional pre-training, this interaction 
effect failed to meet significance (Group x Genotype: F1,24 = 3.73, p=0.065).  
 
Chapter 6                                                                                                                                                                             Operant Pre-training  
148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6. Comparison of attentional and non-attentional pre-training on subsequent 5-CSRTT performance. A. Total trials started demonstrated fewer trials were made at the short 
stimulus length and by HdhQ111/+ animals in comparison to wild type animals. B. Accuracy in responding was improved in animals who had received pre-training in an attention task in 
comparison to animals who had received pre-training in a non-attentional task. C. Response time was decreased in HdhQ111/+ animals but no effect of pre-training regime was seen. D. Time 
outs made were significantly. The data represents a total of 28 animals (group 1 contained 14 animals, 7 of which were HdhQ111/+ and group 2 contained 14 animals, 6 of which were 
HdhQ111/+). Error bars represent ± standard error of the mean.  
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6.4.3. Does pre-training modify the associated neuropathology observed in 
the HdhQ111 mouse model of HD? 
Stereological analysis was conducted for S380, a marker of mutant huntingtin, 
this showed that the number of cells affected by mutant huntingtin did not differ 
in HdhQ111/+ animals when they had received pre-training (Group; F2,17 = 1.24, p 
= n.s., Figure 6.7A). This result was further reflected in cresyl violet staining, as 
no statistically significant effect of pre-training was observed in either wild type 
or HdhQ111/+ animals (Group; F2,35 = 1.58, p = n.s.) (Figure 6.7B). The number of 
cells that stained positive for Neu-N did not differ in wild type or HdhQ111/+ 
animals when pre-training was given to any of the testing groups (Group; F2,33 = 
0.13, p = n.s.), as shown in Figure 6.7C.  Furthermore, pre-training had no 
significant effect on the number of DARPP-32 positive cells in either wild type 
or HdhQ111/+ animals (Group; F2,36 = 1.9o, p = n.s.), as shown in Figure 6.7D.  
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Figure 6.7. Histological results from operant pre-training. A. S830 cells counts demonstrated the number of affected cells was similar in all testing groups. B. Cresyl violet staining was 
similar across all testing groups C. Neu-N staining was similar across all testing groups D. DARPP-32 staining was similar across all testing groups. All cell counts were conducted in the 
striatum. Error bars represent ± standard error of the mean.  
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6.5. Discussion 
When animals were pre-trained on the 5-CSRTT of attention at a young age, 
they demonstrated significant improvements in the all behavioural measures of 
the 5-CSRTT when they were tested at an older age, in comparison to naïve 
animals. These improvements included; initiating a larger number of trials, 
making more accurate responses, making faster responses and making 
significantly fewer time outs. Cognitive training has been previously 
demonstrated to prevent cognitive decline that would otherwise appear as part 
of the normal aging process in both mice (Gower and Lamberty 1993; Forster et 
al. 1996) and humans (Levy 1994; Hanninen et al. 1996; Ball et al. 2002; 
Persson et al. 2006; Willis et al. 2006; Schönknecht et al. 2014).  
Environmental enrichment has previously been used to improve cognitive 
function in HD mice (Nithianantharajah et al. 2008; Wood et al. 2010; Wood et 
al. 2011) although, specifically using operant cognitive training to improve 
cognitive function is yet to be explored in HD. Operant pre-training in an 
attentional task was shown to significantly improve operant performance in 
HdhQ111/+ animals in the 5-CSRTT, as animals were significantly faster to 
respond and made fewer time outs, than comparable HdhQ111/+ animals who had 
not received attentional pre-training and were naïve to the operant boxes. This is 
the first time that operant cognitive training has been used to show improved 
cognitive function in HD mice. These findings are supported by patient studies 
in other neurodegenerative diseases including PD (Sinforiani et al. 2004; 
Sammer et al. 2006; París et al. 2011; Milman et al. 2014) and AD (Hofmann et 
al. 1996; Davis et al. 2001; Farina et al. 2002; Clare et al. 2003; Clare and Woods 
2004), which demonstrated that cognitive training improved both motor and 
cognitive disease symptoms in AD and PD patients. HdhQ111/+ animals were 
shown to have improved response time when they had received attentional pre-
training, which may therefore be reflective of an improvement in motor function. 
Both HdhQ111/+ and wild type animals that had received attentional pre-training 
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demonstrated improved attentional ability, therefore these results are important 
to consider with respect to the HD population, as well as in other 
neurodegenerative diseases and the aging population in general.  
The specific type of pre-training implemented in the cognitive training 
intervention is also an important factor that was considered here. While pre-
training in an attentional task at a young age significantly improved attention at 
an older age, comparable pre-training in a non-attentional task did not improve 
attention in the 5-CSRTT at an older age. Therefore, it can be concluded that the 
attentional pre-training given to animals demonstrated task specific 
improvements in cognitive function. In future iterations of this study it would be 
interesting to give attentional pre-training in the 5-CSRTT and then later test 
animals on a different operant task of attention to probe whether the training 
provides task specific benefits or more general benefits of executive function 
which may be translatable to other tasks. In the present study, equivalent pre-
training in a non-attentional task demonstrated that animals were able to initiate 
as many trials and respond as quickly in the 5-CSRTT as animals who has 
received pre-training in an attentional task. Therefore, although it can be 
concluded that the attentional pre-training specifically improved attentional 
performance at a later age, equivalent pre-training also improved other operant 
behaviours.     
Therefore, it can be concluded that pre-training animals at a young age in an 
operant task will modify subsequent operant behaviours in both wild type and 
HdhQ111/+ animals. This is a particularly important issue in the behavioural 
characterisation of mouse lines, such as the characterisation conducted in 
Chapter 5. Although the type of pre-training given in this experiment was short 
when compared to the operant testing battery implemented in Chapter 5, clear 
behavioural differences were noted even after this comparatively short pre-
training period. In addition, the pre-training was given at 4 months of age and 
animals were tested in the operant task at 12 months of age, therefore despite the 
8 month gap animals were still able to gain a significant benefit from the 
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previous cognitive training. Therefore, pre-training or previously testing animals 
in operant tasks may mask or perhaps improve some of the behavioural deficits 
observed in the HD.  
Furthermore, implementing cognitive training at a young age has the potential 
to improve HD symptoms, as was demonstrated in the response time 
performance of HdhQ111/+ animals in the 5-CSRTT. This suggestion is of huge 
clinical interest as it demonstrates that the HD brain may demonstrate a degree 
of plasticity, particularly if cognitive training can be implemented at a young 
age. Moreover, other environmental enrichment activities such as exercise have 
previously shown benefit in animals models of HD (Hockly et al. 2002; Pang et 
al. 2006; Harrison et al. 2013) and HD patients (Busse and Rosser 2007; Busse 
et al. 2008b; Khalil et al. 2012; Busse et al. 2013; Khalil et al. 2013). Although 
such exercise based therapies can be difficult to implement in this patient 
population and can lead to an increased risk of falls (Busse et al. 2009). 
Therefore, it may be the case that cognitive based intervention therapies which 
may utilise computer programmes, have a greater degree of acceptance and 
uptake as a therapeutic intervention this specific patient population in 
comparison to exercise interventions.    
The 5-CSRTT was used in this case to measure attentional function in the 
HdhQ111/+ mouse model of HD. Although attentional deficits have previously 
been shown in HD patients (Lawrence et al. 1998a; Lawrence et al. 1998c), more 
recently difficulty in sharing attention, often using dual tasks, has been shown to 
be a more robust measure of determining attentional dysfunction in HD 
(Sprengelmeyer et al. 1995; Claus and Mohr 1996; Lawrence et al. 1998b; 
Murphy et al. 2000; Lemiere et al. 2004; Finke et al. 2006; Delval et al. 2008; 
Thompson et al. 2010; Vaportzis et al. 2015). Therefore, in future manipulations 
of this study it may be the case that using a dual task as a measure of attentional 
dysfunction may produce even clearer and more definitive results.   
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Finally, immunohistochemical and stereological analyses were conducted to 
determine any gross neuropathological changes caused as a result of the pre-
training regimes. As the pre-training intervention was relatively short, the lack 
of any significant differences between the numbers of S830 affected cells, cresyl 
violet, Neu-N or DARPP-32 stained cells between testing groups is unsurprising. 
However, it may be the case that the neuronal connections underlying the 
observed behaviour have been strengthened.  
The study conducted in this experimental chapter demonstrated that operant pre-
training, implemented at a young age, can modify the subsequent operant 
behaviour of HdhQ111/+ animals. These results are important to consider in the 
future experimental design of longitudinal behavioural characterisations which 
may utilise operant behavioural testing. Perhaps of most clinical significance is 
the finding that operant pre-training can modify and improve future behavioural 
symptoms in the HdhQ111/+ mouse model of HD. This leads to the exciting 
possibility cognitive training could be used as a therapeutic intervention for 
people with HD.     
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Chapter 7 : The development and utilisation of 
an operant delayed matching and non-matching 
to position operant task for mouse models of 
neurodegenerative diseases. 
 
 
Disclaimer: the results of this Experimental Chapter have recently been 
published. Yhnell E, et al. The utilisation of operant delayed matching and non-
matching to position for probing cognitive flexibility and working memory in 
mouse models of Huntington’s disease. J Neurosci Methods (2015), 
http://dx.doi.org/10.1016/j.jneumeth.2015.08.022 
7.1. Introduction 
In HD, reversal learning deficits and perseveration are particular features of both 
the human disease (Lawrence et al. 1998b; Lawrence et al. 1999) and the HD 
mouse (Lione et al. 1999; Trueman et al. 2007; Brooks et al. 2012e). 
Furthermore, short term memory problems develop in HD patients 
comparatively early in the disease progression (Kirkwood et al. 2001). 
Therefore, reversal learning and short term memory deficits in the HdhQ111 
mouse model of HD require more investigation to understand if they accurately 
replicate the symptoms demonstrated in the human disease.  
Delayed matching to position (DMTP) and delayed non-matching to position 
(DNMTP) tasks allow an investigation of both working memory and reversal 
learning. DMTP and DNMTP tasks performed in rodents, typically utilise a 
water T-maze apparatus (Beracochea and Jaffard 1995; Gibbs 2002; Johnson et 
al. 2002). However, water T-maze tasks are often time consuming to run, are 
strongly affected by motor deficits and are open to subjectivity. Furthermore, the 
swimming component of the task subjects the animal to additional stress. 
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However, operant versions of the DMTP and DNMTP tasks allow a rapid, 
automated and highly sensitive way of measuring deficits in working memory, 
perseverative responding and reversal learning. 
The DMTP operant protocol was initially developed in rats utilising Skinner 
boxes (Dunnett et al. 1989). Since the original description, operant DMTP 
testing has been used in numerous other rat studies (Dunnett et al. 1988; 
Bushnell 1990; Cole et al. 1993; Stephens and Cole 1996; Yamada et al. 2005). 
The DMTP and DNMTP tasks were originally developed to explore the effects 
of lesions and associated drug treatments in rats (Dunnett 1985; Dunnett et al. 
1989). However, the use of DMTP and DNMTP testing protocols in mouse 
studies has been comparatively limited (Beracochea and Jaffard 1995; Estapé 
and Steckler 2001) and DMTP and DNMTP operant protocols are yet to be 
investigated in HD mice.  
The large number of mouse models of HD that now exist means that there is a 
need to continually develop novel behavioural tasks to better understand, 
validate and explore the behavioural symptoms that are demonstrated in these 
mouse models. Therefore, a DMTP and DNMTP operant protocol was designed 
to test working memory and reversal learning in HdhQ111/+ animals. Initially, the 
DMTP and DNMTP protocol was performed in standard 9-hole operant boxes. 
However, the operant boxes were subsequently modified to include an additional 
‘Skinner-like’ operant set up with nose poke responses placed either side of the 
magazine. Therefore, a comparison between the DMTP and DNMTP protocols 
conducted in the standard 9-hole and modified ‘Skinner like’ operant boxes was 
able to be conducted. Based on the results of this comparison study, the DMTP 
and DNMTP tasks were conducted in the more efficient ‘Skinner-like’ operant 
experimental set up to test working memory and reversal learning in the 
HdhQ111/+ mouse model of HD.  
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7.2. Aims. 
To create, establish and test an operant delayed matching to position (DMTP) 
and delayed non-matching to position (DNMTP) task for use in mouse models 
of neurodegenerative diseases, including HD. 
7.3. Materials and Methods.  
7.3.1. Animals 
The C57BL/6J animals used in the comparison of the DMTP and DNMTP tasks 
in differing operant apparatus were obtained from Harlan (Oxfordshire, UK) at 
8 weeks of age. 14 C57BL/6J male animals were used in testing of the DMTP 
and DNMTP task in the conventional 9-hole operant apparatus set up and 15 
C57BL/6J male animals were used in the testing of the DMTP and DNMTP task 
in the ‘Skinner-like’ operant apparatus set up. Mice were, housed in pairs, 
although some had to be separated and housed singly to prevent fighting.  
For the testing of the DMTP and DNMTP tasks in the HdhQ111/+ mouse model, a 
total of 21 littermate animals were used, 12 HdhQ111/+ (6 female and 6 male) and 
9 wild type (5 female and 4 male). Animals were weaned at 3-4 weeks of age 
and tail tipped for genotyping (Laragen, Inc.). CAG repeat length in HdhQ111/+ 
animals ranged from 134-145 repeats with an average of 140 repeats. HdhQ111/+ 
animals began operant testing at 8 months of age. 
Operant testing occurred between 08.00 hours and 14.00 hours five days per 
week. One week prior to the beginning of operant testing animals were 
habituated to Yazoo© strawberry milkshake in their home cages and gradually 
water restricted. For the duration of behavioural testing animals were restricted 
to 3 hours of access to water per day which was given in their home cages 
between the hours of 14.00 hours and 17.00 hours. Animals were allowed ad-
libitum access to food throughout behavioural testing and ad-libitum access to 
water from Friday evening to Sunday evenings.  
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7.3.2. Apparatus 
Testing apparatus consisted on 16 operant boxes, as described in section 2.3.1. 
of Chapter 2. Of particular importance to note, was the modification of the 
existing 9-hole operant boxes to include a ‘Skinner-like’ set up in addition to the 
existing 9-hole set up. The ‘Skinner-like’ operant set up was located opposite 
the 9-hole array, two nose poke holes were positioned either side of the reward 
magazine, as shown in Figure 7.1. 
7.3.3. DMTP Training.  
The operant training protocols were the same for both the 9-hole set up and the 
‘Skinner-like’ set up. In all cases, initial training in the operant boxes began with 
the non-contingent delivery of 150µl of Yazoo® strawberry milk into the 
magazine and illumination of the magazine light. Reward retrieval from the 
magazine was detected via infrared beam breaks. After successful reward 
retrieval the magazine light was extinguished. The process was repeated until 
the 20 minute session time had elapsed. Magazine training was conducted for 1 
20 minute session. 
After initial magazine training animals were required to learn the nose poke 
response. The responding locations differed based on the operant apparatus set 
up, as shown in Figure 7.1. In the 9-hole operant apparatus configuration, 
animals were required to learn to poke into the central hole of the 9-hole array 
and receive reward from the magazine located behind the 9-hole array, on the 
opposite wall, as shown in Figure 7.1A. Whereas, in the Skinner-like operant 
apparatus configuration, animals were required to learn to poke into a response 
hole which was located either side of the reward magazine, and then into the 
reward magazine, located adjacent to the response location, as shown in, Figure 
7.1B.    
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Figure 7.1. Training response locations in different operant set ups.  
A. The 9-hole operant apparatus configuration demonstrates a 9-hole array with a reward magazine 
located behind the 9-hole array B. In the ‘Skinner-like’ operant configuration the response locations are 
located either side of the reward magazine.   
Once animals had successfully learned to the nose poke response, by making 
more than 100 responses on 3 consecutive days, they were moved on to the next 
phase of the training schedule. The response locations for each training schedule 
differed based on the operant configuration used (as shown in Figure 7.2). 
Training was conducted in phases, one additional poke response was required in 
each phase of training, as shown in Figure 7.2. In the 9-hole configuration 
animals were trained on each phase until responding had plateaued, which took 
a total of 7 days. In the ‘Skinner-like’ configuration animals were trained on each 
phase until their responding had plateaued, this took a total of 5 days. Each 
training phase programme lasted for 30 minutes. At the end of training, animals 
were moved on to the full DMTP testing schedule, initially without delays, 
which required a total of three correct responses to obtain a reward.  
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Figure 7.2. Training responses required in different operant set ups for DMTP training.  
A. Training in the 9-hole operant configuration required additional nose poke responses to be made in 
different stages of the operant training regime. The animal was required to poke into either hole 3 or 7 (hole 
3 is demonstrated here), then into the central hole, finally the animal was presented with both holes 3 and 
7 simultaneously to respond into B. Training in the ‘Skinner-like’ operant set up was the same as in the 9-
hole set up but the response locations differed. The animal was required to respond into the hole either to 
the left or right of the magazine (right is shown here) before poking back into the magazine and being 
presented with both left and right hole simultaneously.   
7.3.4. DMTP and DNMTP Testing.  
Upon completion of the training schedule described above, animals were tested 
on the full DMTP program (which required the same responses as the third 
training phase shown in Figure 7.2.), initially without delays. Animals were 
required to make a total of three correct responses before being rewarded. The 
accuracy in responding to ‘matching to the position’ was recorded daily for a 
total of 18 days, until animals had averaged approximately a 90% accuracy. 
After this, the delay schedule was introduced. In the optimisation experiment of 
different operant set-ups two different delays lengths of 2 and 10 seconds were 
utilised. When HdhQ111/+ animals were tested three different delays of 2, 5 and 
10 seconds were used. The delays were presented immediately prior to the 
illumination of both holes. The length of the delay was pseudo-randomly 
generated by the computer programme for each individual trial. Testing on the 
DMTP operant programme with delays was conducted for 10 days.   
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After animals had learned the DMTP task and responded successfully, the delay 
schedule was introduced for 10 days, they were then tested in the reversal of 
delayed matching to position (DMTP) task, delayed non-matching to position 
(DNMTP). As animals had prior training in responding, they were initially 
introduced to the full DNMTP testing schedule without delays. The testing 
schedule was the same as the DMTP task, however, in this task, animals were 
required to make the opposite response to the one that they had previously made 
to successfully obtain a reward. The total program length was 30 minutes. 
Animals were tested on the full DNMTP program for 16 days, until they had 
successfully learnt the task to 90% accuracy. After this, the delay program was 
introduced, as described above for the DMTP task. The delays occurred prior to 
the simultaneous illumination of lights, animals were tested on this task for 10 
days. 
7.3.5. Statistical Analysis.   
Statistical analyses were conducted in IBM SPSS Statistics 20 Software for 
windows. Two or three way analyses of variance (ANOVA) were conducted 
with daily test session, task reversals, and choice delay interval as repeated 
measures and genotype and apparatus configurations as between subject factors. 
Where significance was found post-hoc tests with Bonferroni corrections were 
applied to identify the locus of effects and their interaction(s). 
7.4. Results.  
7.4.1. Optimisation of the DMTP and DNMTP protocols in the 9-hole and 
‘Skinner-like’ operant box.  
For comparison between the conventional 9-hole and ‘Skinner-like’ 
configurations of the operant apparatus, response accuracy was used as the 
principle variable used to determine which was the more effective for learning. 
The number of trials started was used to provide a supplementary measure of 
task compliance and motivation within the different configurations. The 
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sensitivity of the two configurations to detect working memory effects was 
measured upon the introduction of delays into the testing schedule. These 
measures were assessed for both the DMTP and DNMTP tasks. 
7.4.1.1. DMTP acquisition in the 9-hole and ‘Skinner-like’ operant box 
configurations. 
All C57BL/6J mice learned to acquire the DMTP task in both apparatus 
configurations, performing at close to chance (50%) levels at the start of training 
and approaching 70-80% levels of accuracy after 8 days of training. 
Nevertheless, the mice trained in the Skinner-like configuration performed at 
higher levels overall, exhibiting more rapid learning, higher levels of accuracy 
overall, and completing more trials per session, in comparison to those trained 
in the conventional 9-hole configuration (Figure 7.3A, Accuracy; F1,27 = 16.93, 
p <0.001 ; Figure 7.3C, Trials initiated; F1,27 = 34.69, p <0.001). 
 
Upon the introduction of delays into the DMTP testing schedule a significant 
interaction between delay length and apparatus configuration was found (Figure 
7.3E, Delay x Apparatus; F2,54 = 8.64, p<0.001). Post-hoc analysis revealed 
significantly greater response accuracy for the Skinner-like configuration than 
in the 9-hole configuration specifically at the 2s delay length (p<0.001), whereas 
all mice were approaching chance levels of performance (close to 50%) at the 
longer 10s delay length.  
 
7.4.1.2. DNMTP reversal learning acquisition in the 9-hole and ‘Skinner-
like’ operant box configurations. 
Upon reversal of the DMTP task rule to DNMTP all animals initially performed 
well below chance, perseverating on the old rule with a 20-30% level of 
accuracy, but then progressively improved performance over 10 days of training 
and were able to learn the new rule to 70-80% level of accuracy over 15 days of 
training (Figure 7.3B). Although it appeared to be a somewhat lower level of 
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performance asymptote in the Skinner-like configuration, perhaps reflecting the 
heightened learning of the preceding DMTP task, this difference failed to 
achieve significance (Figure 7.3B, Accuracy; F1,27 = 4.13, p = 0.052), nor were 
there any differences in the total number of trials started (Trials; Figure 7.3D, 
F1,27 = 2.00, p = n.s.), which was seen in the DMTP version of the task (Figure 
7.3C, Trials initiated; F1,27 = 34.69, p <0.001). Nevertheless, upon the 
introduction of delays, the Skinner-like configuration revealed a significantly 
higher level of performance at the intermediate 2s delay (Delay; Figure 7.3F, 
F2,54 = 11.74, p<0.001). 
The data presented (Figure 7.3) in this comparison study of operant apparatus 
configurations, therefore suggests that the results obtained from the DMTP and 
DNMTP tasks differ depending on the configuration of the operant apparatus 
used. Specifically animals learn the DMTP task to a higher level of response 
accuracy in a comparatively shorter time when the ‘Skinner-like’ configuration 
of the operant apparatus was used. Upon introduction of delays into both the 
DMTP and DNMTP tasks, significant differences in response accuracy suggest 
that a higher level of performance can be achieved using the ‘Skinner-like’ 
apparatus configuration. Thus, although it is equally feasible to use the DMTP 
and DNMTP tasks in both the conventional 9-hole and ‘Skinner-like’ 
configurations of the operant apparatus, animals learned the DMTP task more 
rapidly and efficiently in the ‘Skinner-like’ configuration. Therefore, for 
practical purposes, the ‘Skinner-like’ configuration of the apparatus is the more 
efficient to yield robust results and consequently is the version we have selected 
for testing the DMTP and DNMTP tasks in the HdhQ111/+ mouse model of HD.  
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Figure 7.3. A comparison of delayed matching to position (DMTP) (Figures A, C and E) and non-
matching to position (DNMTP) tasks (Figures B, D & F) in the 9-hole operant apparatus and Skinner 
operant apparatus. A. DMTP total trials started indicated significantly more trials were started in the 
Skinner operant apparatus. B. DNMTP total trials started indicated no significant differences between 
operant apparatus. C. DMTP responding accuracy indicated animals were able to reach a higher level of 
responding in the Skinner operant apparatus. D. DNMTP responding accuracy indicated no significant 
differences between operant apparatus. E. DMTP responding accuracy with delays indicated animals were 
able to reach a higher level of responding in the Skinner operant apparatus, specifically at the 2 second 
delay length. F. DMTP responding accuracy with delays indicated animals were able to reach a higher level 
of responding in the Skinner operant apparatus, specifically at the 2 second delay length. Error bars indicate 
± standard error of the mean. *** p<0.001. 
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7.4.2. DMTP and DNMTP results in HdhQ111/+ animals. 
To determine the suitability of the DMTP and DNMTP tasks for use in 
determining behavioural deficits in the HdhQ111 mouse model of HD, 
performance was measured for acquisition of the DMTP task and three 
subsequent reversal phases of the DMTP and DNMTP tasks. Response accuracy 
was used to determine learning of the task, the total number of trials initiated 
was used to determine task compliance and the introduction of delays into testing 
was used to determine working memory performance.  
7.4.2.1. Acquisition of the DMTP task reveals significant deficits in 
learning the DMTP task in the HdhQ111/+ mouse model of HD. 
Initial acquisition of the DMTP operant task demonstrated that HdhQ111/+ animals 
had a significant deficit in acquiring the DMTP task as measured by decreased 
response accuracy and reduced levels of trial initiations (Figure 7.4A, Accuracy; 
F1,19 = 5.79, p<0.05, and Figure 7.4B, Trials; F1,19 = 9.41, p<0.01). When delays 
were introduced HdhQ111/+ animals continued to perform less accurately than 
wild type controls at all delay lengths (Figure 7.4C, Genotype; F1,19 = 13.53, p 
<0.01). 
7.4.2.2. The DMTP and DMTP tasks reveal significant reversal learning 
and deficits in the HdhQ111/+ mouse model of HD. 
Upon reversal of the initial DMTP task, to DNMTP, then to DMTP and then 
finally back to DNMTP the HdhQ111/+ animals continued to exhibit marked 
deficits in response accuracy irrespective of trial conditions (Figure 7.4A, 
Accuracy; F1,19 = 11.42, p<0.01), suggesting a consistently significant 
impairment in task acquisition, reversal learning and asymptotic performance in 
comparison to wild type animals. Similarly the HdhQ111/+ animals consistently 
exhibited a reduced rate of trial initiation in the reversal tasks (Figure 7.4B, 
Trials; F1,19 = 12.43, p<0.01), and unsurprisingly, the introduction of the delays  
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further exacerbated their deficits at all delay lengths in comparison to wild type 
animals (Figure 7.4C, Delay; F1,19 = 12.83, p<0.01).   
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Figure 7.4. Delayed matching to position (DMTP) and non-matching to position (DNMTP) results 
for HdhQ111 animals. A. DMTP and DNMTP responding accuracy without delays. HdhQ111/+ animals were 
significantly less accurate in the acquisition phase of the DMTP task. During the three reversal learning 
tasks HdhQ111/+ animals performed significantly less accurately across all tasks than wild type animals. B. 
DMTP and DNMTP total trials started without delays. HdhQ111/+ animals initiated significantly fewer trials 
in the acquisition phase of the DMTP task than wild type animals. During the three reversal learning 
HdhQ111/+ animals initiated significantly fewer trials than wild type animals across all three reversal learning 
tasks. C. DMTP and DNMTP responding accuracy with delays. Upon the introduction of delays into the 
DMTP and DNMTP tasks in the acquisition phase, HdhQ111/+ animals were significantly less accurate than 
wild type animals. In the three reversal learning tasks, HdhQ111/+ animals performed significantly less 
accurately across all delay lengths than wild type animals. For the DMTP and DNMTP tasks n=21 animals, 
12 HdhQ111/+ and 9 wild type. HdhQ111 animals began operant testing at 8 months of age. Error bars indicate 
± standard error of the mean. * p<0.05, ** p<0.01. 
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7.5. Discussion 
We have shown that significantly different results are produced when DMTP 
and DNMTP protocols are performed in different configurations of operant 
apparatus. Although the DMTP and DNMTP tasks are viable in both 
conventional 9-hole and ‘Skinner-like’ operant configurations, acquisition of the 
DMTP task is significantly faster in the ‘Skinner-like’ operant configuration. 
Furthermore, the two configurations have comparatively different levels of 
sensitivity to detect delay-dependent deficits once delays are introduced into the 
DMTP and DNMTP testing schedules.  
The significant differences demonstrated between the two configurations of the 
operant apparatus, specifically that the ‘Skinner-like’ configuration yields more 
robust results than the conventional 9-hole configuration, provide interesting 
guides to be considered in the design of operant tasks for cognitive testing in 
mouse models of neurological diseases. The finding that upon the introduction 
of delays into the DMTP and DNMTP tasks animals are able to reach a higher 
accuracy in the ‘Skinner-like’ operant configuration may be explained by the 
relative distance between the final response location and the reward location. In 
the ‘Skinner-like’ configuration of the DMTP and DNMTP tasks, the reward 
magazine is located 20mm laterally from the response stimulus light. Whereas, 
in the conventional 9-hole configuration the reward magazine is located at the 
opposite side of the operant box, 14cm away from the 9-hole array where the 
response stimulus lights are located. Therefore the delay between the final 
response and the collection of the associated reward in the 9-hole configuration 
of the tasks may weaken the associative strength of the reward and related 
acquisition of response, resulting in slower learning. This distance also increases 
the time for each trial to be completed resulting in fewer trials over a set session 
period (of 30 minutes in the present study). Although the 9-hole operant 
apparatus configuration offers a greater degree of flexibility and variability in 
the operant tasks which are able to be performed, for the DMTP and DNMTP 
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protocols described here, the ‘Skinner-like’ configuration is more sensitive for 
performing these particular response choice and execution rules. 
Furthermore, in comparison to a previous study conducted in mice which used a 
traditional Skinner operant box configuration with retractable levers to complete 
the DMTP and DNMTP tasks (Estapé and Steckler 2001), wild type animals in 
the study presented here were able to achieve similar levels of accuracy using a 
‘Skinner-like’ configuration of the task which utilised the species-prepotent nose 
hole pokes to respond. It is not only more economical to modify existing operant 
boxes in this way to include a ‘Skinner-like’ configuration, but the nose poke 
response holes utilised in this study also provide a naturalistic type of response 
for mice, who may be impaired in their motor function which may affect the 
ability to press a lever. However, this is at the expense of less salient response 
options that are provided with retractable levers. 
The use of mediating behaviours to gain an advantage in accurately responding 
in delayed matching tasks has previously been shown in rats (Dunnett 1985; 
Chudasama and Muir 1997) and pigeons (Blough 1959). In this case animals 
were not observed during the task and thus we cannot conclude that the use of a 
mediating behaviour conferred any specific advantage in either of the operant 
configurations. However, in future iterations of the task mediating behaviours 
may be overcome by requiring animals to perform a specific behaviour such as 
nose poking into the reward magazine during the delay to reduce the opportunity 
of employing a mediating strategy (Dunnett 1985; Bushnell 1990). 
When the HdhQ111 mouse model of HD was tested in the ‘Skinner-like’ 
configuration on the DMTP and DNMTP tasks, significant deficits were seen in 
the ability of HdhQ111/+ animals to acquire and perform the DMTP task. 
Furthermore, when the tasks were reversed, significant deficits were seen in 
HdhQ111/+ animals in terms of response accuracy and the number of trials 
initiated. Upon the introduction of delays into both the DMTP and DNMTP 
tasks, a clear effect of delay was demonstrated in all manipulations of the tasks. 
Chapter 7                                Delayed Matching and Non-Matching to Position  
170 
 
 
 
 
Although, HdhQ111/+ animals were significantly less accurate than wild type 
animals at all delay lengths including, at the zero delay, thus suggesting a 
reduced ability to perform the tasks accurately. Nevertheless, we cannot 
conclude that the HdhQ111 mice exhibit a specific deficit in working memory 
performance, since they were impaired at all delays including the shortest, at 
which the memory load is least. Rather the profile of impairments suggests a 
more executive deficit in learning and performing the choice response rule itself, 
as well potentially of disturbances in response initiation and motivation. 
The reduced ability to acquire, perform and initiate trials in the DMTP and 
DNMTP tasks may suggest an apathetic phenotype or lack of motivation in 
HdhQ111/+ mice as suggested by the fewer number of trials performed. 
Behavioural deficits of this type have previously been seen in people with HD 
(Rosenblatt and Leroi 2000; Paulsen et al. 2001a; Baudic et al. 2005), although 
additional behavioural tests will need to be conducted to determine the 
specificity of deficits within this domain if this is the case in this mouse model. 
Alternatively, it may be that the increased number of trials initiated by the wild 
type animals translates to a practice effect on the performance measure. 
Therefore, among other variables, future iterations of the task should consider 
using a set number of trials per session rather than a fixed time duration to 
overcome this potential confound.   
The DMTP and DNMTP reversal learning results demonstrate that wild type 
animals initially perseverate more on the incorrect response from the previous 
manipulation as signified by their lower initial baselines on the reversal switch. 
This was expected as these animals have clearly learnt the previous manipulation 
of the task and formed a stronger association in learning the rule of the task, than 
the HdhQ111/+ mice. The HdhQ111/+ animals appear to acquire the task less well, 
but upon reversal of the task responding accuracy was higher than in wild type 
animals, this may be due to a general impairment in rule learning of these tasks. 
Overall the ability of the HdhQ111/+ animals to learn the reversal task was 
decreased in comparison to wild type animals. The reversal learning deficits 
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associated with HdhQ111/+ animals in comparison to wild type animals may be 
reflective of perseverance and behavioural inflexibility which have been 
previously described in people with HD (Craufurd et al. 2001; Hamilton et al. 
2003; Ho et al. 2003; Thompson et al. 2014). Therefore, it is possible that 
HdhQ111/+ animals may be able to perform the task to the same level as wild type 
animals, although they may take a significantly longer time to do so. Although 
this suggestion is unlikely as HdhQ111/+ animals seem to reach a plateau in  both 
responding accuracy and the number of trials started over the 30 days of testing 
on each reversal manipulation.  
The DMTP and DNMTP task protocols presented here therefore provide a highly 
sensitive, robust and reproducible method to test spatial learning and its reversal 
and short-term memory function in mice. The results demonstrate that this 
method of behavioural testing provides a valid and robust test of cognition, 
executive function and working memory for use in murine models of 
neurodegenerative diseases, including HD. The DMTP and DNMTP operant 
tests are also suitable to test pharmacological therapeutic interventions in mouse 
models of HD and are translatable to mouse models of other neurological 
diseases. 
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Chapter 8 : General Discussion 
The aims of this thesis were to understand the development of the 
neuropathological and behavioural changes in the HdhQ111/+ mouse model of HD. 
Consequently, we aimed to use these results to determine how accurately the 
HdhQ111/+ mouse model replicates the human condition. We further aimed to 
develop novel tests for use in genetically modified mouse models to probe 
specific behavioural deficits that are associated with the neurological diseases, 
including HD.  
8.1. Summary of Findings 
HdhQ111/+ mice were shown to demonstrate: reduced striatal volume, loss of 
DARPP-32 staining within the striatum and the progressive formation of NIIs 
within the striatum. Weight loss was shown to be progressive in HdhQ111/+ 
animals, from 11 months of age, in relation to wild type controls. Motor 
dysfunction in balance beam performance was shown in HdhQ111/+ mice from 9 
months of age and decreased latency to fall from the rotarod was also 
demonstrated, although this was not seen to be progressive over time. Operant 
testing revealed specific deficits including: reduced FR responding, reduced PR 
responding, reduced 5-CSRTT accuracy, increased 5-CSRTT response time, 
increased 5-CSRTT timeouts, decreased S1 and S2 accuracy in SILT, increased 
S1 and S2 response times in SILT. Operant 5-CSRTT training was used 
successfully as a cognitive training intervention to demonstrate improved 
attentional and motor performance, as measured by 5-CSRTT accuracy and 
response times, in HdhQ111/+ animals. Finally, a novel DMTP and DNMTP 
operant task was developed and tested in HdhQ111/+ mice to reveal significant 
reversal learning deficits.  
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8.2. Does the HdhQ111/+ mouse model represent the human condition of 
HD? 
HdhQ111/+ mice were shown to demonstrate specific neuropathological hallmarks 
which reflect the human condition of HD, including: reduced striatal volume 
(Vonsattel et al. 1985; Aylward et al. 2004), loss of DARPP-32 stained MSNs 
(Deng et al. 2004; Starr et al. 2008) and the formation of overt NIIs within the 
striatum (Vonsattel et al. 1985; DiFiglia et al. 1997; Gutekunst et al. 1999; 
Sieradzan et al. 1999) (as shown in Chapter 3).  
Significant motor dysfunction was seen in HdhQ111/+ animals in balance beam 
and rotarod performance (as shown in Chapter 4). However, the motor 
abnormalities demonstrated were relatively subtle in comparison to the obvious 
chorea and jerking movements which are observed in the later stages of the 
human condition (Huntington 1872; Thompson et al. 1988; Berardelli et al. 
1999a). Deficits in the initiation of movement in balance beam, were shown in 
HdhQ111/+ mice from 9 months of age, this may be reflective of the akinesia (van 
Vugt et al. 1996), which is shown in the human condition. Although, the other 
more obvious motor dysfunctions such as  hypokinesia, bradykinesia  
(Thompson et al. 1988), dystonia, rigidity, tics and tremor (Hefter et al. 1987b; 
Phillips et al. 1996; Berardelli et al. 1999b; Louis et al. 1999) were not evident 
throughout this behavioural characterisation. The motor abnormalities observed 
in HdhQ111/+ mice are therefore likely to reflect subtle motor abnormalities which 
occur early in the human disease, as previously observed in both PREDICT-HD 
and TRACK-HD studies (Paulsen et al. 2008b; Biglan et al. 2009; Tabrizi et al. 
2009; Tabrizi et al. 2011; Tabrizi et al. 2013).  
The cognitive phenotype of the HdhQ111/+ mouse model (as shown in Chapter 5) 
demonstrated specific cognitive deficits in operant tasks (including; FR, PR, 5-
CSRTT and SILT) at 18 months of age. However, these deficits were not 
typically present until the later stages of the disease progression. Therefore, it 
could be concluded that these deficits were not present in the absence of motor 
dysfunction (as shown in Chapter 4) and therefore are not fully representative of 
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the subtle cognitive deficits that precede profound motor dysfunction in the 
human condition (Diamond et al. 1992; Lawrence et al. 1998b; Lawrence et al. 
1998c; Kirkwood et al. 2000; Lemiere et al. 2004; Duff et al. 2007; Robins 
Wahlin et al. 2007; Paulsen et al. 2008b; Tabrizi et al. 2009; Tabrizi et al. 2011; 
Tabrizi et al. 2013).  
There is no rodent test battery currently available that can fully probe all of the 
symptoms associated with the human condition of HD. However, the 
experiments conducted in this thesis have revealed that the HdhQ111/+ mouse 
model replicates some aspects of the human condition in terms of: the 
neuropathology (reduced striatal volume, reduction of MSNs and NII 
formation), motor abnormalities (in rotarod and balance beam) and cognitive 
dysfunctions (FR, PR, 5-CSRTT and SILT) exhibited. Therefore, the HdhQ111/+ 
mouse model of HD is an accurate representation of the early stages of the 
human condition of HD.        
8.3. How does the HdhQ111/+ mouse model compare to other mouse models 
of HD? 
When mouse models of HD are compared in terms of behaviour and 
neuropathology, differences in background strain should be carefully 
considered, as these differences have previously been shown to affect the 
behavioural and neuropathological phenotype observed (Brooks et al. 2004; 
Lloret et al. 2006; Van Raamsdonk et al. 2007). However, HdhQ111/+ mice 
demonstrate a neuropathological and behavioural phenotype which is subtle, 
certainly in comparison to other transgenic mouse models such as the R6/1 
(Mangiarini et al. 1996; Hansson et al. 1999) and R6/2 models (Mangiarini et 
al. 1996; Morton et al. 2000; Meade et al. 2002), which demonstrate an 
extremely rapid and aggressive disease progression. The phenotype of the 
HdhQ111/+ mouse is subtle and comparatively similar to those previously shown 
in other knock-in mouse models of HD with similar trinucleotide repeat lengths; 
such as HdhQ140 (Menalled et al. 2003; Hickey et al. 2008; Rising et al. 2011) 
and HdhQ150 (Lin et al. 2001; Woodman et al. 2007; Brooks et al. 2012d) 
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animals. However, zQ175 mice demonstrate an earlier onset of disease 
progression in both motor dysfunction and neuropathology in comparison to 
HdhQ111/+ mice (Heikkinen et al. 2012; Menalled et al. 2012; Smith et al. 2014), 
which can be attributed to the longer CAG trinucleotide repeat length. 
Furthermore, the nature of the genetic construct in each mouse model is an 
important consideration in the behavioural and neuropathological results 
observed. For example, in the knock-in mouse models, HdhQ150 (Lin et al. 2001) 
and zQ175 animals (Menalled et al. 2012) contain an inserted construct with an 
expanded CAG repeat. Whereas, the HdhQ92 and HdhQ111 mouse models contain 
an insertion which includes an expanded CAG repeat and part of the first intron, 
which may significantly alter the splicing of the mHtt gene and subsequent 
formation of mHtt protein fragments, particularly small N-terminal fragments, 
which have previously been shown to be particularly pathogenic (Sathasivam et 
al. 2013). Therefore, the nature of the genetic construct which is inserted into 
the mouse model is an important consideration in the comparison of different 
models.   
Overall, in comparison to other mouse models of HD, the HdhQ111/+ mouse 
model reflects a subtle behavioural and neuropathological phenotype which may 
be representative of the early stages of the human condition.  
8.4. Is the HdhQ111/+ mouse model of HD suitable to test therapeutics? 
The HdhQ111/+ mouse model has been shown to be an accurate and representative 
model in recapitulating some of the neuropathological, motor and cognitive 
symptoms of HD. Therefore, the next step to consider is the use of the HdhQ111/+ 
mouse model to test therapeutic interventions, with the hope of improving the 
associated disease symptoms. Thus, different types of therapeutic interventions 
will be considered for their suitability for use in the HdhQ111/+ mouse model in 
the light of the neuropathological and behavioural results observed.   
The relatively subtle behavioural and neuropathological phenotype observed in 
the HdhQ111/+ mouse model means that it could be used to trial novel therapeutic 
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interventions that are targeted to treat early stage HD. However, due to the 
relatively slow disease progression observed, it may be more appropriate and 
practical to use a transgenic mouse model, or a knock-in model with a longer 
trinucleotide repeat length to represent the later stages of the human condition of 
HD. Although, it should be noted that the nature of the genetic construct in the 
HdhQ111/+ mouse model and other knock-in mouse models is genetically more 
similar to the human condition than transgenic mouse models, therefore knock-
in mouse models are more genetically representative of the human condition.    
The neuropathology of the HdhQ111/+ mouse model of HD demonstrated in 
Chapter 3 only considered the striatum in stereological quantification of mHtt 
inclusion pathology. Although, mHtt inclusions were visible in other brain 
regions, these were not stereologically quantified and did not appear to be 
widespread until late in the disease progression. Therefore, particularly early 
within the disease progression of the HdhQ111/+ mouse, the neuropathology is 
relatively focused to the striatum. Thus, the HdhQ111/+ mouse model may be a 
suitable mouse model for trialling cell transplantation directly into the striatum 
as a therapeutic intervention. Although transplantation studies have been used to 
successfully demonstrate graft induced functional benefit in HD rat lesion 
studies (Sanberg et al. 1986; Isacson et al. 1987; Bachoud-Lévi et al. 2000; 
McBride et al. 2004; Ryu et al. 2004; Vazey et al. 2006) the development of 
similar transplantation protocols in mice has been troublesome. The few 
transplantation studies in mouse models of HD have generated considerably 
variable results, which often show only modest functional recovery after 
transplantation (Dunnett et al. 1998; Johann et al. 2007). Therefore, 
transplantation in HD mice requires considerably more investigation before it 
can be used as an effective treatment option in any mouse model of HD. 
Furthermore, the topic of cell transplantation, including that of human fetal tissue 
and stem cells transplantation, has numerous practical, ethical and moral 
implications which are important to consider before they are used as therapeutic 
treatment options.  
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The use of both therapeutic and transplantation interventions has been discussed 
in relation to the HdhQ111/+ mouse model of HD. However, in Chapter 6, a non-
pharmacological intervention of cognitive training was explored and 
demonstrated positive results which improved both cognitive and motor function 
in HdhQ111/+ mice. The cognitive training results are supported by previous 
findings in a transgenic mouse model of HD (Wood et al. 2011), although the 
nature of the cognitive training conducted in this experiment differed, as a novel 
maze was used.  Therefore, the results shown in Chapter 6 demonstrate that the 
HdhQ111/+ mouse model of HD is suited to exploring the effectiveness of non-
pharmacological therapeutic interventions such as cognitive training. 
Furthermore, other non-pharmacological interventions such as exercise have 
been shown to improve disease symptoms in both mouse models of HD (Kohl 
et al. 2007; Van Dellen et al. 2008; Harrison et al. 2013) and in human HD 
patient studies (Busse and Rosser 2007; Busse et al. 2008b; Khalil et al. 2012; 
Busse et al. 2013; Khalil et al. 2013). Therefore, it may well be the case that 
non-pharmacological interventions and lifestyle changes such as cognitive 
training or exercise therapies can be implemented in addition to therapeutic 
interventions such as transplantation to further improve functional benefit to 
patients, and the HdhQ111/+ mouse model is a suitable mouse model to test this 
suggestion.   
8.5. Will a single mouse model of HD fully recapitulate disease symptoms? 
The single genetic mutation that is the primary cause of HD (MacDonald et al. 
1993) may suggest that the generation of a single animal model of the disease 
which accurately reflects the human condition would be relatively simple. 
Knock-in models of HD such as the HdhQ111/+ mouse model are the most 
reflective models of the human condition, in that they express the CAG 
trinucleotide repeat in the appropriate genomic and proteomic context to reflect 
the human condition. However, due to the comparative life span of human 
patients and mice, a mouse with the same number of CAG trinucleotide repeats 
as a human patient will not reflect the neuropathology or behavioural symptoms 
Chapter 8                                                                               General Discussion 
178 
 
of HD. Therefore, the CAG repeat is expanded further in mouse models of HD, 
in comparison to humans, to equate for the differences in life span. The HdhQ111/+ 
mouse model appears to reflect a subtle phenotype which models the early 
symptoms of the disease and is comparable to HD patients who are at the early 
stages of HD. In order to model the more advanced stages of HD, knock in mouse 
models with larger CAG repeat lengths, such as zQ175 or HdhQ250 mice, could 
be used, but they do not appear to produce the degree of behavioural and 
neuropathological dysfunction which is reflected in human patients. Therefore, 
it may be the case that knock-in mouse models with comparatively large CAG 
repeat lengths still do not accurately represent the later stages of the human 
condition. Thus, in order to model the neuropathology and behaviour of patients 
in the later stages of the disease it may be more appropriate to use transgenic 
mouse models of the disease, although they are not as genetically similar to the 
human condition as knock-in mouse models. Therefore, the animal model 
chosen to be most representative of the human condition may well depend on 
which stage of HD the researcher requires to be modelled as well as the 
mechanism of therapy that they are investigating, for example: neuroprotective, 
regenerative or symptomatic treatments.  
8.6. Theoretical and Practical Considerations 
The practical logistics of running longitudinal behavioural studies (such as those 
in Chapters 4 & 5) can present several problems, including housing and handling 
large cohorts of mice over extended time periods. Studies of this longitudinal 
design have considerable financial and ethical implications; thus, the sample size 
used in the longitudinal experiments presented in Chapter 4 is low (n = 7 
HdhQ111/+). Due to the complexity of multifactorial analyses conducted for the 
behavioural results, some effects, are unlikely to be drawn out due to the small 
degree of statistical power. This was the case for some findings, in that although 
a clear main effect of genotype was observed, no interaction between age and 
genotype was found. Although restricted analyses of the data can be performed, 
to demonstrate significant genotype differences at specific ages, this does not 
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reflect the longitudinal nature of the experimental design and cannot be used to 
determine any progressive behavioural changes over time.  
An alternative strategy for conducting experiments assessing longitudinal 
characteristics would be to utilise small cohorts of mice to provide early, mid 
and late time points, as well as one cohort of animals which are tested throughout 
the operant test battery (Brooks et al. 2012a; Brooks et al. 2012d, c; Brooks et 
al. 2012f; Brooks et al. 2012h). Thus, histological samples could be taken 
progressively throughout the test battery, rather than just at the end as in 
traditional longitudinal designs. However, this alternative method of performing 
longitudinal characterisations also has drawbacks, with some animals 
demonstrating practice or training effects, due to the nature of the experimental 
design. Although it would be ideal to use separate large cohorts of animals at 
each experimental time point, the practical issues of generating and testing 
cohorts of animals in this way make this approach extremely difficult.  
The way in which animals are housed can have a significant impact on the 
behavioural results obtained when characterising mouse models. Social 
isolation, which may be caused by separating mice that fight while under 
restriction, can significantly alter behaviour; increasing aggression, anxiety, 
depression and irritability (Lagerspetz and Lagerspetz 1971; Brain and Benton 
1983; Rodgers and Cole 1993; Guo et al. 2004; Koike et al. 2009; Ma et al. 
2011). All of these behaviours have previously been demonstrated in the human 
condition of HD (Burns et al. 1990; Craufurd et al. 2001; Paulsen et al. 2001b; 
Slaughter et al. 2001a; Duff et al. 2007; Reedeker et al. 2012; van Duijn et al. 
2013). Thus, housing conditions may impact upon the behavioural results 
observed and it is important to consider that singly housing animals may increase 
the prevalence of certain behaviours which are already shown in the human 
condition of HD. 
The nature of the animal housing conditions are also a fundamental consideration 
in the interpretation of the behavioural results. The animals used in this thesis 
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were housed with the addition of a single cardboard tube and a chew stick, these 
items could be considered environmental enrichment, and, indeed, that is the 
rationale for their use. Environmental enrichments such as the introduction of 
additional items to the cage, has been shown to slow disease progression in other 
mouse models of HD (Hockly et al. 2002; Glass et al. 2004; Spires et al. 2004; 
Lazic et al. 2006), but this is yet to be investigated in knock-in mouse models 
including the HdhQ111/+ mouse model. Although, the housing conditions were 
kept consistent across all of the studies presented in this thesis, this will not be 
the case throughout the literature and, therefore, this should be considered when 
comparing the behavioural results observed in different HD mouse models. 
Although one would ideally wish to keep environmental enrichment to a 
minimum in characterisation studies; environmental enrichments such as those 
used previously  (Hockly et al. 2002; Glass et al. 2004; Spires et al. 2004; Lazic 
et al. 2006) could be utilised in the future as a means of therapeutic intervention 
in the HdhQ111/+ mouse model of HD.   
The water restriction regime imposed for the operant testing conducted in 
Chapters 5, 6 and 7 was required to ensure animals were motivated to respond 
to similar degrees in the operant boxes for the associated reward. In comparing 
operant testing results in HD mouse lines, the type of restriction regime imposed 
is an important experimental factor in the motivation of operant learning and so 
is an important consideration in the interpretation of the results. While the use 
of food restriction in operant testing of mice is common (Trueman et al. 2007, 
2008b; Trueman et al. 2009b; Brooks et al. 2012h; Trueman et al. 2012b); water 
restriction has been shown to provide more stable motivation and to be more 
tolerable than food restriction in C57BL/6J mice (Tucci et al. 2006), thus water 
restriction was used in this study to comply with legal requirements and for 
reasons of experimental consistency. However, it should be noted that the level 
and implementation of water restriction imposed in operant studies can vary 
considerably between studies, often depending on the relevant legal 
requirements under which the study is conducted.  
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In particular, dietary restriction has been shown to cause epigenetic changes in 
mice (Lee et al. 1999; Chouliaras et al. 2011; McKay and Mathers 2011). Food 
restriction has previously been shown to slow HD disease progression and 
extend life span in the HD-N171-82Q transgenic mouse model (Duan et al. 
2003a). Of particular interest is the activation of the histone deacetylase (HDAC) 
Sirt-1, which causes longevity and increased life span in mice (Wakeling et al. 
2009) and has been shown to be neuroprotective in the N171-82Q mouse model 
of HD (Jiang et al. 2012). Furthermore, dietary restriction has also been shown 
to have more general neuroprotective effects in mice; increasing levels of 
endogenous BDNF (Duan et al. 2001a; Duan et al. 2001b; Duan et al. 2003b) 
and enhancing neurogenesis (Mattson 2000; Lee et al. 2002; Bondolfi et al. 
2004). Although these suggestions are yet to be explored specifically in HD 
mice. Therefore, it may be the case that in the same way that food restriction 
may alter HD disease progression, the water restriction imposed in this thesis, 
may well affect disease progression in the HdhQ111/+ mouse model of HD. 
Although, these suggestions were not specifically investigated in this thesis and 
therefore require further experimental exploration.   
8.7. Future Directions  
In subsequent longitudinal tests (such as those conducted in Chapters 4 & 5) it 
may be necessary to increase the sample size of animals used in the study, due 
to the complex multifactorial analyses conducted. However, this will have 
considerable financial and ethical implications.  
Furthermore, imaging studies could be included in future longitudinal studies to 
further explore the gross neuroanatomical changes that underlie the progression 
of HD in the HdhQ111/+ mouse model. If imaging studies of this sort were to be 
undertaken, they could be directly compared to other human HD imaging studies 
(Thieben et al. 2002; Rosas et al. 2003; Reading et al. 2005; Henley et al. 2006; 
Rosas et al. 2008; Henley et al. 2009; Tabrizi et al. 2009; Hobbs et al. 2010; 
Tabrizi et al. 2011), and this would add further clarity to how well the HdhQ111/+ 
mouse model reflects the human condition. Although, practical difficulties in 
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scanning small animals and fundamental differences in the neuroanatomy of 
human and rodent brains should be considered (Flood and Coleman 1988; Parent 
1990) in the comparative use of imaging studies.   
It became evident that the cleanliness of the animal unit in which the mice were 
housed, gradually decreased throughout behavioural testing, and animals were 
increasingly exposed to pathogens including: mouse hepatitis virus, mouse 
parvovirus, mouse norovirus, mouse adenovirus, intestinal helminths and 
helicobacter. While we cannot be certain of the exact impact that this had on the 
behavioural results observed, neuro-inflammation has already been shown to 
occur in neurodegenerative diseases, including HD (Dalrymple et al. 2007; 
Silvestroni et al. 2009; Staal and Möller 2014) and the additional presence of 
these pathogens can only add to the disease burden which is observed in the 
HdhQ111/+ mouse model. Therefore, access to an animal holding unit with a 
comparatively higher health status would be preferable in future studies.   
The results presented in Chapter 6, investigating cognitive training as a 
therapeutic intervention in HD are particularly exciting and further studies could 
be undertaken based on the results obtained. The demonstration of practice or 
training effects, due to repeated testing in the longitudinal experimental design 
has previously been studied in mice (McIlwain et al. 2001). In this study 
significant differences in behavioural phenotypes were demonstrated in rotarod 
and open field performance in wild type mice who had undergone a motor test 
battery in comparison to naïve mice. The results of this previous study are 
therefore directly translatable to the results observed here in Chapter 4, where 
animals were repeatedly tested in a test battery exploring motor dysfunction over 
time. Therefore it may be the case that repeatedly testing HdhQ111/+ animals in 
motor tasks alters the behavioural phenotype observed. Moreover, exercise, 
which may be considered a form of motor training, has been used previously to 
improve behavioural symptoms in mouse models of HD, including; the R6/1 
(Pang et al. 2006; Harrison et al. 2013) and R6/2 mouse models (Hockly et al. 
2002). However, one study in N171-82Q animals showed that exercise may in 
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fact accelerate the onset of motor symptoms, as measured by rotarod 
performance (Potter et al. 2010). Exercise therapies are yet to be investigated 
specifically in knock-in mouse models of HD, including the HdhQ111 model. 
Perhaps most importantly, these observations have significant implications for 
the HD patient population. It may be the case that HD patients who are 
particularly active develop motor dysfunctions at later time points in the disease 
progression than those who are less active. These suggestions are also important 
to consider in terms of therapeutic interventions, as it has been shown that 
physical training can improve HD related motor symptoms (Busse and Rosser 
2007; Busse et al. 2008b; Khalil et al. 2012; Khalil et al. 2013). Thus, motor 
training in the HdhQ111/+ mouse model is a research area of future interest.  
The results presented in Chapter 6 demonstrate a clear difference in the operant 
performance of HdhQ111/+ mice who have received previous cognitive training in 
either an attentional or non-attentional task in comparison to naïve animals. 
Therefore, completing an operant test battery at a young age affects subsequent 
operant performance at an older age, which may well mask cognitive deficits 
that would have otherwise developed if animals were naïve to the task. Although 
further experiments will need to be conducted to validate the suggestion that 
cognitive training impacts upon subsequent testing both in other mouse models 
of HD and in other operant tasks, the results presented in Chapter 6 would 
suggest that this is the case. Furthermore, in translating this work into the HD 
patient population, it may be important to consider that patients who are 
practiced in a particular cognitive skill may develop cognitive dysfunctions later 
in their disease progression. Cognitive training may therefore prove beneficial 
in terms of a possible therapeutic intervention. Indeed, cognitive training 
programmes have been used in other neurodegenerative diseases, such as 
Alzheimer’s disease (Hofmann et al. 1996; Davis et al. 2001; Farina et al. 2002; 
Clare et al. 2003; Clare and Woods 2004) and Parkinson’s disease (Sinforiani et 
al. 2004; Sammer et al. 2006; París et al. 2011; Milman et al. 2014) where 
improvements in both cognitive and motor disease symptoms have been shown. 
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Therefore, the cognitive training results obtained in Chapter 6 combined with 
patient studies in other neurological diseases suggest that a cognitive training 
intervention could offer a viable non-pharmacological therapeutic intervention 
in the HD patient population, which would be an important area of future 
translational research.     
8.8. Concluding Remarks  
The research undertaken in this thesis characterised the neuropathological, motor 
and cognitive phenotype of the HdhQ111/+ mouse model of HD. Further research 
was also undertaken to explore a non-pharmacological cognitive training 
intervention, and the development of a novel operant task. As more mouse 
models of HD become available; continued research will be required to 
successfully understand the associated phenotype and, therefore, the advantages 
and disadvantages of using each mouse model. Furthermore, clinical studies 
which allow us to understand HD as a neurological condition, which will 
increasingly provide feedback into the development of novel behavioural tasks, 
histological stains and molecular techniques which examine these specific 
functions in animal models. Nevertheless, the findings presented in this Thesis 
are of vital importance in further understanding that the HdhQ111/+ mouse model 
is reflective of the early stages of the human condition of HD. Pre-clinical studies 
such as those described here are of vital importance to HD research. However, 
the future translation of this pre-clinical work into a clinical setting, should 
always be an important consideration in the undertaking of any pre-clinical 
research. 
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Appendix 
Solutions 
ABC solution  
5µl A (DAKO) 
5µl B (DAKO) 
1ml 1% serum in 1X TBS 
 
Acid Alcohol  
5ml Glacial Acetic Acid 
200ml 95% IMS 
 
Antifreeze solution  
5.45g Di-sodium hydrogen orthophosphate 
1.57g Sodium di-hydrogen orthophosphate 
400ml Distilled water  
300ml Ethylene glycol 
300ml Glycerol 
pH 7.3 
 
Cresyl violet  
7g Cresyl violet acetate (Sigma, C5052) 
5g Sodium acetate (anhydrous) 
1000ml Distilled water 
pH 3.5  
  
Paraformaldehyde solution (4%) 
90g Di-sodium hydrogen phosphate  
45g Sodium chloride 
200g Paraformaldehyde (Fisher Scientific) 
pH 7.3 
Made up to 5L with Distilled water 
 
Pre-wash (0.1M PBS) 
18g Di-sodium hydrogen phosphate (dihydrate) 
9g Sodium chloride  
pH 7.3 
Made up to 1L with Distilled water 
 
Quench solution  
10ml Methanol (Fisher Scientific) 
10ml Hydrogen peroxide (VWR Prolabo BHD) 
80ml Distilled water  
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TNS  
6g Trisma base (Sigma) 
1000ml Distilled water  
pH 7.4 
 
TRIS buffered saline (concentrated stock solution 4x TBS) 
48g TRIS base (Sigma) 
36g Sodium chloride (Sigma) 
1000ml Distilled water  
pH 7.3 
 
TRIS buffered saline (working solution 1x TBS) 
1: 4 dilution of the concentrated stock solution (above) with distilled water 
pH 7.3 
 
TXTBS  
250ml 1xTBS 
500µl Triton X – 100 (Sigma) 
pH 7.4 
 
Sucrose solution (25%) 
25g Sucrose (Fisher Scientific) 
1000ml Distilled water 
pH 7.3 
 
 
 
 
 
